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General Introduction
This thesis is the result of my exciting quest to tame a beautiful beast. This beautiful beast 
(Guaras and Enriquez 2017), also called the Goliath of the respiratory chain (DiMauro and 
Garone 2010), a complex complex (Formosa et al. 2017) and a treasure trove (Elurbe and 
Huynen 2016) is the mitochondrial oxidative phosphorylation system enzyme protein 
complex NADH:ubiquinone oxidoreductase (E.C. 1.6.5.3), or as it is called in this thesis,
complex I (CI). In this metaphor its taming refers to the elucidation of its assembly in 
health and disease.
For people outside this ﬁeld, it might be difﬁcult to understand that one can spend 4 
years studying how a single enzyme complex is constructed, and why this is important. 
However, I am convinced that after reading this thesis you will appreciate my enthusiasm 
in this intricate multi-protein assembly. 
In the chapter you are currently reading, I will illustrate some of the aspects that make this 
complex so extraordinary, and provide the aim and the outline of this thesis.
Mitochondria and mitochondrial complex I
The study of CI learns us about many aspects of biochemistry and cellular biology and 
shows us how much more is still need to be done. For example, if we take a closer look 
into the complex, we will learn about redox reactions. They comprise NADH oxidation by 
a ﬂavin mononucleotide, intramolecular electron transport along a chain of iron-sulfur 
clusters and lately ubiquinone reduction (Wirth et al. 2016). This redox reaction is coupled 
to proton translocation (Figure 1), how it is coupled remains as a mystery (Hirst and 
Roessler 2016). Therefore, CI could be divided into three different structural and functional 
modules: NADH oxidation module (N-module), quinone binding module (Q-module) and 
proton pumping module (P-module) (Brandt 2006). 
CI is the ﬁrst of the oxidative phosphorylation system (OXPHOS). This system consist 
of 4 enzymes that form the electron transport chain (ETC) and an ATP synthase or else
called complex V (CV), used to generate ATP. The synthesis of ATP is done using the proton 
electrochemical gradient (Mitchell 1966) generated by CI, as mentioned above, but also 
complex III (CIII) and complex IV(CIV) of the ETC. The majority of the ATP generated in the 
cells comes from the mitochondrion.
As explained before, CI oxidizes NADH, and it is the main entry point of electrons in the 
OXPHOS system. NADH, which is produced in the tricarboxylic acid (TCA) cycle and in 
the `-oxidation of fatty acids, donates its electrons to CI. Its oxidized form, NAD+, gets 
regenerated in the matrix of the mitochondria (Hirst 2013). This compound needs to be 
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transported to the cytosol, where is required for glycolysis and converted into NADH, that 
will be transported to the mitochondria. So, the NAD+ availability determines the rate of 
glycolysis (Stein and Imai 2012). Therefore, CI also helps in preserving the NAD+/NADH 
ratio.
ﬁgure 1 | Structure and overview of the reactions catalyzed by mammalian complex I. 
NADH oxidation occurs at the hydrophilic domain of the complex by a ﬂavin mononucleotide. 
4 protons are transferred from the matrix to the intermembrane space for each NADH oxidized. 
The electrons are then transferred by a chain of iron-sulfur clusters to reduce ubiquinone.
Additionally, this peculiar enzyme is also involved in non-energetic roles. For instance, 
it can play an important role determining the fate of a cell, as it is the main generator 
of reactive oxygen species (ROS), which can act as a regulator of intracellular signaling 
pathways, as cell proliferation, cell death and senescence (Sanz 2016; Vinogradov and
Grivennikova 2016). 
From a metabolic aspect, CI, as a complex of the OXPHOS system situated in the mitochondria,
is on the crossroad of metabolic pathways (Figure2). An organelle important not only for
bioenergetics but by its participation in aminoacid catabolism, heme synthesis, ketone
body formation, calcium storage and the urea cycle.
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ﬁgure 2 | Schematic view of catabolic and anabolic mitochondrial metabolism. 
TCA cycle generates reducing equivalents such as NADH and FADH2 that will be used by the 
OXPHOS to generate ATP. The intermediates of the TCA cycle can also be used for the production 
of fatty acid or for protein modiﬁcations. So, mitochondrial metabolites and the production of 
ROS in the OXPHOS act as signaling molecules that will alter protein funtion. Glc: glucose. Pyr: 
pyruvate. TCA: TriCarboxilic Acid cycle. OXPHOS: oxidative phosphorylation system. NAD(H):
Nictinamide Adenine Dinucleotide (reduced). FAD(H2): Flavin Adenine Dinucleotide (reduced).
Ac-Coa: Acetil Coenzyme . 
Given this fundamental role of CI in metabolism, defects in this enzyme severely affect 
the functioning of our body and cause numerous disorders. It has been shown that CI
deﬁciency plays a role in classical mitochondrial disorders such as Leigh syndrome, but
also in neurodegenerative diseases (Giachin et al. 2016) like Parkinson and Alzheimer and 
also in cancer (Urra et al. 2017). 
From an evolutionary perspective, mitochondria are derived from an endosymbiotic event 
(Sagan 1967) two billion years ago, which involves the encapsulation of a free-living alpha-
proteobacterium by a proto-eukaryotic host (Figure 3), which origin is still a matter of
debate (Archibald 2015).
NAD+NADH
2-oxoglutarate
oxaloacetate
Glc
Pyr
Ac-CoA
Gln
citrate
Ac-CoA
Protein modification
Fatty acid synthesis
ADP
ATP
TCA
OXPHOS
H+
FADFADH2
Glycolysis
-oxidationɴ 
O2
-
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ﬁgure 3 | Graphic representation of the endosymbiotic theory. 
A prokaryote grows in size and develops membrane infoldings that will eventually pinch off 
from the cell membrane and form the nuclear membrane and a endoplasmic reticulum. An 
aerobic protobacterium penetrates into the cell and manages to avoid digestion becoming a
endosymbiont, becoming a mitochondrion.
This event gave rise to the occurrence of an eukaryotic cell, and opened the way for the 
evolution of multi-cellular organisms. As a result from this integration, the intruder 
lost its cellular autonomy, and became specialized in producing ATP by fully oxidizing 
carbohydrates, aminoacids and lipids, via aerobic respiration (Roger, Munoz-Gomez, and
Kamikawa 2017). In the course of evolution, the intruder became integrated with the host. 
Most of the proteobacterium genome merged with the host’s and was transferred to the 
nucleus. Nevertheless, a small part of the intruder’s genome, termed mitochondrial DNA 
(Anderson et al. 1981; Andrews et al. 1999), stayed behind in the mitochondria. A separate
DNA replication, transcription and translation machinery was kept to maintain, and 
express essential proteins from this circular 16.x kb genome. Mitochondrial DNA encodes
for 22 transfer RNAs, 2 ribosomal RNAs and 13 messenger RNAs all together required for the 
production of 13 essential proteins of the OXPHOS system (Gustafsson, Falkenberg, and
Larsson 2016). Seven of the thirteen proteins of the mitochondrial DNA are subunits of CI. 
As a consequence, CI is derived from an alpha proteobacterium and, nowadays, is made
from gene products from two genomes, the mitochondrial and the nuclear.
Present human mitochondrial CI contains 44 subunits and several prosthetic groups. 
From these 44 subunits 14, the so called core protein subunits, are the ones present in the
bacterial CI and, in bacteria, they are sufﬁcient for energy transduction. CI evolved from
functional preexisting modules (Friedrich and Weiss 1997; Friedrich et al. 1993) being the 
last common ancestor of all present-day version of CI, the same as NiFe-hydrogenases, 
an 11 subunit version of the enzyme that harbored a NiFe-active site on NuoD (NDUFS2) 
(Moparthi and Hagerhall 2011). By phylogenetic analyses, it was stated that the origin of 
CI central subunits lies in different types of hydrogeneases (Brandt 2006). The N-module 
subunits have homology to NAD+ reducing hydrogenases, with the exception of one 
subunit, NuoG (NDUFS1), that resembles the Fe-only and molybdenopterin containing
enzymes (Sazanov and Hinchliffe 2006). The Q-module subunits show homology to 
[NiFe]-hydrogenases (Mathiesen and Hagerhall 2003; Vignais and Billoud 2007), which are 
Nucleoid
Prokaryotic cell
Nuclear membrane
and endoplasmic reticulum 
Cell membrane
infoldings
First eukaryote
Proteobacterium 
Ancestors of animals, 
fungi and other heterotrophs
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broadly distributed in the Bacteria and Archaea domains. They consist of a large subunit
that contains the [NiFe] active site and a small subunit that contains Fe/S cluster(s). They 
couple the oxidation of ferredoxin to proton reduction, which is coupled to the generation 
of membrane potential through ion pumping, a mechanism analogous to the one
described above for CI. Lastly, the proton pumping module has subunits homologous to 
Mrp-like antiporters (Mathiesen and Hagerhall 2003), that probably contain H+ channels 
and thus, participate in proton translocation. 
Besides that, to achieve the actual CI, a series of modiﬁcations of the [NiFe]-hydrogenase 
were required. This involved adjustments in its active site, acquisition of a quinone 
binding site, and a NADH module, and gaining additional subunits (Friedrich and Scheide 
2000). These are the so called accessory subunits (Carroll et al. 2006; Balsa et al. 2012) and
their function is still another unsolved question.
Understanding how this complex is made will not only help us to advance our 
understanding of evolution, metabolism and disease but will also allow us to provide a 
better diagnosis and therapeutic approaches for patients. 
Aim of the thesis
Human CI is an intricate enzyme and its role and functioning still leaves open numerous 
questions. For example, why does the complex contain 44 different subunits, whereas,
only fourteen subunits are sufﬁcient to perform the enzymatic reaction of NADH 
oxidation to NAD+, and to contribute to the proton gradient required for ATP production. 
Another important issue concerns the regulation of the assembly of CI. How is CI assembly 
regulated in response to the energetic demand, and does this differ per tissue? How is 
the communication between the mitochondrial and nuclear genome regulated? How
is CI assembly coordinated in the context of the other respiratory chain complexes and
supercomplexes? To better understand these questions, it is necessary to understand the 
biogenesis of CI in health and disease.
The aim of this thesis is to elucidate the assembly pathway of CI. For this reason, we
formulated the following questions: Is there a ﬁxed order of the assembly of the subunits? 
And if so, what is the order? Which other proteins, the so-called assembly factors, are
involved in CI assembly? Which are the crucial steps? How is the regulation between 
nuclear and mitochondrial encoded subunits? How is CI assembly interconnected
with the other respiratory chain complexes, and the formation of respiratory chain
supercomplexes? How is CI assembly affected in disease?
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Outline of the thesis
To provide a medical context, I start this thesis with an overview of mitochondrial 
disorders caused by oxidative phosphorylation defects (Chapter 2). It describes that 
there is a large number of genes required to obtain a proper functioning OXPHOS system. 
Therefore, there are many genetic defects possible that can cause mitochondrial diseases. 
This chapter, also gives a good indication of the broad spectrum of clinical phenotypes 
associated with these disorders. 
As the focus of this thesis is CI, and how this complex is being assembled, in Chapter 3
we provide a state-of-the-art background on this topic. These chapters mark the starting 
point for our experimental work described in this thesis. 
Shortly after, we wrote Chapter 4. Our group provided experimental data (Guerrero-
Castillo et al. 2017) to elucidate the whole CI assembly pathway in 143B osteosarcoma cells.
Excitingly, this pathway was very similar to our one presented in Chapter 3. In addition, 
this work identiﬁed several proteins as possible CI assembly factors. One of these proteins 
was TMEM70, a protein which has been described as a complex V assembly protein. Based 
on this ﬁnding, in chapter 4, we explored its putative role in CI assembly.
In Chapters 5-9 we studied the molecular defects in different CI deﬁcient patients. Thanks 
to our detailed knowledge of the CI assembly pathway we could address the speciﬁc effect 
of gene alterations and their role in CI disorders.
The study of CI assembly in patients enabled us:
– to establish the role in disease of novel assembly factor (Chapter 5)
– to ﬁnd new disease phenotypes associated by gene alterations in assembly factors and 
pinpoint their place in the assembly pathway (see Chapter 6 and 7). 
– to establish the role of a genetic alteration in disease and provide a relation with the
severity of the biochemical defect and the clinical phenotype (Chapter 8 and 9). 
In Chapter 9, we also propose a new concept to explain the phenotypical diversity in CI 
deﬁciency in a small family. The synergestic effect of heterozygous mutations, in this 
case, a homoplasmic mitochondrial encoded CI subunit alteration and a heterozygous 
nuclear encoded CI subunit alteration.
Chapter 10 entails the overall conclusions of this thesis ending with a discussion about
how this knowledge will beneﬁt our current state of the ﬁeld. I will also mention important 
open questions which should be addressed in the future.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 23
Introduction 23
References
Anderson, S., A. T. Bankier, B. G. Barrell, M. H. de Bruijn, A. R. Coulson, J. Drouin, I. C. Eperon, 
D. P. Nierlich, B. A. Roe, F. Sanger, P. H. Schreier, A. J. Smith, R. Staden, and I. G. Young. 1981. 
‘Sequence and organization of the human mitochondrial genome’, Nature, 290: 457-65.
Andrews, R. M., I. Kubacka, P. F. Chinnery, R. N. Lightowlers, D. M. Turnbull, and N. Howell. 1999.
‘Reanalysis and revision of the Cambridge reference sequence for human mitochondrial
DNA’, Nature Genetics, 23: 147.
Archibald, J. M. 2015. ‘Endosymbiosis and Eukaryotic Cell Evolution’, Current Biology, 25: R911-21.
Balsa, E., R. Marco, E. Perales-Clemente, R. Szklarczyk, E. Calvo, M. O. Landazuri, and J. A.
Enriquez. 2012. ‘NDUFA4 is a subunit of complex IV of the mammalian electron transport 
chain’, Cell Metab, 16: 378-86.
Brandt, U. 2006. ‘Energy converting NADH:quinone oxidoreductase (complex I)’, Annual Review 
of Biochemistry, 75: 69-92.
Carroll, J., I. M. Fearnley, J. M. Skehel, R. J. Shannon, J. Hirst, and J. E. Walker. 2006. ‘Bovine 
complex I is a complex of 45 different subunits’, Journal of Biological Chemistry, 281: 32724-7.
DiMauro, S., and C. Garone. 2010. ‘Historical perspective on mitochondrial medicine’, Dev 
Disabil Res Rev, 16: 106-13.
Elurbe, D. M., and M. A. Huynen. 2016. ‘The origin of the supernumerary subunits and assembly
factors of complex I: A treasure trove of pathway evolution’, Biochimica et Biophysica Acta,
1857: 971-9.
Formosa, L. E., M. G. Dibley, D. A. Stroud, and M. T. Ryan. 2017. ‘Building a complex complex: 
Assembly of mitochondrial respiratory chain complex I’, Seminars in Cell and Developmental
Biology.
Friedrich, T., and D. Scheide. 2000. ‘The respiratory complex I of bacteria, archaea and eukarya
and its module common with membrane-bound multisubunit hydrogenases’, FEBS Letters, 
479: 1-5.
Friedrich, T., U. Weidner, U. Nehls, W. Fecke, R. Schneider, and H. Weiss. 1993. ‘Attempts to deﬁne
distinct parts of NADH:ubiquinone oxidoreductase (complex I)’, Journal of Bioenergetics and
Biomembranes, 25: 331-7.
Friedrich, T., and H. Weiss. 1997. ‘Modular evolution of the respiratory NADH:ubiquinone 
oxidoreductase and the origin of its modules’, Journal of Theoretical Biology, 187: 529-40.
Giachin, G., R. Bouverot, S. Acajjaoui, S. Pantalone, and M. Soler-Lopez. 2016. ‘Dynamics of 
Human Mitochondrial Complex I Assembly: Implications for Neurodegenerative Diseases’, 
Front Mol Biosci, 3: 43.
Guaras, A. M., and J. A. Enriquez. 2017. ‘Building a Beautiful Beast: Mammalian Respiratory 
Complex I’, Cell Metab, 25: 4-5.
Guerrero-Castillo, S., F. Baertling, D. Kownatzki, H. J. Wessels, S. Arnold, U. Brandt, and L. 
Nijtmans. 2017. ‘The Assembly Pathway of Mitochondrial Respiratory Chain Complex I’, Cell
Metab, 25: 128-39.
Gustafsson, C. M., M. Falkenberg, and N. G. Larsson. 2016. ‘Maintenance and Expression of 
Mammalian Mitochondrial DNA’, Annual Review of Biochemistry, 85: 133-60.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 24
24 Chapter 1
Hirst, J. 2013. ‘Mitochondrial complex I’, Annual Review of Biochemistry, 82: 551-75.
Hirst, J., and M. M. Roessler. 2016. ‘Energy conversion, redox catalysis and generation of reactive
oxygen species by respiratory complex I’, Biochimica et Biophysica Acta, 1857: 872-83.
Mathiesen, C., and C. Hagerhall. 2003. ‘The ‘antiporter module’ of respiratory chain complex
I includes the MrpC/NuoK subunit -- a revision of the modular evolution scheme’, FEBS
Letters, 549: 7-13.
Mitchell, P. 1966. ‘Chemiosmotic coupling in oxidative and photosynthetic phosphorylation’, 
Biological Reviews of the Cambridge Philosophical Society, 41: 445-502.
Moparthi, V. K., and C. Hagerhall. 2011. ‘The evolution of respiratory chain complex I from 
a smaller last common ancestor consisting of 11 protein subunits’, Journal of Molecular 
Evolution, 72: 484-97.
Roger, A. J., S. A. Munoz-Gomez, and R. Kamikawa. 2017. ‘The Origin and Diversiﬁcation of
Mitochondria’, Current Biology, 27: R1177-R92.
Sagan, L. 1967. ‘On the origin of mitosing cells’, Journal of Theoretical Biology, 14: 255-74.
Sanz, A. 2016. ‘Mitochondrial reactive oxygen species: Do they extend or shorten animal
lifespan?’, Biochimica et Biophysica Acta, 1857: 1116-26.
Sazanov, L. A., and P. Hinchliffe. 2006. ‘Structure of the hydrophilic domain of respiratory 
complex I from Thermus thermophilus’, Science, 311: 1430-6.
Stein, L. R., and S. Imai. 2012. ‘The dynamic regulation of NAD metabolism in mitochondria’,
Trends in Endocrinology and Metabolism, 23: 420-8.
Urra, F. A., F. Munoz, A. Lovy, and C. Cardenas. 2017. ‘The Mitochondrial Complex(I)ty of Cancer’,
Frontiers in Oncology, 7: 118.
Vignais, P. M., and B. Billoud. 2007. ‘Occurrence, classiﬁcation, and biological function of
hydrogenases: an overview’, Chemical Reviews, 107: 4206-72.
Vinogradov, A. D., and V. G. Grivennikova. 2016. ‘Oxidation of NADH and ROS production by
respiratory complex I’, Biochimica et Biophysica Acta, 1857: 863-71.
Wirth, C., U. Brandt, C. Hunte, and V. Zickermann. 2016. ‘Structure and function of
mitochondrial complex I’, Biochimica et Biophysica Acta, 1857: 902-14.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 25
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 26
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 27
chapter 2 Oxidative Phosphorylation 
System: Nuclear Genes and Genetic
Disease
aura Sánchez-CabL  allero1* ngin Baertlabia  , F 2* ansmtLeo N, ji 1 Jan AM Snd   a meitink1
1  edicine Radbouddrial Mn , ho  ent of Pediatrics Radboud Centerepartm for MitD ,      oc
dsedical Center, Nijmegen, The Netersity M herlanvUni
2 gyiatric Cardiolode P , UniversityGeneral Pediatrics, Neonatology aepartment of D nd
ersity, Düsseldorf, Germanyvren’s Hospital Düsseldorf, Heinrich Heind ie UnlChi
* contributed equally
hed in eLS. John Wiley & Sons Ltd, siPubl
chester October 2017ihC
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 28
28 Chapter 2
Abstract
The mitochondrial oxidative phosphorylation (OXPHOS) system is located in the inner 
mitochondrial membrane, and it is the major energy provider of the cell. It consists of ﬁve
multiprotein complexes (complex I–V). Defects in one or several of these enzymes cause 
mitochondrial disorders. Identifying underlying mutations within the nuclear genome has 
been an arduous task until the widespread use of whole exome sequencing in recent years. 
Since then, a big effort has been put into deciphering underlying mutations in nuclear 
genes that directly or indirectly affect the OXPHOS system. This led to the discovery of a
great number of new gene defects involved in these multifaceted diseases. These ﬁndings 
not only improved the diagnostic process but also helped to understand the mechanisms 
behind mitochondrial diseases and laid the groundwork for novel approaches to therapy. 
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Introduction
Inherited mitochondrial diseases are caused by defects in the pyruvate oxidation that 
comprises the Krebs cycle and the oxidative phosphorylation (OXPHOS) system. The latter 
consists of ﬁve enzymes that are embedded into the inner mitochondrial membrane. 
The OXPHOS complexes include the four respiratory chain enzymes (complexes I–IV) and 
complex V, also termed ATP (adenosine triphosphate) synthase. The coordinated transport
of electrons by the respiratory chain enzymes, which is aided by the electron carriers 
coenzyme Q and cytochrome c, is coupled to the translocation of protons across the inner
mitochondrial membrane. This produces an electrochemical gradient that, in turn, fuels
the production of the cell’s universal energy currency, ATP, by complex V (Figure 1). 
ﬁgure 1 | Scheme of the OXPHOS (oxidative phosphorylation) system in mammalian mitochondria. 
Electrons (e−) from carbon oxidations are transferred via NADH (nicotinamide adenine dinucleotide) 
into OXPHOS complex I, which is embedded in the lipid bilayer of the mitochondrial inner
membrane (IMM), then transported to coenzyme Q (Q). Some electrons from organic-acid
oxidations are transferred, via other ﬂavin-containing enzyme complexes directly to CoQ. CoQ
delivers electrons via complex III and cytochrome c (Cyt c) to the ﬁnal electron acceptor complex 
IV. Here, oxygen is reduced to water. The electrons lose free energy at each transfer step, and
in complexes I, III and IV, the energy is harnessed and coupled to the movement of H+ from the 
mitochondrial matrix to the intermembrane space (IMS). The proton gradient thus generated is
used for the production of ATP by complex V. Except for complex II, all complexes contain some 
proteins encoded by the mitochondrial genome and others encoded by the nuclear genome. The 
number of subunits for each complex is indicated.
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Mitochondria contain their own protein translation apparatus and their own DNA
(deoxyribonucleic acid) that encodes 37 genes, including 13 of the OXPHOS complex 
subunits. With the exception of complex II, all OXPHOS complexes consist of nuclear DNA-
encoded and mitochondrial DNA-encoded subunits and, thus, underlie a dual genomic 
control. A large number of additional nuclear-encoded proteins are required for proper
subunit synthesis and OXPHOS complexes biogenesis. These are required for processes 
including transcription, translation, posttranslational modiﬁcation, mitochondrial 
import, addition of cofactors and insertion of subunits as well as stabilisation and 
connection of assembly intermediates. 
Mitochondrial diseases caused by defects in the OXPHOS system give rise to a broad
spectrum of clinical signs and symptoms ranging from mild adult-onset myopathy to 
neonatal-onset fatal multisystem disease (Lightowlers et al., 2015). OXPHOS deﬁciency 
mainly affects tissues with a high-energy demand such as the brain, the heart and skeletal 
muscles. Generally, it can not only involve any organ system and cause any symptom but
also it can manifest at any age and follow every mode of inheritance. However, there seems
to be a clear tendency towards severe early-onset phenotypes with rapid progression
when it comes to disease caused by mutations in nuclear-encoded gene (Lightowlers et 
al., 2015).
The lack of symptom speciﬁcity poses a great challenge for diagnostic process. Enzyme
analysis of the individual OXPHOS enzymes in a skeletal muscle biopsy or ﬁbroblasts 
derived from a skin biopsy and nuclear or mitochondrial gene analyses represent the
most common diagnostic tools. Since the 1960s, thousands of patients with isolated
(one enzyme complex involved) or combined (two or more enzyme complexes involved)
deﬁciencies have been diagnosed by enzyme activity measurements of the OXPHOS
system. However, not only has sequencing of the entire mtDNA and its relatively small 
number of genes become standard procedure, the past decade has also given rise to the 
method of whole exome sequencing, which allows high-throughput sequencing of nearly
the entire protein-encoding nuclear DNA fraction. It has led to the rapid discovery of a
large and still growing number of new genes defects associated with OXPHOS enzyme 
deﬁciencies (Haack et al., 2012).
OXPHOS defects can be caused not only by mutations in genes encoding subunits of 
the respective complex but also by defects in nuclear genes encoding proteins required 
for OXPHOS complex biogenesis, mitochondrial translation or mitochondrial redox 
homeostasis. In this article, our focus lies on nuclear gene defects that lead to isolated or
combined OXPHOS deﬁciency.
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Clinical Features of OXPHOS Deﬁciency
‘Mitochondrial disease’ is an umbrella term that refers to a heterogeneous group of 
inherited mitochondrial disorders, which most commonly affect tissues with high-energy
demands (Alston et al., 2017). One of the most outstanding features of mitochondrial
diseases is their great variability in terms of clinical symptoms and in the number and 
types of organ systems involved. The minimum disease prevalence is estimated to be
about 12 per 100 000 in adults and 5 per 100 000 in children.
Mitochondriopathies can manifest at every age, yet patients with nuclear gene mutations 
more commonly develop childhood-onset disease and severe disease phenotypes with
involvement of the central nervous system (Lightowlers et al., 2015). In adult-onset disease, 
mtDNA mutations are generally more common. However, some nuclear gene mutations 
that cause severe phenotypes in children when present homozygously can cause milder 
late-onset diseases in a heterozygous state (i.e. POLG mutations) (Lightowlers et al., 2015).
As research on clinical manifestations of mitochondriopathies progresses, the borders 
delineating classic mitochondrial syndromes such Leigh syndrome and Alper’s syndrome
in children or presentations more common in adult life such as MERRF (myoclonic epilepsy 
and ragged red ﬁbres), LHON (Leber’s hereditary optic neuropathy) and chronic progressive 
external ophthalmoplegia are becoming more vague. In many cases, there seem to be 
overlapping or partial presentations of these syndromes and disease manifestations that 
do not adhere to these syndromes at all.
Isolated OXPHOS Complex Deﬁciency
Isolated complex I deﬁciency
Isolated complex I (NADH:ubiquinone oxidoreductase) deﬁciency is the most common 
cause of neonatal mitochondrial disease and accounts for approximately half of the cases. 
The clinical symptoms caused by isolated complex I deﬁciency associated with mutations 
in nuclear-encoded genes are very heterogeneous (Nouws et al., 2012).
Complex I is the largest OXPHOS complex and consists of 44 different subunits as well as 
prosthetic groups including ﬂavin mononucleotides and iron–sulfur clusters. It catalyses 
a redox reaction that dehydrogenates NADH (nicotinamide adenine dinucleotide) and 
shuttles electrons to coenzyme Q. Furthermore, it translocates protons across the inner 
mitochondrial membrane and thereby contributes to the aforementioned electrochemical
gradient. The enzyme is L-shaped with one arm integrated into the inner mitochondrial
membrane and a second arm protruding into the mitochondrial matrix (Zhu et al., 2016). 
Complex I can be subgrouped into three functional modules: the P-module (proton 
translocation), which represents the membrane arm, as well as the N-module (NADH
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dehydrogenase) and the Q-module (coenzyme Q reduction), which form the matrix arm 
of the enzyme.
Complex I consists of 37 nuclear-encoded subunits and 7 mitochondrial-encoded subunits 
(Table 1). Fourteen of these subunits including all mitochondrial-encoded subunits and
seven nuclear-encoded subunits are considered ‘core’ subunits because they execute the 
speciﬁc functions of complex I and are also present in bacteria. The remaining 30 nuclear-
encoded subunits are called accessory or supernumerary subunits. Most of these are 
required for proper complex I assembly (Stroud et al., 2016). As of 2017, disease-causing 
mutations have been identiﬁed in 27 mitochondrial complex I subunits, including all core 
subunits.
Complex I biogenesis is an extraordinarily intricate process: the different nuclear-encoded 
and mitochondrial-encoded subunits are brought together and assembled in numerous 
parallel and sequential steps. The process mirrors the complex modular architecture, as 
subunits of each functional module are assembled separately with little intermodular 
interaction until the ﬁnal steps of complex I assembly (Guerrero-Castillo et al., 2017).
Complex I biogenesis requires the action of the several so-called assembly factors that 
associate with complex I assembly intermediates or subunits during the assembly process
but are not part of holocomplex itself. At least 16 assembly factors exist and at least 10 of 
them are associated with human disease (Sanchez-Caballero et al., 2016).
Although an association with complex I subunits and assembly intermediates or a 
requirement for the assembly or stability of complex I has been proven for all assembly
factors, there is still a lack of mechanistic details or molecular functions for several of 
them. Most assembly factors associate with assembly intermediates of the membrane 
integrated P-module (Guerrero-Castillo et al., 2017). TMEM126B, which is one of these
P-module assembly factors, seems to be associated with speciﬁcally mild adult-onset 
phenotype characterised by exercise intolerance (Sanchez-Caballero et al., 2016).
Isolated complex II deﬁciency
Complex II (succinate: ubiquinone oxidoreductase) deﬁciency is rare among the OXPHOS 
defects and accounts for less than 10% of mitochondrial disease cases (Hoekstra and 
Bayley, 2013). Disease-causing biallelic mutations are associated with heterogeneous
severe phenotypes such as hypertrophic cardiomyopathy, leukodystrophy, Leigh syndrome 
and encephalopathy. Interestingly, there seems to be an overlap with susceptibility for 
speciﬁc neuroendocrine tumours, which is also present in patients carrying heterozygous
mutations (Timmers et al., 2009).
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Complex II has three traits that make it unique among the OXPHOS complexes: (1) it is
the only OXPHOS complex that consists of nuclear-encoded subunits but mitochondrial-
encoded subunits; (2) it is the only OXPHOS enzyme that does not pump protons across 
the inner mitochondrial membrane and (3) it functions as a part of the Krebs cycle and the
respiratory chain. It catalyses the oxidation of succinate to fumarate as part of the Krebs 
cycle and transfers electrons from FADH2 to coenzyme Q within the respiratory chain.
Complex II can be subgrouped into a soluble active dehydrogenase part and a hydrophobic 
membrane-bound part, both consisting of two subunits each. The soluble part consists 
of the 70-kDa ﬂavoprotein SDHA, which contains the active site and a covalently bound
FAD (ﬂavin adenine dinucleotide), and the 30 kDa iron–sulfur protein subunit SDHB, 
which carries three distinct iron–sulfur clusters as prosthetic groups. The hydrophobic 
membrane-bound fraction consists if the two subunits SDHC and SDHD. It anchors the 
soluble part to the matrix-facing side of the inner mitochondrial membrane. SDHC and
SDHD carry a cytochrome b558 and the ubiquinone-binding site (Table 1).
In 1995, the ﬁrst missense mutation in a nuclear gene encoding the SDHA in two siblings 
with Leigh syndrome was identiﬁed (Bourgeron, 1995). Identiﬁcation of further mutations 
followed, four complex II assembly factors (SDHAF1-4) whose assistance is pivotal
for the correct assembly of complex II (Van Vranken et al., 2015) have been described. 
Disease-causing mutations associated with mitochondrial disease have only been
described for SDHAF1 (Ghezzi et al., 2009), while mutations in SDHAF2 are associated 
with neuroendocrine tumours (Bayley et al., 2010). The molecular basis of the association 
between mitochondrial defects and carcinogenesis has yet to be clariﬁed.
Isolated complex III deﬁciency
Human complex III (ubiquinol:cytochrome c oxidoreductase) deﬁciency is one of the least 
frequently diagnosed conditions that lead to OXPHOS deﬁciency. The complex consists of
11 subunits, of which only cytochrome b is encoded by the mitochondrial genome (Table 
1). Complex III catalyses the electron transfer from reduced coenzyme Q to cytochrome 
b and eventually to cytochrome c, coupled with translocation of protons across the 
mitochondrial inner membrane. Human complex III is usually present as a homodimer 
(Iwata et al., 1998). Each monomer has a molecular mass of approximately 243 kDa. Only 3
of the 11 subunits that form complex III build the catalytic centre, and each of these carries
speciﬁc prosthetic groups: cytochrome b (two haem groups: bH and bL), cytochrome c1 (one
haem group: haem c1) and the Rieske protein (one iron–sulfur cluster) (Schagger et al., 
1995). The exact function of the rest of the supernumerary subunits remains unknown (Xia 
et al., 2013). The mechanism by which electrons are transferred through the redox centres 
and protons are translocated across the inner mitochondrial membrane is termed Q cycle 
(Crofts et al., 2008). The biogenesis of complex III has been extensively studied in yeast
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(Zara et al., 2009). It has been shown to follow a modular pathway and requires several 
assembly factors.
Pathogenic genomic variants have been described in the mitochondrial-encoded subunit 
cytochrome b, in four of the nuclear-encoded subunits and in ﬁve assembly factors
(Mordaunt et al., 2015). While exercise intolerance is a common and recurring feature of 
mitochondrial-encoded cytochrome b mutations (Andreu et al., 1999), defects in the nuclear-
encoded subunits and assembly factors cause a broad spectrum of severe symptoms.
Isolated complex IV deﬁciency
Complex IV (cytochrome c oxidase) deﬁciency is one of the frequently diagnosed 
conditions in patients with inherited mitochondrial disease and makes up for every 
fourth case (Ostergaard et al., 2015). It is the terminal enzyme of the respiratory chain and
catalyses the transfer of electrons from reduced cytochrome c to molecular oxygen and
translocates protons across the mitochondrial inner membrane. The enzyme is composed
of 14 subunits and contains several prosthetic groups including 2 copper centres, 2 haem
groups, 1 magnesium ion and 1 zinc ion (Balsa et al., 2012). Three complex IV subunits
are encoded by the mitochondrial genome and 11 by the nuclear genome (Table 1). The 
mitochondrial-encoded subunits, termed COX1, COX2 and COX3, form the evolutionarily 
conserved core of the enzyme, in which the redox reaction takes place. The 11 nuclear-
encoded subunits surround the enzyme’s core and the precise function of most of them
is known. It has been suggested that their role lies in assembly, stability or functional 
regulation (Fornuskova et al., 2010). Complex IV is almost entirely embedded into the 
inner mitochondrial membrane. The majority of complex IV subunits are hydrophobic
proteins that contain transmembrane domains anchoring them. The exceptions are three 
peripheral hydrophilic subunits that adhere to the holocomplex via interaction with other 
subunits. These include COX6B, which faces the intermembrane space, and COX5B and 
COX5A, which face the mitochondrial matrix.
The ﬁrst human complex IV biogenesis model was established in 1998 and suggested a
strictly sequential process, in which subunits and cofactors are integrated into distinct
assembly intermediates that eventually build the fully assembled holocomplex. It 
was suggested that complex IV assembly begins with the membrane integration of its
largest core subunit COX1, which was considered the ﬁrst assembly intermediate termed 
S1. Subsequently, a preformed heterodimer of COX4 and COX5A was assumed to be
connected to COX1 to form the intermediate S2, followed by the insertion of COX2 and 
COX3 to complete the structural core. Integration of the remaining subunits was proposed 
to lead to the formation of the fully assembled complex.
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This sequential approach has since been challenged by a module-based complex IV 
assembly model, in which the order of events was suggested to be slightly different 
(Vidoni et al., 2017). It was proposed that modules containing several subunits and 
assembly factors, which are anchored to one of the three core subunits, are preassembled 
before being sequentially connected to each other.
Mutations in the genes encoding core subunits COX1, COX2 and COX3 were the ﬁrst
structural complex IV components to be associated with complex IV deﬁciency. Since the 
year 2008, the increasing use of whole exome sequencing has led to the discovery over 
disease-causing mutations on 7 of the 11 nuclear-encoded subunits.
The amount of complex IV assembly factors outnumbers its subunits with over 20 known
assembly factors. Mutations have been identiﬁed in nuclear genes encoding a large 
number of these proteins, which exert a number of different functions (Ostergaard et al., 
2015): (1) early assembly of complex IV (SURF1, COA5 and FAM36A, COA6, COA3), (2) for the
transcription and translation of complex IV subunits (LRPPRC, TACO1 and COX14), (3) haem 
a biosynthesis (COX10, COX15 and PET117) and (4) biogenesis of the copper site of subunit 
COX2 (SCO1 and SCO2). Further mutations have been identiﬁed in genes encoding PET100 
that is assumed to play a role in the intermediate stages of COX assembly, and encoding
FASTKD2, whose function is yet to be unravelled (Ghezzi et al., 2008; Lim et al., 2014).
Isolated complex V deﬁciency
Human complex V (F0–F1 ATP synthetase) consists of 18 subunits of which two are 
encoded by the mitochondrial genome (Table 1). Complex V catalyses the synthesis of ATP
from ADP (adenosine diphosphate) and phosphate using the energy stored within the
proton gradient across the inner mitochondrial membrane generated by complexes I, III
and IV (Abrahams et al., 1994). Furthermore, complex V plays a role in the formation of 
mitochondrial cristae (Jiko et al., 2015).
It contains a membrane inserted part, termed F0, and a part protruding into the
mitochondrial matrix named F1. These are connected by central and peripheral stalks. In 
the F1 part, ATP is synthesised. The F0 part functions as a rotor that gains its energy from
the proton motive force and transfers it to the F1 part.
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table 1 | Recopilation of all subunits and assembly factors of the OXPHOS system.  
The subunits that start with “MT” are mitochondrial encoded, the rest are all nuclear encoded.
Subunits Assembly factors
Complex I
NDUFV1, NDUFV2, NDUFS1, NDUFA2, NDUFS4, 
NDUFV3, NDUFA12, NDUFS6, NDUFA7,
NDUFAB1, NDUFA6, NDUFA9, NDUFA5, 
NDUFS2, NDUFS3, NDUFS7, NDUFS8, MTND1, 
NDUFA3, NDUFA8, NDUFA13, MTND6, MTND3, 
MTND2, NDUFC1, NDUFC2, NDUFA10, NDUFS5,
NDUFB1, NDUFA11, NDUFB5, NDUFB6, 
NDUFB10, NDUFB11, MTND4, MTND4L, 
NDUFB4, NDUFB7, NDUFB8, NDUFB3, MTND5, 
NDUFB9, NDUFB2, NDUFA1
NDUFAF1, NDUFAF2, NDUFAF3, 
NDUFAF4, NDUFAF5, NDUFAF6, 
FOXRED1, NUBPL, TIMMDC1, 
ECSIT, ACAD9, TMEM126B, 
NDUFAF7, c17orf89, ATP5SL, 
DMAC1
Complex II SDHA, SDHB, SDHC, SDHD
SDHAF1, SDHAF2, SDHAF3, 
SDHAF4
Complex III
MTCYB, UQCRC1, UQCRB, CYC1, UQCRC2,
UQCRFS1, UQCRH, UQCRQ, UQCR10, UQCR11
BSC1L, LYRM7, UQCC1, UQCC2, 
UQCC3, TTC19, PTCD2
Complex IV
MTCO1, MTCO2, MTCO3, COX4, COX5A, COX5B, 
COX6A, COX6B, COX6C, COX7A, COX7B,
COX7C, COX8, NDUFA4
COA1, COA3, COA4, COA5, 
COA6, COA7, COX10, COX11,
COX14, COX15, COX16, COX17, 
COX18, COX19, COX20, SCO1,
SCO2, SURF1, PET117, LRPPRC, 
PET100, CEP89, TACO1, APOPT1, 
FASTKD2
Complex V
MTATP6, MTATP8, ATP5A, ATP5B, ATP5C1, 
ATP5D, ATP5E, ATP5F1, ATP5G1, ATP5G2, 
ATP5G3, ATP5H, ATP5I, ATP5O, ATP5J, ATP5J2, 
ATP5L, ATP5L2
ATPAF1, ATPAF2, TMEM70
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Although isolated complex V deﬁciency caused by nuclear gene mutations has already 
been shown in 1999 (Houstek et al., 1999), it took until 2004 for a speciﬁc mutation to
be found in the ATPAF2 gene (De Meirleir et al., 2004). So far, a relatively small number 
of subunits and assembly factors have been identiﬁed as cause of isolated complex V 
deﬁciency. ATPAF2 and TMEM70 are the only assembly factors and ATP5A1 and ATP5E are 
the only nuclear-encoded subunits for which mutations have been described.
Combined Respiratory Chain Deﬁciency
Deﬁciency of more than one respiratory chain enzyme is a very common, perhaps the most 
common ﬁnding in the diagnostic process of mitochondrial energy metabolism (Mayr et
al., 2015). The combinations of affected enzymes can vary. The molecular mechanisms
behind combined respiratory chain complex deﬁciency can be roughly grouped into 
four categories (Mayr et al., 2015): (1) Defects of mitochondrial DNA maintenance and
translation (i.e. mitochondrial ribosomal subunits and mtDNA polymerases), (2) cofactor 
deﬁciency (i.e. coenzyme Q) and (3) impaired mitochondrial homeostasis (i.e. factors 
required for lipid metabolism or redox homeostasis).
Defects of mitochondrial DNA maintenance and translation
Nuclear gene mutations that affect mitochondrial DNA processing and translation can
lead to several combinations of OXPHOS complex deﬁciencies but usually does not affect 
complex II as it only consists of nuclear-encoded subunits.
Mitochondrial DNA replication relies on very few proteins (Holt and Jacobs, 2014). 
Its deﬁciency leads to mtDNA instability that, in turn, causes accumulating mtDNA
mutations. So far, nuclear DNA mutations have been described in POLG and POLG2 genes,
which encoded polymerase gamma and one of its accessory subunits, respectively (Van
Goethem et al., 2001; Longley et al., 2006). Another protein involved in this process is the 
Twinkle helicase (Spelbrink et al., 2001). Interestingly, mutations in the aforementioned 
three proteins were predominantly described in patients who developed progressive 
external ophthalmoplegia. Additional genes with known disease-causing mutations 
include MGME1, encoding an exonuclease, and DNA2, encoding a DNA replication helicase 
and nuclease.
The replication process relies on nucleotides being provided as DNA building bricks. 
Several disease-causing mutations have been identiﬁed in nuclear-encoded proteins that 
process, modify or deliver them. Some examples include deoxyguanosine kinase (DGUOK) 
(Mandel et al., 2001), succinyl CoA ligase subunit alpha (SUCLG1) (Ostergaard et al., 2007)
and the adenine nucleotide translocator (ANT1, SLC25A4) (Kaukonen et al., 2000).
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In the ﬁrst steps of mitochondrial DNA transcription, a large polycistronic RNA (ribonucleic 
acid) transcript is generated that requires processing in order to produce the mRNAs 
encoding OXPHOS complex subunits and the tRNAs and rRNAs required for mitochondrial 
translation. The 5’ end and the 3’ end of the transcript are cleaved by RNase P and RNase 
Z, respectively. Nuclear disease-causing mutations have been identiﬁed in the genes 
encoding RNase Z (ELAC2) and in HSD17B10, which encodes a subunit of RNase P. Both led
to an accumulation of unprocessed RNA transcripts. After cleaving, the mRNA transcripts
are polyadenylated by MTPAP (Mitochondrial Poly(A) Polymerase). Mutation in the gene 
encoding this protein leads to a loss of polyadenylation and a clinical phenotype of spastic
ataxia (Crosby et al., 2010).
Mitochondrial tRNAs are heavily modiﬁed posttranscriptionally in order to ensure precise 
interactions of codons and anticodons. These tRNA modiﬁcations are catalysed by 
numerous enzymes with known disease-causing mutations in genes encoding them such 
as TRMU or MTO1. Interestingly TRMU mutations seem to be predominantly associated 
with liver failure, while MTO1 mutations consistently cause hypertrophic cardiomyopathy
(Ghezzi et al., 2012).
After processing and polyadenylation of mitochondrial mRNAs, these are translated.
Mitochondria contain their own ribosomes, which consist of a large 39S and a small 28S 
portion. These are built by over 80 nuclear-encoded mitoribosomal subunits. Mutations
have been identiﬁed in subunits of the 39S part (MRPL3, MPRL12 and MRPL44) and the 28S 
part (MRPS16 and MPRS22). An important prerequisite for proper translation is loading of 
the tRNAs with their respective amino acid. This is facilitated by sever aminoacyl-tRNA-
synthetases. A total of 19 of these proteins have been identiﬁed and disease-causing
mutations are known for almost all of them (Mayr et al., 2015).
The process of translation itself is regulated by external factors such as elongation factors, 
for which disease-causing have been identiﬁed including elongation factors G (GFM1), Ts 
(TSFM) and Tu (TUFM).
Cofactor deﬁciency
Coenzyme Q, also termed ubiquinone, and cytochrome c function as electron carriers in 
the respiratory chain. Coenzyme Q carries electrons from complexes I and II to complex III,
whereas cytochrome c transfers electrons from complex III to complex IV.
Given its function, coenzyme Q deﬁciency typically leads to combined deﬁciency of 
complexes I and III or complexes II and III (Mayr et al., 2015). It is most commonly caused 
by defects in its biosynthesis, which takes place in the mitochondria. Enzymes involved in 
this process and associated with human disease include PDSS1, PDSS2, COQ2 and COQ6.
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Further regulatory factors of coenzyme Q biosynthesis with known mutations include 
ADCK3, COQ4 and COQ9.
The fact that coenzyme Q can be supplemented has given promising prospects for the 
treatment of these diseases, despite bioavailability being a matter of debate (Baertling et 
al., 2014).
Impaired mitochondrial homeostasis
Mitochondrial homeostasis largely depends on the synthesis of lipids of the mitochondrial
membranes that are not part of the lipid bilayer. Additional factors include redox 
homeostasis, protein import or degradation as well as fusion and ﬁssion.
Most of the nonlipid bilayer lipids are produced inside the mitochondria. The two lipids
most relevant to human disease include cardiolipin and phosphatidylglycerol. Cardiolipin 
plays an important role in Barth syndrome and is associated with combined respiratory
chain defects (Barth et al., 1983). The syndrome is characterised by the symptom 
combination of neutropenia and cardioskeletal myopathy and is caused by mutations in
the X-chromosomal gene encoding the protein Taffazin, which is required for cardiolipin
remodelling (Vreken et al., 2000).
Cardiolipin is synthesised from phosphatidic acid. Synthesis of the latter from 
diacylglycerol is impaired in Sengers syndrome (Mayr et al., 2012), which causes congenital 
cataracts and mitochondrial myopathy (Sengers et al., 1975). Altered phospatidylglycerol
composition caused by SERAC1 mutations is a feature of MEGDEL syndrome (Wortmann et 
al., 2012) that leads to encephalopathy, deafness and Leigh syndrome.
Despite the large number of protein involved in protein import and export, only a few 
disease-causing mutations have been identiﬁed in genes encoding protein involved in 
this process. Mutations in TIMM8A, which encodes an inner membrane protein required 
for protein import, have been identiﬁed in patients with combined respiratory chain 
deﬁciency and Mohr-Tranebjaerg syndrome, which is characterised by deafness, blindness 
and dystonia (Mohr and Mageroy, 1960).
Thioredoxin 2 is a mitochondrial protein needed for the control of mitochondrial redox
homeostasis, apoptosis regulation and cell viability. Mutations have been shown to be
associated with increased reactive oxygen species and hampered defence against oxidative
stress, which, in turn, causes secondary OXPHOS impairment (Holzerova et al., 2016). The 
disease phenotype includes an early-onset neurodegenerative disorder characterised by 
cerebellar atrophy, epilepsy, dystonia and optic atrophy (Holzerova et al., 2016).
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Conclusions
Whole exome sequencing has signiﬁcantly improved the diagnostic process and the 
understanding of the mechanisms behind mitochondrial diseases caused by nuclear gene 
defects. However, for most gene defects, there is no clear genotype–phenotype correlation,
and it remains elusive why the same genetic variants cause different phenotypes. Most 
nuclear gene defects that cause mitochondrial disease lead to a severe and early-onset 
phenotype. The treatment of these disorders remains a great challenge that has to be 
tackled in the coming years.
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Abstract
Mammalian complex I is composed of 44 different subunits and its assembly requires 
at least 13 speciﬁc assembly factors. Proper function of the mitochondrial respiratory 
chain enzyme is of crucial importance for cell survival due to its major participation in 
energy production and cell signaling. Complex I assembly depends on the coordination
of several, crucial processes that need to be tightly interconnected and orchestrated
by a number of assembly factors. The understanding of complex I assembly evolved 
from simple sequential concept to the more sophisticated modular assembly model 
describing a convoluted process. According to this model, the different modules assemble 
independently and associate afterwards with each other to form the ﬁnal enzyme. In this 
review, we aim to unravel the complexity of complex I assembly and provide the latest 
insights in this fundamental and fascinating process. 
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Introduction
One of the largest macromolecular complexes is mitochondrial complex I (Brandt 2006; 
Hirst 2013) which plays an important role in the cellular energy production. Complex I is
involved in respiratory electron transport and contributes to the generation of the proton
motive force needed for ATP synthesis. In addition complex I produces reactive oxygen 
species (ROS), which can be detrimental, but is also of importance for cell signaling (Drose
and Brandt 2012). Defects in this enzyme cause a severe disturbance of energy metabolism 
and often lead to severe inherited metabolic disorders such as Leigh Syndrome (Morris et
al. 1996) (MIM #256000).
Mammalian complex I is composed of 44 different subunits (Balsa et al. 2012; Carroll et 
al. 2006) and the assembly of the holocomplex requires the involvement of at least 13 
established assembly factors. From the 44 subunits, 37 are encoded in the nuclear DNA
and seven are encoded in the mitochondrial DNA. Out of these, the seven mitochondrially 
encoded and seven nuclear-encoded subunits are called central subunits, because 
they are also constituents of bacterial complex I and execute the core bioenergetic 
functions. The remaining 30 proteins are called accessory or supernumerary subunits. 
To comprehend the mechanisms involved, it is of pivotal importance to understand how 
these macromolecular complexes are assembled and how this assembly is regulated. 
Assembly factors play a role in the admittance of mitochondrial and nuclear encoded 
subunits or have been linked to the biogenesis of cofactors such as iron-sulfur clusters to 
form the functional enzyme. 
Complex I is an L-shaped molecule with a peripheral arm, protruding into the matrix, and 
a membrane arm, residing in the inner membrane (Vinothkumar, Zhu, and Hirst 2014;
Zickermann et al. 2015). The peripheral arm contains two functional blocks, the N (NADH 
binding) and the Q (Ubiquinone binding) modules, whereas the membrane arm consists 
of the P (Proton pumping) module (Brandt 2006).
Mechanistically, complex I assembly covers several processes that need to be tightly
regulated and interconnected to ensure a mature and functional complex. The process 
starts with the mitochondrial and nuclear transcription of complex I subunits and
assembly factors, continues with mitochondrial and cytosolic translation, import of
nuclear-encoded proteins, insertion of cofactors, and proceeds until the assembled
complex is completely inserted into the inner membrane. Many of these processes,
ranging from transcription to mitochondrial import are common with other complexes of 
the oxidative phosphorylation system (Hallberg and Larsson 2014). Others, like addition 
of cofactors and insertion into the membrane are speciﬁc for every complex and involve 
dedicated assembly factors (Ghezzi and Zeviani 2012; Nouws et al. 2012).
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In this review, we will give some insights about how proteins of complex I, encoded in the 
nucleus and in the mitochondria, reach their position in this gigantic enzyme and describe
the steps of the assembly pathway taking into account all the players described up to now. 
We will place particular emphasis on human complex I assembly. 
Mitochondrial import of nuclear-encoded subunits
During evolution of eukaryotes, seven of the ‘ancestral’ complex I genes were transferred 
from the mitochondrial DNA to the nuclear DNA (Stewart et al. 2008). Additionally, the
products of another 30 nuclear-encoded genes, which originated in mammals, contribute 
to the fully assembled enzyme. Furthermore, at least 13 proteins directly involved in the
correct assembly of the complex but absent in the mature enzyme, called assembly factors, 
are also encoded by the nucleus. These proteins are translated in the cytosol and have to
be delivered to their ﬁnal destination, the mitochondria. To ensure its proper delivery, 
the majority of these proteins contain a speciﬁc N-terminal signal presequence (Vogtle 
et al. 2009), also called mitochondrial targeting sequence (MTS) that will be removed
after import. Nevertheless, some proteins do not contain a cleavable MTS targeting them 
to mitochondria. These include three complex I assembly factors TMEM126B, FOXRED1
and TIMMDC1 (Table 1), as well as eleven subunits (NDUFA5, NDUFS5, NDUFC2, NDUFB10, 
NDUFB6, NDUFB9, NDUFB3, NDUFA3, NDUFA8, NDUFA13, NDUFB1) (Claros and Vincens 1996).
All nuclear encoded mitochondrial proteins must enter the mitochondria through the
translocase of the outer membrane (TOM) complex, located in the outer membrane of
the mitochondria. Proteins that need to be delivered into the intermembrane space have
two ways to reach it: directly via the TOM complex or being ﬁrst inserted into the inner 
membrane and then released into the intermembrane space by the inner membrane 
peptidase (IMP) (Glick et al. 1992; Mossmann, Meisinger, and Vogtle 2012). The majority of 
proteins that are directed to the inner membrane or to the mitochondrial matrix have an 
MTS required to transfer these preproteins from the TOM complex to the translocase of the
inner membrane 23 (TIM23) complex (Tamura et al. 2009; Lytovchenko et al. 2013; Bajaj et 
al. 2014; Waegemann et al. 2015; Bohnert, Pfanner, and van der Laan 2015; Kulawiak et al. 
2013). If a protein is targeted to the inner membrane it is inserted via lateral sorting by the 
TIM23 complex (Glick, Beasley, and Schatz 1992). And if its destination is the mitochondrial 
matrix (Figure 1), the TIM23 complex will require the cooperation with the presequence
translocase-associated motor, PAM. This process is dependent on the membrane potential 
(Lytovchenko et al. 2013; Popov-Celeketic et al. 2008; Chacinska et al. 2010; Schulz and
Rehling 2014; Dudek, Rehling, and van der Laan 2013). In the matrix, the MTS is removed by 
the mitochondrial processing peptidase (MPP). 
The transport of nuclear-encoded proteins across the inner membrane, including subunits 
of OXPHOS complexes, requires the electrochemical potential generated by complexes I,
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III and IV (Kulawiak et al. 2013; Dudek, Rehling, and van der Laan 2013). Thus, the import 
machinery is not only needed for the biogenesis of the mitochondrial electron transport
chain (ETC), but conversely the functionally assembled complexes are also indispensable 
for the protein import machinery. 
ﬁgure 1 | Origin and destiny of complex I subunits.
The majority of complex I proteins are synthesized in the cytosol and need to enter to the organelle 
through the translocase of the outer mitochondrial membrane (TOM complex). Then they are 
sorted into the different subcompartments within the mitochondrion: intermembrane space, 
inner membrane or matrix, depending on their localization in the ﬁnal enzyme. Intermembrane
space proteins directly leave the TOM complex to the intermembrane space side of the complex (1). 
If the destination is the inner membrane, they could ﬁrst be transported through the presequence 
translocase TIM23, be laterally released (3) and if necessary be cleaved by the inner membrane 
protease, IMP. Proteins destined to the matrix space go from the TOM complex to the TIM23 
complex and its associated import motor complex, PAM (4) where the mitochondrial processing 
peptidase, MPP, removes the MTS. Moreover the seven subunits of complex I with a mitochondrial 
origin need to be inserted into the inner membrane from the matrix side. This process involves the 
OXA machinery (4).
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In addition, there are several other links between the ETC and the import machinery. In 
yeast, Tim21, a subunit of TIM23 complex, has been connected to supercomplex formation
via direct interaction with a complex III subunit (van der Laan et al. 2006; Wiedemann et 
al. 2007; Dienhart and Stuart 2008). Although speciﬁc roles of TIM23 complex in complex
I are unknown, certain Tim proteins have been found in association with complex I. In 
plants, Tim23-2 has been shown to associate with complex I subunit B14.7 (NDUFA11) 
(Wang et al. 2012). Interestingly, the human orthologue of this the complex I subunit,
NDUFA11, belongs to the TIMM17-TIMM22-TIMM23 protein family, together with complex I
assembly factor TIMMDC1. This family of proteins lacks an MTS and contains at least two 
transmembrane domains. Another noteworthy link between mitochondrial protein import
and mitochondrial translation was established by the ﬁnding of association of Tim 21 and 
a complex IV assembly intermediate called MITRAC (mitochondria translation regulation
assembly intermediate of cytochrome c oxidase). Interestingly, there was shown also
association with Tim 21 and a NDUFB8 containing complex I assembly intermediate, 
suggesting a similar regulation between import and mitochondrial translation for
complex I (Mick et al. 2012). 
Another complex involved in the import is the TIM22 complex, a twin-pore carrier
translocase needed for the insertion of proteins with multiple transmembrane domains 
without a cleavable targeting sequence, and it also requires a normal membrane potential
as the energy source. NDUFA11 (Vinothkumar, Zhu, and Hirst 2014) and NDUFC2 (Zhu et al. 
2015) are the only accessory subunits of mammalian complex I that have more than one 
transmembrane domain making TIM22 complex a likely way for its insertion.
The last complex we are referring to in this section is the mitochondrial intermembrane
space assembly (MIA) machinery, which links import with oxidative folding of some 
intermembrane space proteins. It interacts with enriched cysteine substrates involved in 
binding cofactors and metals and in the formation of disulﬁde bonds (Tokatlidis 2005;
Koehler 2004). Subunits NDUFS5, NDUFA8 and NDUFB7 are small (<20 kDa) proteins 
located in the intermembrane space and contain conserved cysteine residues making
them good candidates to be inserted via the MIA machinery (Szklarczyk et al. 2011).
From mitochondrial translation to mitochondrial
membrane insertion
Seven highly hydrophobic subunits are encoded by the mitochondrial DNA: ND1, ND2, 
ND3, ND4, ND4L, ND5 and ND6 (Lazarou et al. 2009). Mitochondrial translation is tightly
connected to the inner membrane. It has been shown that mitochondrial ribosomes are 
mainly localized near the inner mitochon¬drial membrane (Pfeffer et al. 2015), where 
insertion of mem¬brane proteins likely occurs co translationally (Hallberg and Larsson 
2014). Given the hydrophobic nature of these proteins, the ribosome-inner membrane
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interaction is favorable for their rapid insertion into the membrane. A well characterized
mechanism for membrane insertion for some of these hydrophobic subunits from the
matrix to the inner membrane is the OXA machinery (review (Bohnert, Pfanner, and van 
der Laan 2015)), where the protein Oxa1 plays the main role (Figure 1) (Bonnefoy et al.
2009; Bonnefoy et al. 1994). Oxa1 has homologs in bacteria (YidC) and chloroplasts (Alb3) 
(Hennon et al. 2015), indicating its importance and conservation along the evolution. Oxa1 
connects the ribosome with the inner membrane, thereby coupling protein synthesis 
with membrane insertion (Szyrach et al. 2003; Jia et al. 2003). Oxa1L knockdown studies 
in human cells, showed no effect on complex IV or complex III, but instead assembly of 
complex V and, to a lower extent, of complex I were affected (Stiburek et al. 2007). 
Some ﬁndings indicate that TIM23, PAM and Oxa1 cooperate closely to ensure correct 
membrane insertion and quality control. It has been hypothesized that an efﬁcient
assembly of complex I critically depends on the coordination between the synthesis
and import of nuclear encoded subunits and the synthesis of mitochondrially encoded
subunits (Cagin and Enriquez 2015). This cross talk may prevent an accumulation of an 
excess of nuclear or mitochondrial proteins. The accumulation of immature or defective 
complexes is considered as a severe mitochondrial perturbation that can contribute to 
mitochondrial disorders by increasing the production of reactive oxygen species (ROS) by 
the incomplete ETC complexes (Koopman, Willems, and Smeitink 2012). Thereby, quality
control during cross talk between import and insertion of subunits from dual origin 
(Bohnert et al. 2010; Stoldt et al. 2012; Park et al. 2014) adds a third critical reciprocal link 
between function and biogenesis of the ETC complexes.
For complex I there are some indications, how its assembly is linked to membrane 
insertion and translation. Conservation analysis links assembly factor NDUFAF3 with the 
bacterial membrane-insertion gene cluster SecD/SecF/YajC (Saada et al. 2009). Membrane
extraction experiments are also in line with a role of NDUFAF3 in membrane insertion
as they show a possible alternation between NDUFAF3 in a soluble form and NDUFAF3
together with membrane-associated proteins (Zurita Rendon and Shoubridge 2012). 
Studies in human cells showed that depletion of early complex I assembly factors, among
them NDUFAF3, results in increased proteolysis of the ND1 subunit (Zurita Rendon and 
Shoubridge 2012) suggesting that assembly factors might stabilize ND1 in the membrane 
rather than regulating its translation.
The general processes outlined up to here should apply for all oxidative phosphorylation 
complexes of dual origin. For each of them, speciﬁc components and machineries 
are needed for proper assembly, which will be described in the following section for 
complex I. However, it should be noted that due to the enormous size and complexity of 
mitochondrial complex I, the overall picture of its biosynthesis is still far from complete.
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Assembly factors
To obtain fully assembled complex I the process requires a number of complex I speciﬁc 
assembly factors (Mimaki et al. 2012), which are not part of the ﬁnal mature complex. Most 
of these assembly factors have tight interactions with complex I subunits, but there are
probably still more to be discovered, which transiently interact with complex I subunits or
subassemblies. To date 13 assembly factors have been discovered, via homology (Janssen
et al. 2002), via LC-MS/MS (Andrews et al. 2013; Pagliarini et al. 2008), exome sequencing of 
complex I deﬁcient patients (Kevelam et al. 2013; Calvo et al. 2010; Tenisch et al. 2012; Saada 
et al. 2009; Ogilvie, Kennaway, and Shoubridge 2005; Saada et al. 2008; Fassone et al. 2015; 
Sugiana et al. 2008; Gerards et al. 2010), Protein-protein interactions (Andrews et al. 2013; 
Vogel, Janssen, et al. 2007; Nouws et al. 2010; Carilla-Latorre et al. 2010), or co-migration in
native gels (Heide et al. 2012). Mutations in nine of them are proven as disease causing due 
to impairments in complex I biogenesis (Table 1), whereas mutations in the others might
be lethal or remain to be discovered (Guarani et al. 2014; Zurita Rendon et al. 2014). 
Although for these 13 proteins their role in complex I assembly has been established, so 
far their detailed molecular function still needs to be elucidated. Some of these assembly
factors have been related to other function besides complex I assembly, perhaps linking 
complex I with other cellular processes within the cell.Apoptosis Inducing Factor (AIF-1),
was initially also characterized as a complex I assembly factor based on the occurring
complex I deﬁciency in AIF mutated mice, the Harlequin mouse (Vahsen et al. 2004; Joza
et al. 2005). More recent studies in patients demonstrated that AIF-1 mutations resulted
in a combined complex III/IV deﬁciency and mtDNA depletion (Ghezzi et al. 2010) or in 
a complex I and IV deﬁciency (Berger et al. 2011)This indicates that the complex I defect
induced by AIF might be indirect, possibly caused by complex I instability caused increased 
ROS levels. In addition, it is believed that more complex I assembly factors remain to be
discovered. This could include proteins which have been found to be associated with 
complex I assembly intermediates or complex I assembly factors, such as for example 
ATP5SL (Andrews et al. 2013). Nevertheless the role of in complex I assembly remains to 
be proven. In this review, we focus exclusively on the role in complex I assembly factors 
during complex I biogenesis.
Current view of the complex I assembly pathway
Studies of patients with mutations in complex I subunits or assembly factors have proven 
to be very useful for the identiﬁcation and characterization of assembly intermediates. In
fact, the ﬁrst indications for the existence of human complex I assembly intermediates
came from studies of complex I deﬁcient patients (Triepels et al. 2001; Antonicka et al. 2003). 
The presence of complex I subassemblies at molecular masses below the full-size complex 
indicated that the assembled process occurs in several steps (Antonicka et al. 2003). 
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However, based on such studies alone, the sequence of the steps in the overall pathway
remained controversial, because in patients a speciﬁc mutation may result in speciﬁc 
subassemblies deviating in composition and stability from those occurring during regular 
assembly. Compensatory cellular adaptations and difﬁculties in discerning assembly 
intermediates from degradation breakdown products further renders the interpretation
of the ﬁndings obtained from patient cells difﬁcult. Therefore, experimental approaches 
were developed to overcome this problem. In particular, monitoring the assembly process 
after restarting it with the addition and release of mitochondrial translation inhibitors 
in human cell lines has proven useful. As a result, the perspective on complex I assembly
evolved from a sequential process to a convoluted process as described by the modular
assembly model (Vogel et al. 2004), where submodules are independently built and then 
can associate with each other to form higher molecular mass intermediates and ﬁnally,
mature complex I and respiratory supercomplexes. 
The nomenclature for the complex I assembly intermediates is heterogeneous and often 
unclear. The reason is that in most studies they were termed according to their apparent 
molecular masses as determined by blue-native electrophoresis (BNE). However, the 
migration of protein complexes may vary signiﬁcantly depending on the exact conditions 
during sample preparation and electrophoresis. Even the improved mass calibration 
(Andrews et al. 2013) (Formosa et al. 2015) does not take into account the different 
migration behavior of soluble and membrane proteins in blue native gels (Wittig et al. 2010) 
and often soluble standards are inappropriately used to estimate membrane complexes.
As a result, different molecular masses have been assigned by different groups to the 
same intermediates and particularly the masses of higher intermediates do not ﬁt. For
instance, the masses of two intermediates, one containing ND1 and the other containing 
ND2, have been estimated a t 315 and 370 kDa, respectively, and the combination of these 
two resulted in a 550 kDa intermediate (Andrews et al. 2013) instead of the theoretical 685 
kDa. Other research groups, have estimated the same two intermediates containing ND1
and ND2 at 400 and 460 kDa, respectively, and their combination strangely resulted in a
650 kDa intermediate (Moreno-Lastres et al. 2012; Perales-Clemente et al. 2010) . Moreover, 
distinct subassemblies with similar molecular masses were observed, which together 
with an incomplete molecular characterization of the intermediates, further rendered 
their unambiguous assignment difﬁcult.
For many years, immunodecoration or pulse chase after BN-PAGE and 2D-BN/SDS-
PAGE were the preferred methods for the characterization of the different assembly 
intermediates(Vogel et al. 2005; McKenzie et al. 2011). Since in most cases these approaches
allowed to identify only a limited set of proteins, the complete composition of the
different subassemblies remained unknown and in some cases with mass inconsistencies 
(Andrews et al. 2013). Only recently, superior up-to-date mass spectrometry approaches 
(Wessels et al. 2009; Wessels et al. 2013; Heide et al. 2012; Guarani et al. 2014) have been
applied increasingly to characterize complex I assembly intermediates. For a long time, a 
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lack of structural information concerning the position of most of the accessory subunits 
in the complex has further hampered the complete elucidation of the complete assembly 
pathway. Only now, insights into the architecture of the bovine complex by cryo-EM 
(Zhu et al. 2015) and its comparison with the complex I structure from Yarrowia lipolytica 
(Zickermann et al. 2015) the majority of accessory subunits can be tentatively localized. 
These recent developments prompted us to re-evaluate the large literature concerning 
the assembly of complex I. This resulted in an updated and more detailed model of the 
modular assembly pathway providing a more complete description of the whole process 
that is in line with the structural data and clariﬁes some of the discrepancies regarding 
the composition of the assembly intermediates. Furthermore, we propose a consolidated 
nomenclature for the assembly intermediates that is consistent with that of the structural 
description of the functional modules of complex I (Brandt 2006)
Assembly of the N module.
The N module comprises subunits NDUFV1, NDUFV2, NDUFS1, NDUFA2, NDUFS4 and 
most likely NDUFV3. Subunits NDUFS6 and NDUFA12 are located at the interface between 
modules N and Q (Vinothkumar, Zhu, and Hirst 2014; Zickermann et al. 2015). It is generally 
accepted that the incorporation of subunits of the N module is one of the ﬁnal steps to 
complete the assembly of human complex I. It has been suggested that the N module 
is pre-assembled before it is bound to the rest of the complex. However, so far there is 
no evidence for an assembly intermediate containing all N module subunits. Only some 
interactions between N module subunits have been characterized providing clues on the 
ﬁrst steps of N module formation. A subassembly containing NDUFV1 and NDUFV2 was 
proposed based on their co-migration in BNE (Ugalde, Vogel, et al. 2004). In addition,
in a TIMMDC1 knockdown, N module subassemblies containing NDUFS1, NDUFV2 and 
NDUFV1 were reported to accumulate. The presence of NDUFV3 was also claimed, although
this was not clearly backed up by experimental data (Guarani et al. 2014). Actually, the 
position of NDUFA2 in the structure and its accumulation in the same fractions as NDUFS1 
after two different separation methods, i.e. BNE and gel ﬁltration (Guarani et al. 2014)
rather suggest that subunit NDUFA2 and not NDUFV3 interacts with NDUFS1 at this early
stage. Therefore, we suggest that in the ﬁrst step two subassemblies are formed, one 
containing NDUFV1 and NDUFV2 and the other containing NDUFS1 and NDUFA2, which
are then put together into a higher mass intermediate made of these four subunits (N 
module subassembly, Figure 2A). There are no clear indications of stable associations 
with assembly factors during the formation of the N module-subassembly. Interactions 
with proteins involved in the insertion of prosthetic groups are perhaps transient or too
labile to be detectable by fractionation of subcomplexes. Thus far, only one protein has 
been characterized with a likely role in the assembly of the N module. NUBPL (huInd1) has 
been proposed to be speciﬁcally involved in the incorporation of iron-sulfur clusters of 
complex I of which ﬁve reside in the N-module (Sheftel et al. 2009). NUBPL most likely acts 
early in the process (Kevelam et al. 2013) and might not be speciﬁc for the N module, since 
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two subunits of the Q module also contain iron-sulfur clusters. However, such hypothesis
remains to be experimentally validated. It contains a conserved cysteine motif (CXXC) that 
binds an iron-sulfur and is also present in P-loop NTPases involved in general iron-sulfur 
protein biogenesis (Bych, Netz, et al. 2008; Lill 2009). In complex I-deﬁcient patients with 
mutations in NUBPL (Kevelam et al. 2013), NUBPL protein levels are severely decreased, 
which was also found when the mutation was reconstructed in the Y. lipolytica ortholog
Ind1 (Wydro and Balk 2013). 
The remaining N module subunits that do not form part of the N-module-subassembly, 
NDUFS4 and NDUFV3, and the two subunits located at the N/Q module interface are
inserted in the ﬁnal steps of the pathway, like the N module subassembly (Pereira, Videira, 
and Duarte 2013; Kmita et al. 2015).
Assembly of the Q module
The Q module is composed of nine subunits: the central subunits NDUFS2, NDUFS3,
NDUFS7 and NDUFS8 (Brandt 2006) and accessory subunits NDUFA5, NDUFA6, NDUFA9,
NDUFAB1 (Vinothkumar, Zhu, and Hirst 2014) and NDUFA7 (without known localization). 
The assembly of the Q module has been thoroughly explored since antibodies against 
NDUFS2 and NDUFS3 are among the best and most widely used in complex I research 
(Ugalde, Janssen, et al. 2004; Saada et al. 2009; Perales-Clemente et al. 2010) and NDUFS3
could be traced easily after GFP-labeling (Vogel, Dieteren, et al. 2007). This allowed 
deciphering a consistent model for the number of assembly intermediates and the
stepwise molecular mass increase, as subunits and/or assembly factors are incorporated 
(Saada et al. 2009; Heide et al. 2012; Guarani et al. 2014; Ugalde, Janssen, et al. 2004; Perales-
Clemente et al. 2010). The earliest subassembly of the Q module is formed of by subunits 
NDUFS2, NDUFS3 and NDUFA5, to which NDUFS7 and NDUFS8 are added in a second step. 
Next, assembly factors NDUFAF3 and NDUFAF4 are attached to form a subassembly, which
probably does not yet integrate into the inner mitochondrial membrane, since none of the
seven protein components contains any transmembrane helices. It can be hypothesized
that assembly factors NDUFAF3 and NDUFAF4 are involved in the stability of the Q module
or in the binding of the Q and the P modules. Since subunits NDUFS7 and NDUFS8 contain 
iron-sulfur clusters, formation of the Q-module could also involve assembly factor NUBPL,
but it remains unclear at what stage of the entire process the redox-centers are introduced.
It has been a matter of debate whether or not subunit NDUFA9 is part of the Q module 
subassembly. Some groups have considered this possibility (Mimaki et al. 2012; Guarani 
et al. 2014), but most of the data in the literature point to the incorporation of NDUFA9 
in a later step (Stroud et al. 2013; Saada et al. 2009). Deletion of the NDUFA9 homolog in 
Y. lipolytica abolished completely NADH:ubiquinone oxidoreductase activity and severely 
decrease complex I total amount (Abdrakhmanova et al. 2006) reﬂecting an assembly
defect. The incorporation of accessory subunits NDUFA6 and NDUFAB1 must occur in a later 
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step, since deletion of NDUFA6 homolog in Y. lipolytica interfered only with the binding of 
NDUFAB1 homolog, but the assembly of the rest of the complex was not impeded (Angerer 
et al. 2014). The insertion of NDUFA7 might take place in one of the last steps since, so far, 
there are no indications of intermediates containing this subunit.
Subassemblies of the PP module. 
The proximal half of the membrane integral P-module (PP) is preassembled in two parts.
The components of submodule PP-a, consisting of subunits ND1, NDUFA8, NDUFA3,
NDUFA13 and NDUFA1 (Vinothkumar, Zhu, and Hirst 2014) are put together by attaching 
the transmembrane subunits to the preformed Q-module, which is thereby recruited to
the membrane (Figure 2A). Speciﬁcally, the Q-module still binding NDUFAF3 and NDUFAF4
docks onto the mitochondrial encoded subunit ND1. This step is aided by binding of the 
transmembrane assembly factor TIMMDC1, with sequence similarity to the TIM17/TIM22/
TIM23 protein family (Andrews et al. 2013; Guarani et al. 2014). Then the other four subunits, 
NDUFA8, NDUFA3, NDUFA13 (Andrews et al. 2013) and probably NDUFA1 are inserted. This 
intermediate can be traced using an antibody against ND1 (Vogel, Dieteren, et al. 2007) and 
we termed it Q/PP-a.
The association of the assembly factors NDUFAF3, NDUFAF4 and TIMMDC1 with the Q/
PP-a intermediate seems rather robust, since they are still bound to later subassemblies. It 
has been proposed that during the early steps of the assembly of this module, assembly 
factors might prevent degradation by proteases thus stabilizing the intermediates (Zurita
Rendon and Shoubridge 2012). Additional assembly factors were not found to be associated
with this subassembly, but are likely to be transiently involved. Translation assays using 
cells from patients with mutations in assembly factors NDUFAF5 and NDUFAF6 had no 
detectable ND1 suggesting a possible link with ND1 biogenesis, but there is no clear 
evidence of direct interaction (Sugiana et al. 2008). Similar observations were made for 
NDUFAF7, where the Dictyostelium NDUFAF7 ortholog, MidA was shown to bind to NADH-
ubiquinone oxidoreductase-chain 49 (NDUFS2) in yeast two-hybrid screenings and in pull 
down experiments (Carilla-Latorre et al. 2010). NDUFAF7 contains a methyltransferase 
domain involved in the posttranslational modiﬁcation of NDUFS2 that is essential
for formation of early steps intermediates)(Zurita Rendon et al. 2014) .This interaction
appears to be transient since no stable association of the human protein with higher mass 
subcomplexes was found (Carilla-Latorre et al. 2010). In humans NDUFAF7, NDUFS2 and 
ND1 appear in the same fraction of sucrose gradients and immunoprecipitation assays
of subunit ND1 identiﬁed among other proteins NDUFAF7 supporting that they might be 
in the same subcomplex. Moreover, pulse chase analysis with NDUFAF7 knockdown cells 
showed a severe reduction in abundance of ND1 (Zurita Rendon et al. 2014). 
Consistent with previously proposed ideas of a modular assembly process (Ugalde, Janssen,
et al. 2004; Schefﬂer, Yadava, and Potluri 2004), distinct entry points for mitochondrial
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encoded subunits were described (Perales-Clemente et al. 2010). It was shown that subunit 
ND1, the core component of submodule PP-a, and subunit ND2, by far the largest component 
of submodule PP-b, assemble independently during the early steps of the process. The ND2 
containing subassembly PP-b, described previously as a 400-460 kDa subcomplex, also
contains the small mitochondrially encoded subunits ND3, ND6 and ND4L and many of the 
so far described assembly factors, namely ECSIT, NDUFAF1, ACAD9 and TMEM126B (Figure 
2A). A complex that included these four assembly factors, termed mitochondrial complex
I assembly (MCIA) complex, was ﬁrst identiﬁed in rat heart mitochondria by complexome
proﬁling (Heide et al. 2012). With the same technique it was shown that knocking
down TMEM126B in human osteosarcoma 143B cells led to a severe decrease in complex 
I-containing supercomplexes (Heide et al. 2012). In the PP-b subassembly, there seems to be
a correlation between the number of assembly factors and the number of mitochondrial
encoded subunits being put together. To date nearly nothing is known regarding the 
order in which the mitochondrially encoded subunits belonging to the PP-b intermediate
are incorporated. More than one population containing subunit ND2 was observed by
pulse-chase experiments (Hornig-Do et al. 2012), suggesting that the process leading to 
the PP-b intermediate starts with a core around subunit ND2. Given the migration patterns 
of ND4L and ND3 in the mentioned pulse-chase experiments (Hornig-Do et al. 2012), one 
could speculate that ND4L is incorporated before ND3, since ND4L was identiﬁed in a 
slightly lower mass range in comparison to ND3. The nuclear-encoded subunits NDUFC1 
and NDUFC2 might as well be part of subassembly PP-b. The incorporation of NDUFA10 
into the complex must occur in a later step, since ﬁbroblasts of a Leigh syndrome patient 
with a mutation in NDUFA10 accumulated early assembly intermediates (Hoefs et al. 2011).
However, for NDUFA11 it remains unclear at which step it is inserted.
Subassemblies of the PD module. 
The PD module is the distal part of the membrane arm of complex I and comprises two 
large core subunits which are mitochondrially encoded, ND4 and ND5, plus 12 accessory 
subunits, NDUFB1-11 and another copy of NDUFAB1 (Zhu et al. 2015)[Wirth et al, this 
special issue]. Previous complex I assembly models suggested that the incorporation
of ND4 occurs in a late step together with ND5 (Mimaki et al. 2012; Gershoni et al. 2010).
However, identiﬁcation of subassemblies that contain ND4 but not ND5 led to propose 
that intermediates containing these subunits are sequentially incorporated and 
not simultaneously (Vartak et al. 2015). This idea is supported by recent quantitative
proteomics analysis of complex I subassemblies showing the stepwise incorporation of
subunits into an intermediate containing subunit ND4 (Guarani et al. 2014). Gel ﬁltration 
separation indicated that the ﬁrst subassembly contains only nuclear-encoded subunits
NDUFB5, NDUFB6, NDUFB10 and NDUFB11 (Guarani et al. 2014). Then, the incorporation of 
subunit ND4 presumably together with NDUFB1 forms an intermediate corresponding to
the proximal half of module PD that we termed PD-a (Figure 2A). The proposed composition 
of the PD-a subassembly is consistent with experiments showing that NDUFB6-containing 
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subassemblies are not stable in ND4 knockouts (Perales-Clemente et al. 2010). So far no 
assembly factors involved in the formation of this intermediate have been described. 
There are only a few weak indications for a subassembly corresponding to the distal part
of the PD module of complex I that should contain subunit ND5 as its core component.
In pulse chase experiments intermediates containing subunit ND5 were observed at
molecular masses clearly below that of fully assembled complex I (Hornig-Do et al. 2012).
Perhaps biased by previous models, quantitative proteomics analysis (Guarani et al. 
2014) grouped together subunits ND5, NDUFB3 and NDUFB9 with the ND4 intermediate
containing NDUFB5, NDUFB6, NDUFB10 and NDUFB11. However in the BNE separation heat 
map of Guarani et al. (Guarani et al. 2014) subunits ND5, NDUFB3 and NDUFB9 showed 
a migration pattern that was clearly different from the ND4-containing intermediate, 
which may have corresponded to submodule PD-b (Figure 2A). The tentative structural 
assignment of accessory subunits suggests that the putative PD-b intermediate might
also contain subunits NDUFB8, NDUFB7 and one copy of NDUFAB1, bound to the LYR
domain of subunit NDUFB9 (Angerer 2015). However, it remains obscure at which point 
subunits NDUFB2 and NDUFB4 are inserted.
Combining the subassemblies 
The next phase of the assembly process consist of the association of the ﬁve assembly 
intermediates described above, i.e. N, Q/PP-a, PP-b, PD-a and PD-b, four of which are 
membrane embedded. Most studies on human complex I assembly agree that ﬁrst the 
central part of the membrane arm expands as the preassembled submodule PP-b interacts
with submodule PD-a forming the PP-b/PD-a intermediate ( Figure 2B). This subassembly 
has been consistently observed in datasets from different research groups using 
diverse techniques (Perales-Clemente et al. 2010; Guarani et al. 2014; Heide et al. 2012). 
For instance, using the NDUFB6 antibody several intermediates containing this subunit
were described and termed a-e (Perales-Clemente et al. 2010). Of these, intermediate d, 
a membrane-bound subassembly containing at least subunits NDUFB6 and ND4 and 
migrating at around 650 kDa, most likely corresponds to the PP-b/PD-a subassembly. In 
addition, the mass spectrometric analysis of intermediates separated by gel ﬁltration 
revealed that a small subassembly containing NDUFB6 shifts towards higher molecular
mass as ND4 and NDUFB1 are incorporated yield a ~680 kDa subcomplex representing 
the PP-b/PD-a subassembly (Guarani et al. 2014). Finally, complexome proﬁling analysis of 
mitochondria from rapidly proliferating 143B osteosarcoma cells showed peaks of most 
components of the PP-b/PD-a subassembly at a mass of around ~680 kDa (Heide et al.
2012). During formation of the PP-b/PD-a subassembly most likely also subunits NDUFS5, 
NDUFA10 and NDUFB4 are attached. Based on the association of subunits NDUFS5 and
NDUFB10 with FOXRED1 (Formosa et al. 2015), this assembly factor seems to take part from 
this point on. Another predicted mitochondrial protein, ATP5SL, has been found associated 
with complex I subunits and assembly factors of the PP-b/PD-a subassembly (Formosa et 
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al. 2015; Andrews et al. 2013). ATP5SL was discovered as a protein associated with complex
I intermediates upon silencing subunit NDUFA11(Andrews et al. 2013). However, knocking
down ATP5SL, to the achieved extent, did not result in a complex I deﬁciency. Therefore 
it could not be concluded that it is an assembly factor of complex I. Conﬁrming the 
interaction of ATP5SL with complex I subassemblies, Formosa et al. (Formosa et al. 2015) 
have identiﬁed an association of this protein with FOXRED1. However this protein was not
mentioned in their publication just because it was not present in the Mitocarta inventory, 
even though it fulﬁlled all criteria set by the authors to prove the interaction. The PP-b/PD-a
subassembly is now ready to interact with the Q/PP-a and the PD-b intermediates to form
the Q/P subassembly, previously described as 815/830/940 kDa subassembly (Andrews et
al. 2013; Vogel, Dieteren, et al. 2007; Vartak et al. 2015). At this point, subunit NDUFA9 (Saada
et al. 2009) and the assembly factor NDUFAF2 (Ogilvie, Kennaway, and Shoubridge 2005; 
Kirby et al. 2004) are most likely incorporated and the resulting intermediate comprises 
essentially the complete Q and P modules plus at least eight assembly factors (Figure 2B). 
It is not clear which of the two submodules binds to the central part of the P-module ﬁrst.
In fact, since the two parts are added from opposite sides of the PP-b/PD-a subassembly
there may be no predetermined or preferred order in which this occurs. Probably, also the 
subcomplex of similar mass described previously as intermediate e (Perales-Clemente et
al. 2010) corresponds to the Q/P subassembly plus assembly factors.
In the ﬁnal steps of complex I assembly only the N module, located at the most distal part
of the peripheral arm, needs to be added, and the assembly factors are removed (Figure 
2C). It has been proposed that binding of the N module is aided by NDUFAF2. However, 
this assembly factor seems to be important but not essential, since mature complex I was
observed even in knockout mammalian cells (Schlehe et al. 2013) and in deletion strains of 
its orthologs in the fungal models Neurospora crassa (Pereira, Videira, and Duarte 2013) and 
Y. lipolytica (Kmita et al. 2015). Moreover, assembly factor NDUFAF2, is a paralog of subunit
NDUFA12 (Ogilvie, Kennaway, and Shoubridge 2005), which along with NDUFS6 seems to 
be added to the complex after the N-module at an apparently exclusive interaction site
at the interface between modules (Kmita et al. 2015; Pereira, Videira, and Duarte 2013). 
Since deletion of the NDUFS6 ortholog in Y. lipolytica results in the missing of the nearby
iron-sulfur cluster N4, it was proposed that assembly factor NDUFAF2 homolog holds the
premature complex I available for insertion of this iron-sulfur cluster, before it is ﬁnally
replaced and the last subunits are added (Kmita et al. 2015).
It remains unclear whether the assembly factors bound to the Q/P subassembly leave 
concomitantly when the N-module and the ﬁnal subunits are added. The fact that 
complexome proﬁles gave indications for a ~1.3 MDa complex containing the complex I
subunits and assembly factors (Heide et al. 2012) suggesting that the release of assembly 
factors may be the ﬁnal step. Further experiments will be needed to test this possibility. 
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It is important to note that the describedmodel of complex I assembly reﬂects the
consensus of a number of studies and includes evidence obtained with different
organisms. One has to consider that the order of events during this complicated process
and the exact composition of the subassemblies may vary e.g. depending on the cell type 
or the proliferation state. In particular, under pathological conditions, deviations should 
be expected and aberrant assembly intermediates may occur and accumulate.
ﬁgure 2 | A) Current view of the modular assembly of human complex I. In the early stage of 
the assembly pathway ﬁve subassemblies are independently formed. B) The preassembled
modules interact with each other resulting in higher molecular mass subassemblies. C) Complete 
view of the assembly pathway indicating the steps where assembly factors are involved (See 
text for details). The cartoon representation is based on the bovine heart cryo-EM structure
((Vinothkumar, Zhu, and Hirst 2014); PDB 4UQ8.). In panels A and B, the composition of each 
assembly intermediate is indicated using gene names; complex I subunits are in black and
assembly factors in red. In brackets are the components whose indications as part of the
subassemblies are less solid. The subunits/assembly factors that are incorporated in each step are
indicated in bold letters.
NDUFS2
NDUFS3
NDUFA5
NDUFS2
NDUFS3
NDUFA5
NDUFS7
NDUFS8
Q 
NDUFS2
NDUFS3
NDUFA5
NDUFS7
NDUFS8
ND1
NDUFAF3
NDUFAF4
TIMMDC1
P -a
P
NDUFS2
NDUFS3
NDUFA5
NDUFS7
NDUFS8
NDUFAF3
NDUFAF4
NDUFS2
NDUFS3
NDUFA5
NDUFS7
NDUFS8
ND1
NDUFA1
NDUFA3
NDUFA8
NDUFA13
NDUFAF3
NDUFAF4
TIMMDC1
Q 
P -b
P
ND2
NDUFC1
NDUFC2
NDUFAF1
ECSIT
ACAD9
COA1
ND2
NDUFC1
NDUFC2
ND3
NDUFAF1
ECSIT
ACAD9
COA1
TMEM126B
TMEM186
ND2
NDUFC1
NDUFC2
ND3
ND6
ND4L
NDUFAF1
ECSIT
ACAD9
COA1
TMEM126B
TMEM186
P -a
D
NDUFB5
NDUFB10
NDUFB11
NDUFB5
NDUFB10
NDUFB11
NDUFB6
NDUFB5
NDUFB10
NDUFB11
NDUFB6
ND4
NDUFB1
TMEM70
N 
NDUFS1
NDUFA2
NDUFV1
NDUFV2
NDUFV1
NDUFV2
NDUFS1
NDUFA2
680 kDa
ND2
NDUFC1
NDUFC2
ND3
ND6
ND4L
NDUFAF1
ECSIT
ACAD9
COA1
TMEM126B
TMEM186
P -b
P
P -a
D
NDUFB10
NDUFB11
NDUFB6
ND4
NDUFB1
NDUFB4
NDUFA10
NDUFS5
NDUFB5
TMEM70
FOXRED1
ATP5SL
940 kDa
Q 
P -a
P
P -b
P
P -a
D
P -b
D
NDUFS2
NDUFS3
NDUFA5
NDUFS7
NDUFS8
NDUFA6
NDUFAB1*
ND1
NDUFA1
NDUFA3
NDUFA8
NDUFA13
NDUFAF3
NDUFAF4
TIMMDC1
NDUFB10
NDUFB11
NDUFB6
ND4
NDUFB1
NDUFB4
NDUFA10
NDUFS5
NDUFB5
TMEM70
ND2
NDUFC1
NDUFC2
ND3
ND6
ND4L
NDUFA9
NDUFAF1
ECSIT
ACAD9
TMEM126B
NDUFAF2
ND5
NDUFB9
NDUFB8
NDUFB7
NDUFB3
NDUFAB1
+
ND5
NDUFB9
NDUFB8
NDUFB7
NDUFB3
NDUFAB1
P -b
D
Complex I
N 
Q 
P -a
P
P -b
P
P -a
D
P -b
D
P -b
P
P -a
D
680 kDa
P -b
P
P -a
D
P -a
P
Q 
P -b
D
940 kDa
Q 
P -a
P
P -b
P
P -a
D
P -b
D
N 
Q 
NDUFAF3
NDUFAF4
TIMMDC1
NDUFAF2
FOXRED1
ATP5SL
TMEM70
Assembly 
factors
NDUFAF1
ECSIT
ACAD9
COA1
TMEM126B
TMEM186
A
B
C
(NUBPL)
(NUBPL)
(NUBPL)
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 63
Unraveling the complexity of mitochondrial complex I assembly; a dynamic process 63
Complex I
N 
Q 
P -aP
P -bP P -aD
P -bD
P -bP
P -aD
P -b/P P -aD
P -aP
Q 
P -bD
Q/P
Q 
P -aP
P -bP P -aD
P -bD
N 
NDUFAF3
NDUFAF4 TIMMDC1
NDUFAF2
FOXRED1
(ATP5SL)
Assembly 
factors
NDUFAF1
ECSIT
ACAD9
TMEM126B
M
ol
ec
ul
ar
 m
as
s
Q 
N Q P  P P  D
Module 
(NUBPL)
(NUBPL)
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 64
64 Chapter 3
Conclusion
The biogenesis of complex I is a very intricate process during which 44 different proteins
synthesized in two different compartments need to be assembled in a controlled and 
correct way and the subunits need to be directed to three different sub-compartments of 
the mitochondria. At least 13 assembly factors are needed for proper formation of complex 
I, most of which are involved in membrane arm assembly. Complex I assembly is a stepwise 
process. First subassemblies are formed correlating with the functional modules of the 
complete complex.
Development of new techniques in the past years greatly improved our understanding 
of complex I assembly and led to the identiﬁcation of several novel assembly factors. 
However, the overall picture is probably not yet complete and the function of some 
assembly factors is not fully understood. Moreover, it seems likely that more factors with 
a speciﬁc role in complex I assembly will be discovered.
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Abstract
Despite that the inner mitochondrial membrane protein TMEM70 has been described as 
an assembly factor of complex V, its direct interaction with this complex has never been
documented and its molecular function has remained elusive. Furthermore, patients
harbouring mutations in TMEM70 do not always show an isolated complex V deﬁciency
but also a combined complex I – complex V impairment or even an isolated complex I
deﬁciency. To shed light on the molecular function of TMEM70, we studied in depth the 
consequence of its absence on the oxidative phosphorylation system using a TMEM70
knockout in HAP1 cells. Using complexome proﬁling, we show how, in the absence of
TMEM70, the ATP-synthase assembly process lacks an intermediate stage that consists
of the soluble part anchored to the c-ring octamer that is located in the mitochondrial
inner membrane. Furthermore, in the absence of TMEM70, also complex I assembly 
is impaired showing intermediates accumulating relative to the holocomplex. The 
intermediates of complex I and complex V that show disturbances suggest a role of 
TMEM70 in the membrane recruitment of subunits into the forming complex. TMEM70 is
part of a protein family that is widespread among eukaryotes and that in human has two 
paralogs: TMEM186 and TMEM223. Here, we show that both proteins are mitochondrial 
and that they have a similar predicted membrane topology as TMEM70. Members of the 
TMEM70/186/223 family only occur in species with OXPHOS complexes suggesting a role 
of this family in OXPHOS biogenesis, as this study shows in great detail for one of the 
protein members, TMEM70.
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Introduction
The oxidative phosphorylation (OXPHOS) system, situated in the mitochondrial inner 
membrane, is composed of ﬁve enzyme complexes (I–V) and two electron carriers, 
coenzyme Q and cytochrome c (Alston et al. 2017). The ﬁrst four complexes form the
electron transport chain (ETC) that couple the transfer of electrons from NADH to oxygen, 
to the transfer of protons across the membrane. The thus generated proton gradient 
is used by complex V (CV) or ATP synthase to generate adenosine triphosphate (ATP)
(MITCHELL 1961). From the ﬁve enzymes of the OXPHOS system, the ﬁrst and the last, i.e., 
complex I (CI) or NADH:ubiquinone oxidoreductase and CV are particularly relevant to this 
study. Mammalian CI is a 45 subunit L-shaped complex, seven of which are mitochondrially 
encoded, (MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5 and MT-ND6) with
a lipophilic arm integrated into the inner mitochondrial membrane and a hydrophilic
peripheral arm jutting out into the mitochondrial matrix (Zhu, Vinothkumar, and Hirst
2016). The enzyme can be subdivided into three different functional modules (Brandt
2006) that are assembled separately (Sanchez-Caballero, Guerrero-Castillo, and Nijtmans 
2016; Guerrero-Castillo et al. 2017): the P-module (proton translocation) that represents 
the lipophilic membrane arm, the N-module (NADH dehydrogenase) and the Q-module 
(coenzyme Q reduction). Mammalian CV is an enzyme complex composed of 18 subunits
(considering the regulatory protein IF1), two of which are mitochondrially encoded (MT-
ATP6 and MT-ATP8) (Pedersen and Amzel 1993). It comprises two modules, a globular F1 that 
contains the catalytic region, and a membrane-embedded F0, that contains the rotary 
motor. The F1 module (subunits_and` ) is connected to F0 (subunits DAPIT, 6.8PL, a, A6L, e,
f, g and the c-subunit) by two stalks, one central, with subunits a,b,¡ and one peripheral
that consists of the oligomycin sensitivity conferral protein (OSCP) and subunits b, d, and
F6. The central stalk and the c-subunits establish the rotor of the fully assembled enzyme 
(Walker 2013).
For the optimal assembly of the OXPHOS complexes extra proteins are needed: the so-
called assembly factors, that assist in the assembly of a complex, but are not part of 
the ﬁnal complex. Assembly factors have been discovered by genetic and experimental 
approaches, often in combination with bioinformatic analyses (Ghezzi and Zeviani 2018). 
Those analyses have exploited that the assembly factors are often part of large protein 
families (Elurbe and Huynen 2016). They show conservation of molecular function and 
co-evolve with CI itself (Huynen, de Hollander, and Szklarczyk 2009). This is e.g. the 
case for the CI assembly factor IND1, that was predicted to play a role in the assembly of 
Fe-S clusters in CI via the role of its cytoplasmic homologs in the assembly of other Fe-S 
proteins and via its co-evolution with CI proteins (Bych et al. 2008). However, the exact 
molecular function of many assembly factors has not been elucidated. 
From all the complexes that are part of the OXPHOS system, the one with the lowest 
number of known assembly factors is CV. Its assembly factors are ATPAF1 and ATPAF2 
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(Pickova et al. 2003), both interact with the F1 module, and TMEM70 (Cizkova et al.
2008). TMEM70 is a transmembrane protein that localizes in the inner membrane of the 
mitochondria (Calvo et al. 2006; Hejzlarova et al. 2011). It contains two transmembrane 
regions that form a hairpin structure of which the N- and C-termini are located in the 
mitochondrial matrix (Kratochvilova et al. 2014). Mutations in TMEM70 have been reported 
to severely diminish the content of CV in a large cohort of patients (Wortmann et al.
2009; Catteruccia et al. 2014; Cizkova et al. 2008; Diodato et al. 2015; Honzik et al. 2010; 
Jonckheere et al. 2011; Magner et al. 2015; Shchelochkov et al. 2010; Spiegel et al. 2011;
Torraco et al. 2012), and of all nuclear encoded proteins affecting CV, TMEM70 is the most
commonly mutated in disease (Houstek, Kmoch, and Zeman 2009). This observation, led
to the hypothesis that TMEM70 is a CV assembly factor. However, there is no evidence of 
its direct interaction with CV proteins, and its speciﬁc role in CV assembly remains unclear 
(Torraco et al. 2012; Hejzlarova et al. 2011). 
The present study aims to elucidate the full role of TMEM70 in the oxidative
phosphorylation system using standard biochemical techniques combined with two 
novel techniques: complexome proﬁling and BioID proximity-dependent labelling assay,
together with an in-silico approach to detect TMEM70 homologs and reconstruct the co-
evolution of TMEM70 with other mitochondrial proteins.
Materials and methods
Enzyme Measurements
Respiratory chain enzyme analysis in HAP1 were performed as described before [12-17] .
Values are expressed relative to the mitochondrial reference enzyme citrate synthase [18].
Cell culture
HAP1 cells were grown in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) in the presence of
10% fetal calf serum and penicillin/ streptomycin.
HEK293 cells were cultured in DMEM (Biowhitaker) supplemented with 10% fetal calf 
serum (FCS) (v/v) and 1% penicillin/streptomycin (GIBCO). Inducible cell lines were 
selected on 5 μg/ml blasticidin (Invitrogen) and 200 μg/ml hygromycin (Calbiochem), and 
for expression of the transgene, 1 μg/ml doxycycline (Sigma Aldrich) was added for 24 hr.
TMEM70 knockout cell line
TMEM70 knockout (HZGHC003615c010) was ordered at Horizon (Austria). A near-
haploid human cell line (HAP1) was edited using CRISPR/Cas (Guide RNA sequence: 
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CGGCTGGAGTACGGGGCCTT) resulting in a frameshift mutation of 32bp in exon 1 26. This
results in a 100% knockout. In table 1 an overview of the knockout cell line is shown.
Blue-Native, SDS-PAGE Analysis and Complex I In Gel Activity Assay
One-dimensional 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and 4%–12% blue-native (BN)-PAGE was performed as described previously. Lanes 
were loaded with 40 (SDS analysis) or 80 (BN analysis) μg of solubilized mitochondrial
protein. For the 1D and 2D BN SDS-PAGE followed by immunoblotting, mitoplast were 
solubilized with n-dodecyl- `-D-maltoside, whereas for complexome proﬁling the
solubilization was done with digitonine to preserve supercomplexes. After electrophoresis, 
gels were processed further for in-gel complex I activity assay, in-gel ﬂuorescence 
detection, immunoblotting, or two-dimensional 10% SDS-PAGE or blotting, proteins were 
transferred to a PROTAN nitrocellulose membrane (Schleicher & Schuell).
Antibodies and ECL detection
Immunodetection was performed by the use of the following primary antibodies: CI-
NDUFS3, CII-SDHA, CIII-core 2, CIV-COX4, CV-ATPase-_/` (gift from the “Molecular
Bioenergetics Group, Medical School, Goethe-University Frankfurt” (Wittig et al. 2008)), 
C3ORF60 (Eurogentec) and V5 (Invitrogen). Goat-anti-rabbit and goat-anti-mouse IRDye 
CW 680 or IRDye CW 800 were used as secondary antibodies, to detect the proteins 
using the Odyssey system from LI-CORBiosciences. Secondary detection was performed 
using peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Life Technologies). 
Immunoreactive bands were visualized using the enhanced chemiluminescence kit
(Thermo Scientiﬁc) and detected using the Chemidoc XRS+system (Biorad).
Pulse labeling of mitochondrial translation products
In vitro labeling of mitochondrial translation products was performed as described 
previously [19]. First, cells were incubated for 30 minutes with methionine, cysteine and
glutamine free DMEM (Gibco) supplemented with glutamax (1Xconc), 10% dialyzed FBS 
and 1.1mg/l sodium pyruvate. Afterwards, emetine was added to a ﬁnal concentration of
100μg/ml, after 5 minutes 200μCi/ml 35S methionine label was added during 1 hour. Cells
were refreshed with 10% FBS DMEM media and harvested after 1h and after 5h of labeling 
and treated for SDS-PAGE or BN-PAGE.
Generation of inducible cell lines
TMEM70, TMEM223 and TMEM186 were cloned into pDONR201 as described (Vogel 
et al. 2007). The complete open reading frame was created by PCR according to the
manufacturer’s protocol and cloned into pDONR201 by the Gateway BP Clonase II 
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Enzyme Mix. The pDONR201-TMEM70, pDONR201-TMEM186 and the pDONR201-223 were
recombined with the TAP destination vector or the pDEST5-BirA*-FLAG-C-ter using the 
LR Clonase II Enzyme Mix (Invitrogen). Flp-In T-Rex HEK293 cells were grown in DMEM
supplemented with 10% FBS and 1% pen/strep (100 U/ml). When reached 60-80% 
conﬂuence cells were transfected with each of the constructs and pOG44 mixed with
Superfect. Cells were refreshed 3h after transfection. After 48h cells were selected by
the addition of 200μg/ml of hygromycin (Calbiochem). Clones were selected and when 
reaching 60-80% conﬂuency, protein expression was induced by using 1 μg/ml doxcycline 
(Sigma Aldrich) for 24h and checked by Western blot analysis.
Complexome proﬁling
Complexome proﬁling was performed essentially as described previously (Heide et al. 2012;
Guerrero-Castillo et al. 2017). Speciﬁcally, BN- PAGE gel lanes of mitochondrial enriched 
fraction of TMEM70 KO and controls were incubated in ﬁxing solution (50% methanol, 10%
acetic acid, 10 mM ammonium acetate [pH 3]) for 60 minutes, washed twice for 30 minutes 
with ultrapure water, cut in 60 even slices and transferred into a 96-well plate (Milipore
MABVN1250) containing 150μl of destaining solution (50% methanol, 50 mM ammonium
hydrogen carbonate, AHC). Then all the slices were washed three times for 30 minutes 
under gentle agitation at room temperature with the same solution (AHC) to remove the 
excess of dye. Afterwards by centrifugation (600 x g, 3min, RT) the excess of solution was
removed and in-gel tryptic digest of the gel slices was performed as described before [20]. 
First, all the gel slices were incubated with 120 μl of 5mM dithiothreitol for 60 minutes 
which afterwards was removed by centrifugation, and then 120μl of 15mM chloracetamide 
were added to each well and also removed after 45 minutes of incubation. After drying 
the gel pieces for 45 minutes at room temperature the gel slices were rehydratated in 20μl
of trypsin solution or chymotrypsin (5 ng/μL in 50 mM AHC and 1 mM CaCl2) for 30 min at
4°C. After addition of 150μl of 50mM AHC solution the gel pieces were incubated overnight
at 37°C. The supernatant, containing the peptides was collected by centrifugation (600 
x g, 3min, RT) into a new 96-well plate. The column was washed subsequently with 80% 
acetonitril and re-equilibrated with 5% acetonitril for 5 minutes once by adding elution
solution (30% acetonitrile, 3% formic acid) for 20 minutes and transferred to a sterile
(unﬁltered) 96-well plate. The supernatant was dried using a SpeedVac concentrator, 
remaining peptides were additionally extracted in 20μl of 5% acetonitrile/0.5% formic 
acid.
Tryptic peptides were analysed by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) in a Q-Exactive 2.0 Orbitrap Mass Spectrometry System equipped with a 
nano-ﬂow high-performance liquid chromatography system Agilent1200 at the front 
end and the Thermo Scientiﬁc Xcalibur 2.2 SP1 Software Package [21]. Peptide separation
was performed on a PicoTip emitter column ﬁlled with 3 mm C18 beads (Dr Maisch GmbH,
Germany) using 30 min linear gradients of 5 to 35% acetonitrile with 0.1% formic acid.
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The mass spectrometer was operated in a Top 20 dependent, positive ion mode switching 
automatically between MS and MS/MS. Full scan MS mode (400 to 1400 m/z) was 
operated at a resolution of 70 000 with automatic gain control (AGC) target of 1 × 106 ions 
and a maximum ion transfer of 20 ms. Selected ions for MS/MS were analysed using the 
following parameters: resolution 17500; AGC target of 1 × 105; maximum ion transfer of
50 ms; 4.0 m/z isolation window; for CID a normalized collision energy 30% was used; 
and dynamic exclusion of 30.0 s. A lock mass ion (m/z=445.12) was used for internal 
calibration(Olsen et al. 2005).
All raw ﬁles were analyzed by MaxQuant software (version 1.5.0.25; www.maxquant.
org). Spectra were searched against the H.sapiens NCBI RefSeq database with additional
sequences of known contaminants and reverse decoy with a strict FDR of 0.01. Database 
searches were done with 20 ppm and 0.5 Da mass tolerances for precursor ions and
fragmented ions, respectively. Trypsin was selected as the protease with two missed 
cleavages allowed. Dynamic modiﬁcations included N-terminal acetylation and oxidation
of methionine. Cysteine carbamidomethylation was set as ﬁxed modiﬁcation. For protein 
quantiﬁcation unique plus razor peptides were considered. Protein abundance migration 
proﬁles were normalized from 0 to 1 taking into account all values from 120 slices, 60 
values of each of the two samples. Proﬁles were hierarchically clustered using Cluster 3.0 
software by distance measures based on Pearson correlation coefﬁcient (uncentered) and 
the average linkage method. 
Biotin ligase proximity assay (BioID)
After 24h of doxycycline cells were washed with PBS 1X twice and add complete medium 
for 3h, afterwards a ﬁnal concentration of 50uM of biotin was added to the cells (Firat-
Karalar and Stearns 2015). After 24h cells were washed, collected and lysed in lysis buffer 
(50 mM Tris-HCl pH7.4, 500 mM NaCl, 0.4% SDS, 1 mM DTT and 1x Protease inhibitor) with 
2% TX100 and then sonicated twice. Pre-chilled 50 mM Tris-HCl pH7.8 was added before
the third sonication and then all samples were collected at 16.500g for 10 minutes at 4 °C. 
Supernatant was added to the pre-equilibrated dynabeads and it was incubated overnight 
in the rotator. Next day, beads were collected in the magnetic separation stand and
supernatant was removed. Beads were washed 4 times with 4 different washing buffers 
(Washbuffer 1: 2% SDS. Washbuffer 2: 0.1% (w/v) deoxycholic acid, 1 % TX100, 1 mM EDTA, 
500 mM NaCl, 50 mM HEPES pH 7,4. Washbuffer 3: 0.5 % (w/v) deoxycholic acid, 0.5 % (w/v) 
NP-40 (Igepal), 1 mM EDTA, 250 mM LiCl, 10 mM Tris-HCl pH7.8) for 8 minutes in the rotator. 
After the washing 50ul 50mM ABC / 8M Urea was added to the beads and resuspended 
gently by pipetting, then the sample was snap frozen in LN2 and stored at -80 degrees.
To prepare the beads ﬁrst we added 1ul of reduction buffer (10mM DTT) for 30’ at RT, then 
1ul alkylation buffer (50mM chloroacetamide in 50mM ABC) and incubated for 20’ at room 
temperature (light protected). Afterwards 1ug of LysC was added and incubated for at least 
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3 hours at room temperature. Subsequently the sample was diluted in 50mM ABC and 
1ul of trypsin was incorporated for digestion overnight at 37 degrees on a thermomixer 
on continuous agitation at 700 rpm. The supernatant containing the peptides was 
transferred to a new eppendorf tube and TFA was added to a ﬁnal concentration of 2%. 
All samples were incorporated into STAGE TIPS that were previously washed, once all 
sample has pass the ﬁlter 50 μl of buffer A (0.1% Formic Acid in HPLC water) was added 
and centrifuged. Then 40 μl of buffer B (80% ACN and 0.1% Formic Acid in HPLC water) was
added and the eluated was collected in 0.5 ml reaction vials. All samples were concentrated 
and dried. Afterwards, 25 ul of buffer A was added and sonicated 2’ in waterbath before 
using the detergent removal kit. Measurements were performed by nanoLC 1000 (Thermo
Scientiﬁc) chromatography coupled online to Q Exactive hybrid quadrupole-Orbitrap
mass spectrometer (Thermo Scientiﬁc). Chromatography was performed with an 
Acclaim PepMap 0.3 x 5 mm 5μm 100Å trap column (Thermo scientiﬁc) in combination
with a 15cm long x 100μm ID fused silica electrospray emitter (New Objective, PicoTip 
Emitter, FS360-100-8-N-5-C15) packed in-house with ReproSil-Pur C18-AQ 3 μm 140Å resin 
(Dr. Maisch) (Ishihama et al. 2002). Tryptic peptides were loaded and analysed by liquid
chromatography tandem mass spectrometry (LC-MS/MS) as previously explained. Raw 
data ﬁles provided by MaxQuant (version 1.5.0.25; www.maxquant.org) were further 
analysed taking the log10 value of their iBAQ and comparing experiment values (with
doxycycline and biotin) with control ones (without doxycycline and with biotin and vice
versa). Proteins with a signiﬁcant increase in their iBAQ values (wilcox test, FDR 0.05) with 
respect to their own control runs, were considered as potential interacting candidates.
Alignment and Gene Set Enrichment Analysis of complexome proﬁling 
data 
To be able to compare the six complexome proﬁles on two gels the control and the TMEM70
knockout, they have to be aligned with each other to weed out the effect of technical 
variations between the gels. We aligned the complexome proﬁles with each other using 
a multidimensional implementation of the dynamic time warping technique (Sakoe
and Chiba, 1970van Strien et al, submitted, bioRxiv 411660). To subsequently determine 
differences between TMEM70 knockouts and the controls in protein migration per protein,
all proteins were scored separately based on the difference between their migration 
proﬁles in the TMEM70 knockout and in the control, divided by the average distance 
among the knockouts and the controls. Proteins with a decreased abundance in TMEM70
KO lines relative to its parental cell line were selected to focus on the direct effects of 
TMEM70. Gene set enrichment analysis was performed on the resulting rank-ordered list 
of proteins, using the CORUM comprehensive resource of mammalian protein complexes
as gene sets(Ruepp et al. 2010).1000 permutations were performed to obtain normalized 
enrichment scores and p-values using the gene set enrichment analysis tool a software.
broadinstitute.org/gsea/.
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Microscopy
For confocal imaging, HEK293 cells expressing inducible NDUFAF3-GFP were cultured in 
a Wilco dish (Intracel, Royston, UK), washed with phosphate-buffered saline (PBS), and 
incubated with 1 μM Mitotracker Red (Invitrogen) for 15 min and with 10 μM Hoechst 3342
(Invitrogen) for 30 min, both at 37°C. Before imaging, the culture medium was replaced by 
a colorless HEPES-Tris (HT) solution (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 
5.5 mM D-glucose, and 10 mM HEPES, pH 7.4) and ﬂuorescence images were taken on a 
ZEISS LSM510 Meta confocal microscope (Carl Zeiss). Images were acquired at a rate of 
10 Hz with the use of a ×63 oil-immersion objective (N.A. 1.4; Carl Zeiss). Zoom factor 2 
and pinhole settings were selected for the attainment of an optical section thickness of
< 1 μm. Measurements were performed at 20°C in the dark. Confocal images of GFP and 
MitoTracker Red ﬂuorescence were simultaneously collected with the use of an argon 
laser (laser power 1%) with a 488 nm dichroic mirror and a 500–530 nm band-pass barrier
ﬁlter in combination with a helium-neon (HeNe) 1 laser (laser power 43%) with a 543 nm 
dichroic mirror and a 560 nm long-pass ﬁlter. With the multitrack setting used, Hoechst
ﬂuorescence was subsequently imaged with the use of a 405 nm diode laser (laser power 
10%) and a 420–480 band-pass barrier ﬁlter.
Phylogenetic reconstruction of TMEM70 family
Homolog sequences were manually selected from sets obtained with the jackhmmer 
tool from HMMER (Finn et al. 2015) version 3.1b2. We initiated the search with TMEM70, 
TMEM186 or TMEM223 = and searched against the UniProtKB database, iterating until 
getting back all three human paralogs (6, 6 and 5 iterations, respectively). In order to 
obtain as many sequences from different phyla as possible, we repeated the strategy using 
the PSI-BLAST algorithm from BLAST (Altschul et al. 1997) searching against the refseq 
protein database. After selecting the sequences, we aligned them with MAFFT (Katoh and 
Standley 2013) v7.306 using the L-INS-I algorithm with default parameters except for the 
following: “Leave gappy regions” and “Mafft-homologs: ON”. The obtained alignment was
manually reﬁned by deleting large gaps in very few sequences. Finally, in order to unravel 
the orthologous groups, we reconstructed the phylogenetic tree with PhyML (Guindon et 
al. 2010) version 20120412 and its automatic model selection SMS (Lefort, Longueville, and 
Gascuel 2017) using Bayesian Information Criterion. The resulting tree was plotted with 
iTOL (Letunic and Bork 2016) version 3.5.4.
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Results
A comprehensive assessment of the TMEM70 knockout effect on the
oxidative phosphorylation system
Previous studies in patients harbouring TMEM70 mutations have shown a CV deﬁciency 
accompanied with a less severe CI deﬁciency (Jonckheere et al. 2011), a combined OXPHOS 
deﬁciency (Braczynski et al. 2015) or even an isolated CI deﬁciency (Diodato et al. 2015). 
To shed light on this diversity of phenotypes, we performed a BN-PAGE/immunoblotting 
analysis of an enriched mitochondrial fraction in wild-type and TMEM70 depleted cells 
to compare the abundance of OXPHOS complexes in both conditions. Such conditions 
consisted of HAP1 cell lines, one wild-type and other mutant, with a 32bp deletion in exon 
1 of the TMEM70 gene, which causes a frameshift and a premature stop codon in the cDNA 
with no expression of the protein. Consistent with previous results, our analyses revealed
reduced levels of CI and CV (Figure 1a) in the TMEM70-defective cell line. To obtain a more 
comprehensive view on how the absence of TMEM70 affects the mitochondrial protein
complexes, we performed complexome proﬁling, which consists of a BN-PAGE followed by
mass spectrometry (Wessels et al. 2009; Heide et al. 2012).
This experimental technique allows us to see the majority of the proteins belonging to 
each of the native complexes and their distribution over the different intermediates 
(Wessels et al. 2009; Heide et al. 2012). It also allowed us to conﬁrm the absence of TMEM70 
in the TMEM70 knockout cell line (Supplemental Figure S1). Two technical replicates were 
done. In the ﬁrst replicate we detected 3258 proteins (Supplemental Table S1), of which 
768 are annotated as mitochondrial in MitoCarta 2.0 (Calvo, Clauser, and Mootha 2016).
In the second replicate we detected 2358 proteins (Supplemental Table S2), 589 of which 
annotated as mitochondrial. 1668 proteins were detected in both replicates, of which 476 
were annotated as mitochondrial. The six proﬁles were normalized such that the sum of
the intensities, expressed as iBAQ values, of the mitochondrial proteins per sample were 
equal and the proﬁles were aligned (Methods, Supplemental Table S3). The proteins that 
showed on average a decrease in intensity in the mutants relative to the controls and 
thus, were most likely directly affected by the absence of TMEM70, were ranked based 
on differences between their migration proﬁles in control cell lines (parental and wild-
type clone) on the one hand and in the TMEM70 knockout cells on the other hand, divided
by the variation within either (Methods). Then, in order to comprehensively detect the 
protein complexes that were signiﬁcantly affected by the TMEM70 knockout, the ranked 
list was analysed using gene set enrichment analysis (Subramanian et al. 2005) using all 
known mitochondrial complexes as the gene sets (Ruepp et al. 2010). The results show that 
CI and CV are the only signiﬁcantly enriched complexes (Figure 1b, complex I adj. p = 0.018,
complex V adj. p < 0.001), corroborating that both complexes are affected by the absence 
of TMEM70. We also tested their enzymatic activities by spectrophotometric analysis
and, accordingly, results showed a decrease in CI and CV activity (around 30% and 70% 
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decrease, respectively (wilcox test, p values = 0.156 and 0.009); Supplementary Figure S2), 
whereas the rest of the OXPHOS complexes showed no apparent disturbance.
ﬁgure 1 | TMEM70 deﬁciency affects the assembly of complexes I and V and interacts directly 
with their subunits.
(a) BN-PAGE/immunoblotting analysis of CI (NDUFS3), CII (SDHA), CIII (UQCRC2), CIV (COX4) and 
CV (_ subunit) reveals deﬁcincy of CI and CV in TMEM70 depleted hap1 cells (KO) compared with its
parental hap1 (WT). Levels of complex II (CII, SDHA) serve as loading control. (b) Proﬁle of the GSEA 
of proteins belonging to complex I (b1) and complex V (b2) ranked by differences shown in their
migration proﬁles upon mutation of TMEM70. (c) Combining interaction candidates obtained with 
the BioID experiments with the differences in the migration proﬁle shown by the complexomics 
data through a GSEA, reveals a signiﬁcant enrichment of those candidates among the proteins
most affected by the mutation. Proteins that belong to complex I and V found in the BioID 
experiment are depicted on top of the proﬁle.
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TMEM70 interacts with complex I and complex V proteins
To study whether there was a direct interaction of TMEM70 with components of CI and CV, 
and thus TMEM70 deﬁciency was the direct cause of both deﬁciencies, we used HEK293 
Flp-In T-Rex293 cell lines engineered to express BirA*- tagged TMEM70 in a doxycycline-
inducible manner (BioID).
Through this experiment designed to biotinylate proteins that occur in close proximity to 
our protein of interest, and after analysing the outputted results (Supplemental Table S4), 
we obtained a list of putative interaction partners of TMEM70 based on proteins showing
a signiﬁcant increase in biotin positive – doxycycline positive conditions (Supplemental 
Figure S3, Supplemental Table S5). The set of proteins biotinylated by BirA-TMEM70 
was signiﬁcantly enriched for proteins involved in CI and CV (analysis done with DAVID 
(Huang da, Sherman, and Lempicki 2009), Supplemental Figure S4), as well as for both the
mitochondrial and nuclear translation and cell-cell adhesion (Supplemental Table S6). After
obtaining these interaction candidates, we assessed whether this set as a whole depended
on the presence of TMEM70. We did this by deﬁning the interaction candidates as a gene 
set in the gene set enrichment analysis, basically repeating the analysis in which we 
systematically assessed the effect of the lack of TMEM70 on proteins belonging to known
protein complexes, but now, for a set of BioID based TMEM70 interaction candidates. This
analysis showed that the set of interaction proteins was indeed enriched among proteins
showing differences in the migration pattern between wild type and TMEM70 knockout
conditions (Figure 1c, BioID NES = 1.80; p val = 0.014), supporting that TMEM70 is involved 
in the assembly of its interaction partners into mitochondrial complexes.
ﬁgure 2 | Migration proﬁles of complex I modules in parental HAP1 cells (dark grey) and TMEM70 
KO HAP1 cells (red) normalized based on the maximum iBAQ value in both conditions
(a) and based on the maximum value in each condition separately (b). Each module is represented 
by the average of the iBAQ values of all the subunits detected by mass spectrometry that belong
to that module (Supplemental Table S2). Arrowheads indicate the apparent molecular mass where
all proteins belonging to the correspondent pre-assembled intermediates are found together. The 
accumulation shown by the Q/PP-a module at ~280kDa and the Q/PP module at ~750kDa (empty
arrowhead) in the TMEM70 knockout cells suggests an impairment in the incorporation of these 
modules in later stages of the assembly. (c) Two-dimensional Blue Native PAGE analysis of HAP1 
control cells (WT) and HAP1 TMEM70 depleted cells (TMEM70 KO). (lMitoplasts were lysed with
n-dodecyl-`-D-maltoside. Blots were stained with antibodies directed against representative 
subunits of different CI intermediates: NDUFS3 (Q-module) and NDUFAF1 (PPb) to detect Q/PP
intermediates.
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Abnormal assembly of complex I
Given the phenotypic heterogeneity in TMEM70 patients, the reported co-migration of
TMEM70 with CI (Guerrero-Castillo et al. 2017) and our results, we decided to focus on
the differences in the assembly process of CI, both in TMEM70 wild-type and in TMEM70
knockout HAP1 cells, by 2D BN-PAGE followed by immunoblotting and by complexome 
proﬁling. As mentioned above, there was a reduction of fully formed CI in cells lacking 
TMEM70 (Figure 1a). CI assembly proceeds via pre-assembled intermediates that later on
interact, until the fully formed and active enzyme is made (Sanchez-Caballero, Guerrero-
Castillo, and Nijtmans 2016). When analysing the assembly steps of CI under TMEM70
KO conditions, we observed a clear accumulation of the Q/PP-a intermediate (Figure 2a)
relative to controls. At this stage, the Q-module formed by NDUFS2, NDUFS3, NDUFS7, 
NDUFS8 and NDUFA5 and the assembly factors NDUFAF3 and NDUFAF4 is anchored to 
the membrane with proteins belonging to the proximal P-module, TIMMDC1 and MT-ND1. 
Following the formation of this intermediate, the remaining subunits of the proximal 
module (Pp-b) are added to form the intermediate Q/PP, an intermediate that in the 
TMEM70 depleted cells also accumulates, relative to the controls (Figure 2a). The most 
distal part of the enzyme, the intermediate (PD) is composed by 2 different intermediates, 
PD-a and PD-b. TMEM70 was found to comigrate with this distal membrane part (PD) of 
CI (Guerrero-Castillo et al. 2017), and within this distal part, with the intermediate PD-a, 
that is just next to the proximal membrane part of the complex, that accumulates under
TMEM70 abscence. When we normalize both knockout and wildtype conditions separately 
by their respective fully assembled CI rather than by the complete set of mitochondrial 
proteins, the disturbance in the assembly process becomes more apparent (Figure 2b). 
The largest differences are shown again by the intermediates Q/PP-a, Q/PP, and also PD-b. 
The Q/PP-a intermediate shows a 7-fold increase (from 8.9% relative to fully formed CI in 
controls to 64% relative to the fully formed complex in the mutants). The abundance of 
the Q/PP intermediate increases by 3.25-fold compared to the fully assembled holoenzyme
in the absence of TMEM70 (from 11.6% to 33% for QPP-a and from 19.2% to 70% for PP-b). 
Lastly, an increase of 3-fold (5.1% to 15.5%) is observed in PD-b compared to the controls, 
thus conﬁrming a disturbance in the stoichiometry of the CI assembly that is reﬂected in 
these three intermediates particularly.
Loss of the interaction between the c-ring and F1 module in the TMEM70
knockout
In order to understand the defects in CV assembly in the absence of TMEM70, we
examined the assembly process using the aforementioned complexomics data. The ﬁrst
complexomics replicate with the two controls and the mutant was particularly successful, 
identifying all subunits of CV except for the components of the c-ring octamer (which were 
also absent in the second run). In the data from the controls of this particular replicate, 
the subunits of CV were distributed over multiple modules: the F1 module with subunits
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_,`,a, b and¡, the F0 module with subunits ATP8, ATP6, DAPIT, 6.8PL, f, g and e and the
peripheral stalk with subunits OSCP, F6, d and b. Subunits belonging to F1 show a migration
pattern matching previously suggested states (Nijtmans et al. 1995), namely, F1 soluble
(_-` hexamer together with a,band ¡ monomers), F1 attached to the membrane bound 
c-ring, and F1 forming part of the fully assembled complex (Figure 3a). No C1 subunits were 
detected, but their presence in the aforementioned intermediate is consistent with the 
apparent molecular mass reported by our experiments (~450kDa) and the mass calculated 
based on its components, including 8 c-subunits (425.2 kDa). With respect to the F0 module,
our results show a co-migration pattern that suggests that all subunits belonging to this 
module assemble together into one intermediate except for F6 and OSCP, which are only 
added in the fully assembled form of the enzyme (Figure 3b and 3c). Previous studies have
linked TMEM70 mutations primarily with CV deﬁciency (Wortmann et al. 2009; Catteruccia
et al. 2014; Cizkova et al. 2008; Diodato et al. 2015; Honzik et al. 2010; Jonckheere et al. 
2011; Magner et al. 2015; Shchelochkov et al. 2010; Spiegel et al. 2011; Torraco et al. 2012).
Accordingly, we detected a lower abundance of the fully assembled CV in cells lacking 
TMEM70 (Figure 1a). When explored into detail, we found that the above-mentioned 
association of the c-subunit octamer with the _-` hexamer and thea,b and ¡subunits 
that form the F1 module was missing in the absence of TMEM70, whereas the canonical 
soluble F1 intermediate showed no differences between the two conditions (Figure 3d). 
With respect to the c-ring components in the complexome analysis by mass spectrometry, 
we reasoned that the tryptic in-gel digestion leads to difﬁculties generating enough
detectable peptides of proteins that are small, and highly hydrophobic, as the c-subunit
(C1). To address this issue, we repeated the BN-PAGE followed by mass spectrometry, but 
now digesting the samples with chymotrypsin instead of trypsin. Results conﬁrmed that
the intermediate with an apparent mass of ~450 kDa indeed represents the F1 module
associated with the c-subunits (Figure 3e). Interestingly, the absence of this ~450kDa 
intermediate in TMEM70 devoid cells was accompanied by the absence of subunit C1, 
conﬁrming the interaction of the soluble F1 with the membrane subunit C1 (Figure 3f).
When focusing on the subunits belonging to the F0 module and/or the peripheral stalk,
we found no differences between the TMEM70 knockout and the control (Supplementary 
Figure S5a and S5b). Together, these results suggest a role of TMEM70 in the interaction
between the octamer of C1-subunits and the F1 module.
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ﬁgure 3 | Migration proﬁles of ATP synthase components in HAP1 cells.
The interaction between F1 module and the c-ring during assembly does not occur in the absence 
of TMEM70. (a) Subunits of the F1 module, showing three peaks corresponding to the soluble form, 
anchored to the membrane interacting with the c subunit octamer and forming part of the fully 
assembled complex, from lower to higher molecular mass. (b) and (c) show components of the FO
stator stalk and FO stator, respectively. (d) Average of F1 subunits in wild-type (black) and knockout
(red) conditions. (e) Two-dimensional Blue Native PAGE analysis of HAP1 control cells (WT) and HAP1
TMEM70 depleted cells (TMEM70 KO). (lMitoplasts were lysed with n-dodecyl-`-D-maltoside. Blots
were stained against ATP synthase _ subunit to detect F1 intermediates (d) complexome proﬁling
results after chymotrypsin digestion showing the average of detected F1 subunits and C1 protein in
wild-type and knockout conditions.
ATP synthase subunit a has a reduced stability in TMEM70 defective
cells 
As the CV assembly intermediate that comprises the F1 module anchored to the membrane
through the C1-subunit ring is missing in the TMEM70 knockout cells, we decided to
test if this was due to an unstable F0 module that has a high turnover in the absence of
TMEM70. To do so, we studied the stability of its mitochondrially encoded subunits (MT-
ATP6 encoding for ATP synthase subunit a, and MT-ATP8 encoding for ATP synthase protein 
8), by labelling newly translated mitochondrial products with 35S-methionine (Boulet,
Karpati, and Shoubridge 1992). After 1h of permanently inhibiting cytoplasmic translation 
(0h) we identiﬁed severely reduced levels of subunit a, whereas the other mitochondrially
encoded subunits did not appear to be signiﬁcantly affected by the absence of TMEM70 
(Figure 4a). Similarly, the chase at 5h and 24h after the removal of the transient inhibitor 
of cytoplasmic translation revealed reduced levels of ATP synthase subunit a compared
to the parental cell line. The abundance of NADH-ubiquinone oxidoreductase subunit 1 
(encoded by MT-ND1) and NADH-ubiquinone oxidoreductase subunit 2 (encoded by MT-
ND2) was also reduced at 24h, consistent with the lower abundance of the assembled
CI in the knockout as observed in the proteomics and enzyme kinetics data. To test the
stability of the newly synthesized products, and to discard less efﬁcient synthesis of 
subunit a as an alternative explanation for the loss of this subunit, we chased at shorter 
times i.e., 5 minutes, 15 minutes, 30 minutes and 60 minutes. ATP synthase subunit a is
equally abundant in the TMEM70 KO cell line in comparison with the parental cell at short
pulses but becomes less abundant at longer pulses (Figure 4b). These results indicate an 
enhanced turnover of the mitochondrially encoded subunit a, suggesting a less efﬁcient 
incorporation of this subunit into the complex, rather than a synthesis impairment.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 92
92 Chapter 4
ﬁgure 4 | Pulse labelling of mitochondrial translation products after A) 1h pulse and 5h and 24h 
chases. B) short pulses (5 min, 15 min, 30 min and 1 h).
The mitochondrial protein family TMEM223/TMEM186/TMEM70 co-
evolves with oxidative phosphorylation
In order examine whether TMEM70 has co-evolved with oxidative phosphorylation 
proteins we determined its phylogenetic distribution. Homology analysis of TMEM70 
using Hidden Markov Models (Methods) revealed that it has two paralogs in human: 
TMEM223 (E=2.9e-8) and TMEM186 (E=1.2e-28) (Figure 5a). Results obtained from cellular 
fractionation (Figure 5b) and microscopy (Figure 5c and 5d) indicate a mitochondrial
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localization of both paralogs. Although the level of sequence identity between the three 
family members is low (e.g. in human TMEM70-TMEM186: 14%, TMEM70 -TMEM223: 9%, 
TMEM186-TMEM223: 15%), in silico predictions indicate a similar asymmetric hairpin 
topology for all three proteins; a short N-terminal sequence located in the mitochondrial 
matrix followed by an in/out and an out/in transmembrane region and a longer C-terminal 
sequence (Supplemental Figure S6), consistent with the experimental results for TMEM70 
(Kratochvilova et al. 2014). We subsequently examined whether the TMEM70/186/223 
phylogenetic distribution is similar to other proteins. All three members of the 
TMEM70/186/223 family are phylogenetically widespread (Figure 5a), and they appear to
have been present in the last eukaryotic common ancestor (LECA). We then asked whether 
any other mitochondrial proteins have a similar phylogenetic distribution as members 
of the TMEM70/186/223 family. Given the low sequence identity between orthologs in
this protein family and their potential interactors, e.g. the identity between human
TMEM223 and S. cerevisiae TMEM223(YNR040W) is 15%, we used a two-tier approach. First,
we examined via automated Blast searches which human proteins had the most similar
distributions to TMEM70, using an operational deﬁnition of best bi-directional Blast hit
orthology (E<0.01) and Dollo Parsimony that assumes that there is no horizontal gene 
transfer to measure co-evolution. For TMEM70, the protein with the highest co-evolution 
signal (NDUFAF1) and four of the ten most co-evolving proteins were CI proteins (Table S3). 
Second, we manually analysed, using the top hits of the ﬁrst approach and using more 
sensitive, proﬁle-based analyses, the co-evolution of TMEM70/186/223 with CI, CV and 
TMEM14. The latter is, based on the ﬁrst step of the analysis, a protein family that co-
evolves withTMEM70/186/223, and is like that family and like CI and CV located in the inner 
mitochondrial membrane. Overall, we observe that members of the TMEM70/186/223
protein family only occur in species with oxidative phosphorylation, and are absent from 
species without CI and or CV. Nevertheless, the reverse does not apply as there are taxa, 
like the Kinetoplastida, that do have CI and CV but do not have detectable homologs of the 
TMEM70/186/223 family (Table S8).
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ﬁgure 5 | TMEM70 has two paralogs, TMEM186 and TMEM223 that are both located in the 
mitochondria.
Furthermore, for TMEM70 orthologs in Arabidopsis thaliana and Schizosaccharomyces pombe, 
there is experimental evidence that localizes them in the mitochondria (Nikolovski et al. 
2012; Matsuyama et al. 2006). (a) Phylogenetic distribution of TMEM70 homologs (b) Cellular 
fractionation of cells expressing TMEM186-TAP and TMEM223-TAP. Immunodetection against
NDUFB11, as a marker of the mitochondrial enriched fraction (M), Alpha-tubulin as a marker of the 
cytoplasm (C), and CBP. (T) stands for total fraction. (c) and (d) Fluorescence microscopy images of 
cells expressing TMEM186-GFP (c) and TMEM223-GFP (d) stained with Mitotracker (mitochondrial
network) and DAPI (nucleus).
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Discussion 
Our results describe a role of TMEM70 in the assembly of CI and CV of the OXPHOS 
system. This ﬁnding is in line with previous studies of patients harbouring mutations in 
TMEM70, that did not always have an isolated CV deﬁciency but rather combined OXPHOS
deﬁciencies or even isolated CI deﬁciency (Braczynski et al. 2015; Jonckheere et al. 2011;
Diodato et al. 2015; Wortmann et al. 2009). The conclusions are supported by results
from BN-PAGE/immunoblotting analysis and enzyme measurements of the oxidative 
phosphorylation complexes, by complexome proﬁling and by BioID analyses. Although 
both CI and CV are signiﬁcantly affected in all analyses of TMEM70 knockout, the effect
on CV is in the proteomics data and in the enzyme measurements more pronounced 
than that on CI, which might explain the preponderance of CV phenotypes relative to CI 
phenotypes reported in the literature.
To determine the role of TMEM70 in the assembly of CI and CV in more detail, we studied all
the proteins of both complexes meticulously by complexome proﬁling (Heide et al. 2012;
Wessels et al. 2009) and by two-dimensional blue native gel electrophoresis followed by 
western blot of speciﬁc subunits. Thus, we were able to detect the majority of the proteins
of each complex and of their preassembled intermediates. This allowed us to determine 
the effects that the lack of TMEM70 has on CI and CV assembly. For CI, a preassembled Q/
PP intermediate clearly accumulates in the absence of TMEM70. This suggests that this
module is assembled as in wild-type conditions and that the impairment in the pathway 
comes right after its assembly, in the association of the proximal module (PP) with the 
most distal membrane part of the enzyme (PD).
To further substantiate a physical interaction of TMEM70 with CI during its assembly, 
we also performed a biotin ligase proximity-dependent assay (BioID) of BirA* tagged
TMEM70. As a result, we also obtained subunits and assembly factors of CI (Table S4) that
show evidence of interaction with TMEM70. The interaction between CI and TMEM70 is in 
line with a previous study done by Guarini et al.(Guarani et al. 2014), where pull downs of 
11 subunits and 4 assembly factors were done, showing TMEM70 as a signiﬁcant interactor
of ECSIT and NDUFS5, both proteins belonguing to the PP intermediate. Taking into account
the just mentioned interaction of TMEM70 with proteins of the PP intermediate (Guarani et 
al. 2014), the comigration with the distal part (PD) of CI (Guerrero-Castillo et al. 2017), and
the accumulation of Q/PP intermediates, and also the PD-b intermediate, that we see in our
results, we suggest that the participation of TMEM70 in CI is in the assembly of the membrane 
arm (P-module) of the enzyme, joining the PD intermediate with the Q/PP intermediate. 
This is also consistent with the membrane architecture of the protein consisting of two 
transmembrane helices followed by a long C-terminal tail (Jonckheere et al. 2011).
With respect to CV, we delineate a speciﬁc role of TMEM70 in its assembly. Through BN-PAGE 
followed by mass spectrometry, we observed how upon lack of TMEM70, the intermediate 
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where F1 is bound to the membrane-embedded C1-subunits octamer (Nijtmans et al. 1995)
is completely absent. Furthermore, via pulse and pulse-chase experiments, we detected 
a lower abundance of newly synthetized subunit a (mitochondrially encoded, MT-ATP6),
which sits adjacent to the C1-ring (Naumenko et al. 2017), in TMEM70 knockouts than in 
controls. At short pulses, the abundance of subunit a was very similar if not equal in the 
control and TMEM70 knockout, but it decreased at longer intervals, leading us to conclude
that the decreased abundance of ATP-synthase subunit a was due to an enhanced turnover 
rather than decreased synthesis. As the synthesis of mitochondrial encoded subunits was 
not altered in TMEM70 devoid cells, the hypothesis of nucleoid disruption (Cameron et al.
2011) seems unlikely to us. Despite the absence of TMEM70, as well as the F1-C1 intermediate,
although minimal, there was still some CV being assembled. Taking into account the 
assembly of the complex, we suggest that in TMEM70 depleted cells the assembly of the 
complex follows an alternative path already described (He et al. 2018), where F1 instead of 
being attached to the C1-ring octamer, it attaches to the F0 and the peripheral stalk.
Through our homology analyses and phylogenetic reconstruction of the co-evolution 
of TMEM70/186/223 family with CI and CV we could not detect a TMEM70 ortholog in
Saccharomyces cerevisiae. Interestingly, it has been described how in this species, F1 does 
not undergo the same assembly steps as in human and does not interact with the c-ring 
(Song, Pfanner, and Becker 2018). Furthermore, S. cerevisiae lacks CI, ﬁtting our hypothesis 
of a double role of the protein in human, that is absent from S. cerevisiae because one of 
the target complexes has been lost in evolution (CI), and the manner in which the other 
target complex is assembled has changed. Sensitive homology detection does however 
reveal the presence of a TMEM70 homolog in S. cerevisiae, TMEM223. TMEM70, TMEM223 
and the third member of this family that we could detect, TMEM186, appear widespread in
eukaryotic evolution and only occur in species with Oxidative Phosphorylation complexes.
We performed confocal microscopy for analysis of GFP-tagged TMEM186 and TMEM223. 
The analysis showed the predominant localization of both proteins in the mitochondria, 
something that we could conﬁrm by fractionation of pure mitochondria. Like TMEM70, 
TMEM186 was also identiﬁed to co-migrate with CI assembly intermediates following
dynamic complexome proﬁling (Guerrero-Castillo et al. 2017) . Little is known about this 
protein; however, it was recently identiﬁed as an interaction partner of ECSIT (Guarani et 
al. 2014), suggesting a role in CI assembly. Additional studies are required to determine if
this protein functions in CI assembly.
It is interesting and unusual that a single protein, TMEM70, would be involved in the 
assembly of two different oxidative phosphorylation complexes, CI and CV. A common 
denominator based on our results is that, in both cases, it appears to recruit proteins to 
membrane intermediates during the assembly of the enzyme. Such a combination of 
hydrophobic and hydrophilic interactions would be consistent with the topology of the
protein that contains two well conserved transmembrane helices together with a long 
(~100 amino acids) tail that protrudes into the matrix.
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Supplementary ﬁgures and tables
ﬁgure S1 | TMEM70 knockout cells shown no presence of TMEM70 in contrast with control HAP1
cells.
ﬁgure S2 | Enzymatic activities shown by TMEM70 KO with respect to the parental wild-type
cell line. 
Complex I shows a decrease on its activity, although not statistically signiﬁcant (p.val = 0.156, 0.8,
0.51, 0.577 and 0.009, respectively).
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ﬁgure S3 | Putative interaction partners of TMEM70. 
Signiﬁcant increased proteins in biotin positive – doxycycline positive conditions in the TMEM70 
biotin proximity-dependent analysis were coloured in red.
ﬁgure S4 | Proteins biotinylated by BirA-TMEM70 were signiﬁcantly enriched for proteins
involved in CI and CV (analysis done with DAVID), as well as for both the mitochondrial and nuclear 
translation and cell-cell adhesion. Gene Ontology categories: Biological Process (BP), Molecular 
Function (MF) and Cellular Component (CC).
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ﬁgure S5 | Migration proﬁles of ATP synthase intermediates F0 and peripheral stalk (PS). 
In contrast of that with F1 module, F0 module (a) and PS module (b), albeit reduced, do not show 
missing subassemblies along the assembly of the ATP synthase in TMEM70 KO cells.
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ﬁgure S6| Topology predictions calculated with TMHMM (doi: 10.1006/jmbi.2000.4315) 
for (a) TMEM70, (b) TMEM186 and (c) TMEM223 show a similar in-out-in topology with two 
transmembrane domains close to the N-terminal.
The following tables would be sent upon request to the correspondant authors and they
will be published online:
table S1 | List of 3258 proteins (768 annotated as mitochondrial) detected in the ﬁrst complexome 
proﬁling replicate of HAP1 control and HAP1 TMEM70 depleted cells. 
table S2 | List of 2358 proteins (589 annotated as mitochondrial) detected in the second
complexome proﬁling replicate of HAP1 control and HAP1 TMEM70 depleted cells. 
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table S3 | List of 1668 proteins (476 annotated as mitochondrial) detected in the both complexome
proﬁling replicates of HAP1 control and HAP1 TMEM70 depleted cells. The six proﬁles were 
normalized such that the sum of the intensities, expressed as iBAQ values, of the mitochondrial 
proteins per sample were equal and the proﬁles were aligned. 
table S4 | List of biotynilated proteins in the TMEM70 biotin proximity-dependent analysis.  
table S5 | List of proteins in biotin positive – doxycycline positive conditions in the TMEM70 biotin 
proximity-dependent analysis. 
table S6 |List of signiﬁcant increased proteins in biotin positive – doxycycline positive conditions 
in the TMEM70 biotin proximity-dependent analysis.  
table S7 | Top co-evolving mitochondrial proteins with TMEM70. Mitochondrial proteins sorted by
similarity of their phylogenetic proﬁles compared to TMEM70 as determined by differential Dollo 
parsimony. The orthologous group ids indicate to which OrthoMCL based orthology a protein 
belongs to, and thus on which orthologous group the phylogenetic proﬁle is based. Proteins with 
the same orthologous group id are considered in-paralogs and thus share the same phylogenetic 
proﬁle.
table S8 | Phylogenetic distribution of TMEM70, TMEM186 and TMEM223. Separation of the family 
into the various orthologous groups has been done using the phylogeny (Figure 5), the ciliate 
(T. thermophila and P. tetraurelia) members of the TMEM70/TMEM186/TMEM223 protein family
could not conﬁdently be assigned to any speciﬁc group however, and where therefore left blank. 
Phylogenetic distribution of complex I, V and TMEM14 has been established using reciprocal best
hits established with Blast searches and, when homologs were not detectable using the Blast,
using proﬁle based searches (Szklarczyk et al. 2012).
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Species TMEM70 TMEM186 TMEM223 TMEM14 Complex I Complex V
Homo sapiens 1 1 1 1 1 1
Mus musculus 1 1 1 1 1 1
Xenopus tropicalis 1 1 1 1 1 1
Takifugu rubripes 1 1 1 1 1 1
Danio rerio 1 1 1 1 1 1
Branchiostoma ﬂoridae 1 1 1 1 1 1
Ciona intestinalis 1 1 1 0 1 1
Drosophila melanogaster 1 1 1 1 1 1
Anopheles gambiae 1 1 1 1 1 1
Caenorhabditis elegans 1 0 0 0 1 1
Nematostella vectensis 1 1 1 1 1 1
Trichoplax adhaerens 1 1 1 1 1 1
Monosiga brevicollis 1 0 1 1 1 1
Encephalitozoon cuniculi 0 0 0 0 0 0
Batrachochytrium dendrobatidis 0 0 1 1 1 1
Rhizopus oryzae 1 0 1 1 1 1
Phycomyces blakesleeanus 1 0 1 1 1 1
Ustilago maydis 1 0 0 1 1 1
Cryptococcus neoformans 0 0 0 1 1 1
Schizosaccharomyces pombe 1 0 1 1 0 1
Neurospora crassa 1 0 0 1 1 1
Yarrowia lipolytica 1 0 1 1 1 1
Debaryomyces hansenii 1 0 1 1 1 1
Kluyveromyces lactis 0 0 1 1 0 1
Candida glabrata 0 0 1 1 0 1
Saccharomyces cerevisiae 0 0 1 1 0 1
Dictyostelium discoideum 0 0 1 1 1 1
Entamoeba histolytica 0 0 0 0 0 0
Cyanidioschyzon merolae 0 0 1 1 1 1
Micromonas pusilla RCC299 1 1 0 1 1 1
Ostreococcus tauri 1 1 0 1 1 1
Chlamydomonas reinhardtii 1 1 0 1 1 1
Volvox carteri 1 1 0 1 1 1
Physcomitrella patens 1 1 0 1 1 1
Selaginella moellendorfﬁi 1 1 0 1 1 1
Arabidopsis thaliana 1 0 0 1 1 1
Oryza sativa 1 0 0 1 1 1
Phytophthora infestans 1 0 1 1 0 1
Phytophthora sojae 1 0 1 1 0 1
Phaeodactylum tricornutum 1 0 0 1 0 1
Thalassiosira pseudonana 1 0 0 1 1 1
Emiliania huxleyi 1 0 0 0 1 0
Paramecium tetraurelia 0 1 1
Tetrahymena thermophila 0 1 1
Plasmodium falciparum 0 0 0 0 0 1
Cryptosporidium parvum 0 0 0 0 0 0
Toxoplasma gondii ME49 0 0 0 1 0 1
Naegleria gruberi 0 0 1 1 1 1
Trichomonas vaginalis 0 0 0 0 0 0
Giardia intestinalis 0 0 0 0 0 0
Leishmania major 0 0 0 0 1 1
Trypanosoma brucei TREU 927 0 0 0 1 1 1
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Abstract
Mitochondrial complex I deﬁciency results in a plethora of often severe clinical phenotypes
presenting already in early childhood. Here we report three complex-I-deﬁcient adult 
subjects with relatively mild clinical symptoms, including isolated, progressive exercise 
induced myalgia and exercise intolerance but with normal later development. Exome
sequencing and targeted exome sequencing revealed compound heterozygous mutations
in TMEM126B, encoding for a complex I assembly factor. Further biochemical analysis of 
subject ﬁbroblasts revealed a severe complex I deﬁciency caused by a defective assembly.
Lentiviral complementation with the wild-type cDNA restored the complex I deﬁciency,
demonstrating the pathogenic nature of these mutations. Further complexome analysis 
of one subject indicated that the complex I assembly defect occurred during assembly 
of its membrane module. Our results show that TMEM126B defects can lead to complex I 
deﬁciencies and, interestingly, that symptoms can occur only after exercise.
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Introduction
Isolated complex I (CI) deﬁciency is the most frequent cause of respiratory chain defects 
in childhood and accounts for various clinical presentations. Neurological presentations
are often observed, as numerous individuals present with Leigh syndrome (OMIM
256000), Leber hereditary optic neuropathy (LHON, OMIM 535000), mitochondrial
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS, OMIM 540000). In
addition, numerous other clinical presentations combining hypotonia, developmental 
delay, seizures, cardiomyopathy, optic atrophy or retinopathy and other organ 
involvement have been reported (Nouws et al. 2012; Koene et al. 2012; Fassone and Rahman 
2012). Mitochondrial CI is the largest enzyme of the oxidative phosphorylation (OXPHOS)
system (Brandt 2006; Hirst 2013). It is embedded in the inner mitochondrial membrane 
(Vinothkumar, Zhu, and Hirst 2014; Zickermann et al. 2015) and is composed of three 
different functional and structural modules (Brandt 2006). The entry point of electrons 
is the NADH dehydrogenase module (N module) that contains a ﬂavin mononucleotide 
where NADH is oxidized, after which the electrons are transferred along a chain of iron-
sulfur clusters to the Q module, where ubiquinone is subsequently reduced. For every 
two electrons transferred from NADH to ubiquinone, four protons are ejected from the 
mitochondrial matrix via the proton pumping module (P module) (Brandt 2006; Baradaran 
et al. 2013; Hirst et al. 2003; Walker 1992; Carroll et al. 2003). It has been established that 
the assembly of CI in vivo is a stepwise process in which different pre-assembled modules 
are combined into the mature holo-enzyme (Ugalde et al. 2004; Vogel et al. 2004). CI 
deﬁciencies are associated with mutations in mitochondrial and nuclear genes encoding
structural subunits, but also in nuclear genes encoding CI-speciﬁc assembly factors
(Nouws et al. 2012). Interestingly, most of these assembly factors were ﬁrst discovered in
patients with a mitochondrial CI deﬁciency (Kevelam et al. 2013; Tenisch et al. 2012; Tucker 
et al. 2012; Ogilvie, Kennaway, and Shoubridge 2005; Saada et al. 2009; Saada et al. 2008; 
Fassone et al. 2010; Sugiana et al. 2008; Gerards et al. 2010; Dunning et al. 2007; Fassone 
et al. 2011). Only a few CI assembly factors have been identiﬁed by functional studies in 
normal cellular models (Andrews et al. 2013; Janssen et al. 2002; Vogel et al. 2007; Nouws 
et al. 2010; Heide et al. 2012; Pagliarini et al. 2008; Carilla-Latorre et al. 2010). One of these 
is TMEM126B (OMIM 615533), a mitochondrial transmembrane protein. Deﬁciency of this 
protein has been shown to reduce the total amount of CI in a cellular model system (Heide 
et al. 2012; Andrews et al. 2013). Furthermore, it has been shown that TMEM126B forms 
a complex with other assembly factors, NDUFAF1 (OMIM 606934), ACAD9 (OMIM 611103) 
and Ecsit (OMIM 608388) (Heide et al. 2012; Andrews et al. 2013). We identiﬁed TMEM126B 
mutations in 3 unrelated subjects with exercise intolerance, hyperlactatemia and isolated
CI deﬁciency.
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Results and discussion
Subjects
Subject 1 is a 38-year-old Caucasian man born from non-consanguineous healthy parents. 
He had progressive muscle complaints from the age of 38 years onwards and was referred 
to our clinic with progressive exercise induced myalgia (most predominantly in his calves). 
Resting relieved the symptoms and there was no second wind phenomenon. Fasting did
not affect the myalgia, and signs of rhabdomyolysis were absent. He also suffered from 
excessive daily fatigue. His early development had been normal and he reported normal 
functional abilities. Neurological examination and electromyography were normal. 
Laboratory investigations revealed hyperlactatemia (2.9-4.8 mmol/L, control values <2
mmol/L) and hyperalaninemia (772 μmol/L, control values 150-450 μmol/L) and a blood
pH of 7.25 at rest. Other laboratory tests, including creatine kinase, were normal. A 
muscle biopsy showed no abnormalities with standard immunohistochemical staining
techniques, including Gomori trichrome and oxidative staining. However, electron 
microscopy showed several abnormalities indicating mitochondrial dysfunction: most
mitochondria were swollen with some giant mitochondria, most of the mitochondria
were surrounded with lipid droplets and few mitochondria showed crystalline inclusions
(Figure 1A). Activity of respiratory chain enzymes indicated a severe CI deﬁciency in muscle 
and ﬁbroblasts (Table 1).
Subject 2, a 30-year-old woman of European descent, was born to healthy unrelated parents 
after a normal pregnancy and delivery. Her younger brother is healthy. Psychomotor
development was normal. From the age of 9 years, she experienced exercise intolerance, 
manifested by premature exertional muscle fatigue, myalgia, dyspnea and cardiac 
palpitations for relatively intense efforts such as running but not for moderate efforts. 
Indeed, her walking distance was not markedly reduced. Levels of blood creatine kinase
were always normal at rest and during acute episodes. At the age of 23 years, she was
admitted for investigations. Height and weight were 1.61 m and 49 kg respectively. She had 
a normal physical appearance but had mild proximal muscle weakness at examination.
Electrocardiography and echocardiography were normal. Ophthalmological examination 
was completely normal, with no sign of retinitis pigmentosa at fundoscopy and no optic 
atrophy. Metabolic investigations showed hyperlactatemia (7 mmol/L, control values 
<2 mmol/L) and hyperalaninemia (1120 μmol/L, control values 274±50 μmol/L), and an 
increased lactate/pyruvate ratio (33, control values: 10-20). Measurement of urine organic
acids showed elevated lactate levels (8000 μmol/mmol creatinine, control values <84 
μmol/mmol creatinine). CI activity was severely reduced in muscle mitochondria (Table 1).
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Subject 3, a 22-year-old man of European descent, was the ﬁrst child born to healthy 
unrelated parents after a normal pregnancy and delivery. His younger brother is healthy.
He was able to walk at 18 months. He was noted to have proximal muscle weakness at 
3 years of age. He had lifelong exercise intolerance marked by myalgia followed by 
vomiting. Nevertheless he was reported to have normal physical activity. At 14 years of 
age, neurological examination was normal. His height and weight were 1.49 m and 37.7 kg 
respectively. Metabolic investigations showed permanent hyperlactacidemia (2.8 to 7.4 
mmol/L) and elevated lactate/pyruvate ratios (21 to 32) with hyperalaninemia (702 μmol/L,
normal range 274±50 μmol/L) and elevated lactate levels in urine (2775 μmol/mmol
creatinine, control values <84 μmol/mmol creatinine). Ophthalmological and cardiac
examination was normal. A severe CI deﬁciency was observed in muscle (Table 1).
Informed consent for diagnostic and research studies was obtained for all subjects in 
accordance with the Declaration of Helsinki protocols and approved by local Institutional 
Review Boards in Nijmegen and Paris. 
Gene and Conservation Analyses 
To identify the disease-causing genetic defect, we performed whole-exome sequencing of 
subject 1. Putative pathogenic variants were selected after ﬁltering against known SNPs 
in dbSNP, 1000 Genomes, the National Heart, Lung, and Blood Institute (NHLBI) Exome
Variant Server, intergenic variants and an in-house variant database. This revealed two 
heterozygous variants in TMEM126B (NM_018480.4): c.635G>T, p.(Gly212Val) and c.397G>A, 
p.(Asp133Asn) (Figure 1B,C,D). These variants were conﬁrmed by Sanger sequencing.
Segregation analysis revealed that the mother of the subject 1 carries the c.635G>T variant
and the father carries the c.397G>A variant.
The genetic defect in subject 2 was identiﬁed by targeted exome sequencing of a panel 
of 215 genes, including the known genes for mitochondrial disorders and genes of CI 
subunits and assembly factors. This revealed two TMEM126B heterozygous variants
that were conﬁrmed by Sanger sequencing (c.635G>T inherited from the mother and
c.208C>T, p.(Gln70*)) inherited from the father) (Figure 1B,C,D). Considering the similar 
clinical presentation of subjects 2 and 3, we performed Sanger sequencing of TMEM126B
for subject 3 and detected two TMEM126B heterozygous variants (c.635G>T and c.397G>A, 
inherited from the mother and the father respectively; Figure 1B,C,D).
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ﬁgure 1 | Mutations in TMEM126B are associated with mitochondrial dysfunction.
(A) Electron micrographs of skeletal muscle sections from subject 1 showing a mitochondria with 
cristalline inclusions (left), a giant mitochondrion (center), and mitochondria surrounded by 
lipid droplets (right). (B) Exon/intron organisation of the TMEM126B gene (MIM 615533) depicting 
the three human cDNA isoforms (TMEM126B.1(NM_018480.4), TMEM126B.2 (NM_001193537.2) and
TMEM126B.3 (NM_001256546.1)). The positions of the TMEM126B variants identiﬁed in the subjects 
are indicated. (C) Sequence analysis of TMEM126B of subjects 1-3 (S1-S3). The arrows indicate the
mutations. (D) Sequence analysis of RT-PCR of TMEM126B exons 3-5 shows in subject 3 (S3) a 
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heterozygous exon 3 deletion starting at c.295 underneath with the normal allele (left) and a much 
lower amount of the c.635G>T variation in exon 5 in subject 3 than in control (right). (E) Partial
structure of TMEM126B (gDNA) and cDNA. The exon-intron junctions, as well as the consensus
splice sites, are presented. c.294 indicates the putative consensus splice site (AGGT) that should
have been used as new splice site in subject 1 and 3.
table 2 | TMEM126B variations identiﬁed in the subjects (S1, S2, S3) and predicted consequences. 
Effect of the variations on the protein was predicted by Alamut software that includes SIFT, 
MutationTaster and Polyphen. The frequency of the variations in dbSNP, ClinVar and ExAC are 
presented. The predicted splicing modiﬁcations were determined by Alamut software that 
includes MaxEnt, NNSPLICE and HSF. TEM126B reference sequence is NM_001193537.
The c.397G>A and c.635G>T variants are present in the European population with a very
low allele frequency (Table 2). The p.Gly212Val change was predicted to be deleterious by 
three different prediction software packages, namely SIFT, MutationTaster and Polyphen-2 
(Table 2). The c.397G>A (rs573006534) variant is predicted to lead to the loss of the 3’splice 
site of exon 3. Sanger sequencing of RT-PCR products encompassing exon 3 revealed two
superimposed sequence traces (Figure 1D) suggesting that an alternative splice site, 
located at position 293-296 was used instead, which generated a truncated cDNA that
lacks 104 bp from exon 3 (Figure 1E). This truncated transcript most likely had a reduced
Subjects S2 S1, S3 S1, S2, S3
Nucleotide change c.208C>T c.397G>A c.635G>T
Aminoacid change p.Gln70* p.Asp133Asn p.Gly212Val
SIFT Tolerated (score: 0.12) Deleterious (score: 0.03)
MutationTaster Disease causing 
(p-value: 1)
Disease causing 
(p-value: 0.946)
Polyphen Benign (score: 0.084) Probably damaging 
(score: 0.995)
Predicted change at
donor site
1 bp downstream
-56.8%
MaxEnt -77.6%
NNSPLICE -80.5%
HSF -12.2%
dbSNP(MAF/Minor
Allele Count)
rs573006534 (< 0.01/1) rs141542003 (unknown)
ClinVar - - -
ExAC allele frequency A=0.0089% T=0.13%
ESP - T=16/G=8582 (European
American)
T=0/G=4406 (African 
American)
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stability giving that sequencing of exon 5 from total cDNA detected predominantly 
the c.635G>T variant (Figure 1D). Using RT-PCR we ampliﬁed three distinct TMEM126B
transcripts, TMEM126B.1 (NM_018480.4), TMEM126B.2 (NM_001193537.2) and TMEM126B.5 
(NM_001256546.1), the ﬁrst and the last of which have been previously reported. Transcript
5 is generated by an alternative start codon downstream of the initiating methionine 
of transcript 1, whereas transcript 2 is a result of an alternative splicing (Figure 1B). All
isoforms have identical exons 3-5. Thus, the identiﬁed mutations, which localize in exons
3 and 5, affect all three TMEM126B isoforms. Therefore, the three subjects have the same 
c.635G>T mutation resulting in p.Gly212Val from the maternal allele and either a splice
mutation resulting in an unstable transcript or a premature stop codon from the paternal 
allele. The low allelic frequencies of c.397G>A and c.635G>T, absence of c.208C>T in SNP
databases, the compound-heterozygous state of TMEM126B variations, and the recurrence
of these mutations in three independent subjects with a similar clinical phenotype and an 
isolated CI deﬁciency, are highly suggestive for a pathogenic effect on CI activity.
Mutations in TMEM126B lead to complex I deﬁciency
Blue-Native PAGE (BN-PAGE) analyses revealed a marked decrease in fully assembled CI
in cultured skin ﬁbroblasts of the three subjects (Figure 2A and 2B), consistent with the
isolated CI defect detected in muscle biopsies. Although the other OXPHOS complexes 
were all present at similar levels between subjects and control ﬁbroblasts, we detected a
mild increase in the CIII2-CIV supercomplex, suggesting that supercomplex composition 
undergoes a general rearrangement as a result of the decrease in CI levels. To further
investigate this, we solubilize mitoplasts isolated from ﬁbroblasts of subject 1and control
cells in digitonin, a detergent that preserves the high-molecular-weight respiratory-chain 
supercomplexes. The amount of CI-containing supercomplexes, detected either by an in-
gel enzyme assay (IGA) or by immunoblotting, was lower in subject 1 than in control cells 
(Figure 2C). Similarly, we found a decreased level of CI-CIII2-CIVn supercomplexes visualized
with speciﬁc antibodies for complex III and complex IV (Figure 2C). On the other hand, 
supercomplex CIII-CIV and monomeric CIV were found to be slightly increased in subject
1 ﬁbroblasts (Figure 2C). Consistent with these results, immunoblot analyses of total
protein extracts from subjects 2 and 3 and control ﬁbroblasts revealed decreased levels 
of the CI subunit NDUFB8 for subject 2 and increased steady-state levels of CIII and CIV, 
UQCR2 and COX1 for subject 3 (Figure 2D).
Because TMEM126B had been recently reported to function as an assembly factor for
CI (Heide et al. 2012), we proceeded to study in more detail the assembly defect of CI in 
subjects’ ﬁbroblasts. The decreased level of fully assembled CI was accompanied by an 
accumulation of subassembled intermediates in all the three subjects (Figure 3A and 
3B). These intermediates belong to the Q and P modules, given that they are detected 
by antibodies against NDUFS3 and NDUFA13, respectively, which localize in these
modules. Using two-dimensional BN-SDS-PAGE (BN-PAGE followed by SDS-PAGE) further
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characterization of the subassembled intermediates in subject 1 ﬁbroblasts using two 
dimensional revealed a profound reduction in the molecular weight of the NDUFS3-
containing module (Figure 3C). Similarily, we detected an accumulation of ACAD9, an 
assembly factor of CI membrane arm, at a lower molecular level in subject 1 ﬁbroblasts 
(Figure 3C). These results indicate that the assembly of the individual CI functional 
modules is impaired in subjects carrying TMEM126B mutations.
Interestingly, NDUFAF1 and ACAD9, assembly factors acting at the level of the membrane 
arm of CI where TMEM126B is expected to interact (Andrews et al. 2013; Heide et al. 2012; 
Guarani et al. 2014), showed increased steady-state levels in protein extracts from subject 
1 ﬁbroblasts. In ﬁbroblasts of subject 2 and 3, CI subunits, NDUFS3, NDUFB8 and NDUFA9 
were decreased ,which is in line the decreased assembly of complex I (Figure 3D, E).
ﬁgure 2 | Isolated complex I deﬁciency in subjects with TMEM126B variants.
(A-B) BN-PAGE analysis reveales isolated CI assembly defect in subjects’ ﬁbroblasts. Mitoplasts
(20 or 80 μg) isolated from control and subject skin ﬁbroblasts were solubilized with 1% DDM, 
fractionated through 3-12% native gel and transfered to either PVDF or Protan nitrocellulose 
membrane. The individual complexes were identiﬁed using speciﬁc antibodies. (C) Mitoplasts 
form C1 and subject 1 were solubilized in 2% digitonin and subjected to BN-PAGE as in A.
Supramolecular organization of the respiratory chain complexes were detected by in gel enzyme 
activity assay (IGA) for CI or immunoblotting using speciﬁc antibodies. (D) SDS-PAGE analysis 
of the steady-state levels of OXPHOS proteins. Total protein cell extracts (20 g) from control (C2
and C3) and subjects 2 and 3 ﬁbroblasts were fractionated through 12% polyacrylamide gels
and transferred on PVDF membranes. Individual OXPHOS proteins were detected using speciﬁc 
antibodies. SDHA is used as a loading control.
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ﬁgure 3 | Defect in Complex I and accumulation of Complex I assembly intermediates in 
subjects’ ﬁbroblasts were restored after lentiviral expression of wild type TMEM126B.
(A and B) Mitoplasts isolated from C1-3 and subjects 1 and 3 ﬁbroblasts were solubilized with
DDM and analyzed as in Figure 2A-B. NDUFS3 and NDUFA13 proteins in CI subassemblies were
detected using speciﬁc antibodies. (C) Mitochondria isolated from C1 and subject 1 ﬁbroblasts
were solubilized in 2% DDM, subjected to 2D BN-SDS PAGE analysis and transfered onto
Protan nitrocellulose membrane. NDUFS3 and ACAD9 were detectes using speciﬁc antisera. (D)
Steady state levels of the CI structural protein NDUFS3 and the CI assembly factors ACAD9 and
NDUFAF1determined by SDS-PAGE analysis and western immunoblotting of total cell extracts (40 
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μg) from C1 and subject 1 using speciﬁc antibodies. SDHA is used as a loading control. (E) Steady
state levels of structural proteins of CI determined by SDS-PAGE and western immunoblotting 
of total cell extracts (30 ug) from controls and S2-3 ﬁbroblasts, Hela and Hela rho 0 cells using 
speciﬁc antibodies. SDHA is used as a loading control. (F) Subject 3 ﬁbroblasts were transduced
with lentiviral particles expressing wild type TMEM126B.1, 2 or 3 fused to a C-terminal Flag-tag  
(iso1F, iso2F and iso3F). Mitoplasts (20  g, upper panel) were analyzed by BN-PAGE as in Figure 2A,B. 
CI assembly is partially restored by expression of the three isoforms. SDS-PAGE analysis (lower 
panel) of total cell protein extracts (20  g) performed as in Figure 2D shows expression of all three
TMEM126B isoforms and the partial restoration of NDUFA13 and NDUFB8 steady-state levels.Actin 
is used as a loading control. (G) Fibroblasts form subject 1 were transduced with lentiviral particles
expressing wild type TMEM126B isoform 3 (iso3) or GFP. CI assembly and activity were analyzed by 
BN-PAGE followed by immunoblotting or IGA. 
Functional complementation restored complex I deﬁciency
In order to conﬁrm that the CI deﬁciency observed in the three subjects is indeed due 
to the TMEM126B variants, we performed functional complementation studies using
lentiviral expression of the different wild type TMEM126B isoforms carrying a C-terminal
FLAG tag. Lentiviral expression of three isoforms in ﬁbroblasts from subject 3 (Figure 3F)
and 2 (data not shown) partially restored CI assembly and resulted in increased steady
state levels of NDUFB8 and NDUFA13, whereas CI subassemblies were reduced in the 
complemented ﬁbroblasts. Similarly, expression of TMEM126B.5 in subject 1 ﬁbroblasts
partially restored assembly (Figure 3G) and in vitro activity of CI (Table 1). These results
demonstrate the causal role of TMEM126B mutations for the CI assembly defect observed 
in the three subjects.
Complexome proﬁling to study complex I deﬁciencies
To obtain more in-depth information concerning the disturbed CI assembly process, we
performed complexome proﬁling (Wessels et al. 2009; Wessels et al. 2013; Heide et al. 2012)
in control, subject 1- and complemented subject 1-ﬁbroblasts. This mass-spectrometry-
based approach provides an unbiased insight in the amount and composition of 
complexes, including CI subassemblies. This analysis led to several observations. We 
could demonstrate a clear improvement in CI assembly, showing more mature CI and less
subassemblies accumulating in the complemented cells compared to the subjects cells 
(Figure 4A). The only peptide of TMEM126B detectable by mass spectrometry is not present
in isoform 5. Therefore, we could only monitor isoforms 1 and 2 by complexome proﬁling 
that were almost undetectable in the subject 1 ﬁbroblasts. (Figure 4B). This also meant 
that we could not observe an increase in TMEM126B in the ﬁbroblasts complemented with
isoform 5. Still, the accumulation of higher-molecular-mass versions of the assembly 
factor complexes observed in the patient ﬁbroblast was largely reversed, indirectly
indicating successful complementation. In addition we observed accumulation of CI 
subassemblies of the ubiquinone binding part, a decrease of the NADH binding part and a
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disturbed proton pumping part in the subject 1 ﬁbroblasts (Figure 4A), consistent with our
western blot data (Figure 3). TMEM126B was decreased in subject 1 ﬁbroblasts but present
together with ACAD9, Ecsit and NDUFAF1 in control ﬁbroblasts (Figure 4B). Interestingly, its
paralogue TMEM126A was detectable in mitochondrial complexes only in the ﬁbroblasts of 
the subject with a defect in TMEM126B. Moreover, it seems to co-migrate with CI assembly 
factors ACAD9 and NDUFAF1, whereas in control ﬁbroblasts, TMEM126A was not associated
with any mitochondrial complex. This observation of TMEM126A co-migrating with CI 
assembly factors has been reported before in HEK293 cells (Wessels et al. 2013). TMEM126B
comes from a duplication of its ancestor TMEM126A (OMIM 612988), and they share 85% 
similarity in their nucleotide sequence. TMEM126B is evolutionary one of the most recent 
CI assembly factors and is only present in mammals. The replacement of TMEM126B 
with its paralogue TMEM126A in the CI assembly process in the subjects might suggest a 
compensatory mechanism. Analyses of the steady-state levels of TMEM126A showed that 
the protein was unchanged between control ﬁbroblasts and those from subjects 2 and
3, whereas it was found upregulated in rho° HeLa cells, in which expression of the seven
hydrophobic core subunits is abolished (Figure 4C). Interestingly, homozygous mutations 
in TMEM126A have been associated with isolated optic atrophy (Desir et al. 2012; Hanein et 
al. 2013; Meyer et al. 2010). Nevertheless, the role of TMEM126A in CI assembly has not been 
demonstrated and requires further research.
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ﬁgure 4 | Blue Native complexome proﬁling of patient, complemented and control ﬁbroblasts. 
(A) Heat maps (top panel) and migration proﬁles (bottom panel) of CI subunits belonging to N, 
Q and P module, obtained by complexome proﬁling of mitochondria isolated fom ﬁbroblasts 
from C1, subject 1 and complemented subject 1. (B) Heat maps (top panel) and migration 
proﬁles (bottom panel) mitochondrially encoded subunits ND1, ND2, ND4 and ND5 obtained by
complexome proﬁling of mitochondria isolated fom ﬁbroblasts from C1, S1 and complemented 
S1. (C) Heat maps (top panel) and migration proﬁles (bottom panel) of CI assembly factors 
(ACAD9, ECSIT, NDUFAF1 and TMEM126B) and TMEM126A, obtained by complexome proﬁling of 
mitochondria isolated fom ﬁbroblasts from C1, S1 and complemented S1. (D) Steady state levels of 
TMEM126A determined by SDS-PAGE analysis and western immunoblotting of total cell extracts
(30 μg) from controls, subject 2-3 and Hela and Hela rho 0 cells using speciﬁc antibodies. Actin is 
used as a loading control.
Conclusion
In conclusion, by using whole exome sequencing and targeted sequencing, we found
mutations in the gene encoding the CI assembly factor TMEM126B in three subjects. Using 
any of the wild type TMEM126B isoforms to restore the biochemical defects establishes
that the TMEM126B defects are disease causing in these subjects. The clinical phenotype, 
compared with other complex I defects, is relatively mild. In-depth analysis using 
complexome proﬁling allows to pinpoint the defect to a speciﬁc stage of the CI assembly 
process.
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Abstract
NDUFAF3 is an assembly factor of mitochondrial respiratory chain complex I. Variants in 
NDUFAF3 have been identiﬁed as a cause of severe multisystem mitochondrial disease. 
In a patient presenting with Leigh syndrome, which has hitherto not been described as 
a clinical feature of NDUFAF3 deﬁciency, we identiﬁed a novel homozygous variant and 
conﬁrmed its pathogenicity in patient ﬁbroblasts studies. Furthermore, we present an
analysis of complex I assembly routes representative of each functional module and, 
thereby, link NDUFAF3 to a speciﬁc step in complex I assembly. Therefore, our report
expands the phenotype of NDUFAF3 deﬁciency and further characterizes the role of
NDUFAF3 in complex I biogenesis. 
Keywords  NDUFAF3; OXPHOS; Leigh syndrome; complex I; assembly factor
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Introduction
Mitochondrial complex I (NADH:ubiquinone reductase; EC 1.6.5.3) is the largest oxidative 
phosphorylation (OXPHOS) component and one of the main entry points of electrons into
the respiratory chain. It contains three functional modules: the Q-module (ubiquinone
reduction), the P-module (proton pumping) and the N-module (NADH dehydrogenase). Its 
intricate biogenesis involves 37 nuclear-encoded and 7 mitochondrial-encoded subunits 
as well as several so-called assembly factors, which aid the biogenesis process but are
not part of the holo-enzyme (Guerrero-Castillo et al. 2016). During complex I biogenesis, 
assembly intermediates are formed, which are joined together in several steps that
eventually build the holo-complex. In the early assembly steps, the components of each 
functional module are assembled separately with hardly any intermodular association.
The latter largely takes place in the late steps of complex I biogenesis. Therefore, the 
process of complex I assembly mirrors its modular architecture (Guerrero-Castillo et al. 
2016).
NDUFAF3 has been assigned to be an assembly factor of the Q-module because it physically 
associates with Q-module subassemblies during complex I biogenesis (Guerrero-Castillo 
et al. 2016; Saada et al. 2009). However, its function and its speciﬁc role in complex I
assembly remain unclear. Clinical information on patients with pathogenic NDUFAF3
variants is restricted to short case reports in the manuscript originally describing NDUFAF3
as a mitochondrial disease gene (Saada et al. 2009).
Materials & Methods
Whole exome sequencing
Exome enrichment was performed using the SureSelect Human All Exon 50 Mb Kit (Agilent,
Santa Clara, CA), covering ~21,000 genes. The exome was sequenced on a HiSeq2000TM 
sequencher (Illumina). Color space reads were iteratively mapped to the hg19 reference
genome, and the variants were annotated using an in-house annotation pipeline 
(Hoischen et al. 2010). Quality criteria were applied to ﬁlter out variants with less than 5 
variant reads and less than 20% variation. Synonymous variants, deep intronic, intergenic 
and UTR variants were excluded from further analysis. Common variants were ﬁltered out 
based on a frequency of <0.3% in our in-house database, a frequency of <0.5% in dbSNP 
(v.137), the genome of the Netherlands (GoNL) (Boomsma et al. 2014), Exome Variant Server
(ESP) (http://evs.gs.washington.edu/EVS/) and Exome Aggregation Consortium (ExAC) 
data (http://exac.broadinstitute.org). Variants in mitochondrial candidate genes were 
selected. Based on a recessive inheritance model only a single candidate gene remained,
which was subsequently validated by Sanger sequencing.
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Cell culturing and enzymatic analysis
Patient derived skin ﬁbroblasts were cultured in M199 medium (Gibco, Life Technologies) 
supplemented with 10% v/v fetal calf serum (GE Healthcare) and 1% v/v penicillin/
streptomycin (Gibco) in a humidiﬁed atmosphere with 5% CO2 at 37°C. The activity of the 
OXPHOS enzymes and citrate synthase were measured as previously described (Janssen et 
al. 2007; Rodenburg 2011). 
Lentiviral complementation of patient ﬁbroblasts
C-terminally V5-tagged NDUFAF3WT or the Cox8 leader sequence were cloned into a 
pDONR201 vector and recombined with pLenti6.2⁄V5-DEST Gateway Vector using the 
Gateway LR Clonase II enzyme mix (Invitrogen) as previously described (Nouws et al. 2010; 
Nouws et al. 2014). HEK293FT cells were transfected to produce lentivirus according to the 
manufacturer’s protocol (Invitrogen) for 24 hours. After 48 hours, the transfected cells 
were selected with blasticidin. Blasticidin resistant cells were used for further analysis
after 14 days of culturing.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
two dimensional blue native polyacrylamide gel electrophoresis/SDS-
PAGE (2D-BN-PAGE/SDS-PAGE) and immunoblotting
SDS-PAGE using a 10% SDS gel, 2D-BN-PAGE/SDS-PAGE and immunoblotting were 
performed as previously described (Baertling et al. 2015; Calvaruso, Smeitink, and Nijtmans
2008). For 2D-BN-PAGE/SDS-PAGE the native protein complexes were ﬁrst separated in a 
4-12% blue native gel. The components of these protein complexes were then separated
and visualized by a second dimension denaturing SDS-PAGE/immunoblotting step
using a 10% SDS-PAGE gel. The following primary antibodies were used: NDUFS3 (Abcam,
Ab14711), NDUFA5 (gift of Professor John Walker, Cambridge, UK), NDUFB11 (Abcam,
Ab183716), NDUFV2 (Sigma, HPA003404), complex II/70kDa (MitoSciences, MS204), COREI 
(MitoSciences, MS303), COX1 (MitoSciences, MS404), complex V/_ subunit (MitoSciences, 
MS502), ACAD9 (kift from John Vockley, University of Pittsburgh, USA), V5 (Genscript,
A00641). As secondary antibodies, peroxidase-conjugated goat anti-mouse or goat anti-
rabbit IgGs (Life Technologies) were used. Proteins were transferred to a nitrocellulose 
membrane (Protran) and visualized using the enhanced chemiluminescence kit (Thermo 
Scientiﬁc) and the Chemidoc XRS+ system (Biorad).
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Results
Case report
The female patient was the second child of consanguineous parents (ﬁrst cousins) of
Indian ethnicity. She was born at a gestational age of 39 weeks with a birth weight of 
3400g. The pregnancy and the perinatal period were uneventful. In the neonatal period
she developed transient binocular horizontal nystagmus, which spontaneously resolved 
after three weeks. Further development was normal. At the age of three months, she
followed objects with her eyes, she started rolling over at four months, sat unsupported
at seven months and babbled double syllables sounds at seven months. At eight months 
of age, the horizontal nystagmus reappeared and persisted and frequent vomiting began. 
Furthermore, her head began tilting to the left and she displayed abnormal posturing of
lower limbs. On examination at the age of 15 months her weight was 6.9 kg (<3rd centile),
length 66 cm, (<3rd centile) and head circumference 41.5 cm (<3rd centile). Her muscle tone
was normal but reﬂexes were brisk. Ophthalmological assessment revealed bilateral optic 
atrophy. Visual evoked potentials were abnormal. Blood lactate was elevated on multiple 
occasions, ranging from 3.4 mmol/L to 6.1 mmol/L (reference range: <2.4 mmol/L). Plasma 
alanine was slightly elevated and ranged from 549 μmol/L to 683 μmol/L (reference range: 
185 – 537 μmol/L). Urine organic acid analysis showed increased excretion of fumaric acid 
and aconitic acid. Other laboratory investigations including blood cell counts, serum urea,
serum electrolytes, liver function tests, ammonia, creatine kinase and blood gas analyses 
were normal. 
A brain MRI revealed symmetric bilateral basal ganglia and brainstem lesions, consistent
with Leigh syndrome. These signal alterations were located in the substantia nigra, the
periaqueductal grey matter and the lateral parts of the pons and medulla oblongata. MR
spectroscopy (MRS) revealed lactate peaks in the basal ganglia and the frontal subcortical 
white matter. The according sequences were acquired using intermediate echo time
acquisition (135ms).
At 20 months of age, her condition began to deteriorate rapidly. She developed dysphagia 
and intractable vomiting and she required feeding via nasogastric tube. Eventually, she
lost her motor skills and speech. At the age of 21 months, she died due to cardiorespiratory 
failure following an episode of aspiration.
Whole exome sequencing identiﬁes pathogenic variants in NDUFAF3
Whole exome sequencing resulted in the identiﬁcation of a homozygous variant in the 
NDUFAF3 gene (NM_199069.1): c.494C>T; p.(Ala165Val). Each parent of the patient carried 
this variant heterozygously. The amino acid alanine at this position as well as the domain 
of the NDUFAF3 protein in which the variant is located are highly conserved (Fig. 1). The
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variant is known in dbSNP (rs138275059) and is present with a very low frequency of
0.00082% in the ExAC database (http://exac.broadinstitute.org). Polyphen2, SHIFT and 
MutationTaster2 in silico prediction pointed at a possible pathogenic effect. 
ﬁgure 1 | Comparison of the amino acid sequence of NDUFAF3 protein across different species.
The alanine in position 165 of human NDUFAF3 and the domain it is in are highly conserved.
NDUFAF3 deﬁcient patient ﬁbroblasts reveal isolated complex I deﬁciency, which can be
rescued by lentiviral complementation
In order to analyze the effects of the variant described above on the OXPHOS complexes, 
patient derived skin ﬁbroblasts were examined for the activity of the respiratory chain 
enzymes. The results showed an isolated complex I deﬁciency, combined with a normal to 
slightly elevated activity of the other OXPHOS enzymes (Table 1).
table 1 | Enzyme activities of the oxidative phosphorylation system (OXPHOS) complexes in
cultured skin ﬁbroblasts of the patient.
Activity Reference range
(mU/U CS)
Complex I 54 163 - 599
Complex II 720 335 - 888
Complex III 875 570 - 1383
Complex IV 1104 288 - 954
Complex V 854 193 - 819
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In order to prove the pathogenicity of the NDUFAF3 variant, patient ﬁbroblasts
were complemented with wild- type NDUFAF3 via stable lentiviral transfection. 
Complementation rescued complex I enzymatic activity to near control levels (Fig. 2B). 
Analysis of the expression levels of various subunits by SDS-PAGE/immunoblotting 
revealed that the levels of complex I subunit NDUFS3 were signiﬁcantly reduced in 
the patient cells, whereas the levels of representative subunits of the other OXPHOS 
complexes were not negatively affected (Fig. 2A).
ﬁgure 2 | Cultured skin ﬁbroblasts of the patient with the c.494C>T variant reveal isolated 
complex I deﬁciency that can be rescued by lentiviral complementation with wild-
type NDUFAF3.
A) Immunoblot analysis of mitochondrial fractions reveal reduced levels of complex I subunit
NDUFS3 in the patient ﬁbroblasts (Pat) in comparison to control ﬁbroblasts (Ctrl). NDUFS3 levels 
in patient cells complemented with wild-type NDUFAF3 (Pat+AF3) are restored to control levels.
Subunits of complex II (70 kDa subunit), complex III (CoreI), complex IV (COX1) and complex V (_
subunit) are either not reduced or even slightly elevated in comparison to control cells. Patient
cells transfected with an empty vector as mock transfection (Pat+ev) remained unaffected.
B) Complex I activity relative to citrate synthase (CS) is signiﬁcantly increased and restored to
levels within the reference range (163 – 599 mU/U CS) in patient ﬁbroblasts transfected with wild-
type NDUFAF3 (Pat+AF3) in comparison to patient cells transfected with an empty vector (Pat+ev). 
Transfection of control ﬁbroblasts with wild-type NDUFAF3 (Ctrl+AF3) does not alter complex I
activity in comparison to control cells transfected with an empty vector (Ctrl+ev). *p<0,05
NDUFAF3 deﬁciency leads to accumulation of components of the 
proximal and the distal P-module
To further analyze the effects of NDUFAF3 deﬁciency on the complex I assembly process 
we performed 2D-BN-PAGE/SDS-PAGE. The ﬁrst dimension BN-PAGE allows separation of 
native protein complexes. Here levels of fully assembled complex I were clearly reduced
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(Fig. 3A). The levels of the other OXPHOS complexes were not negatively affected (not 
shown). The second dimension SDS-PAGE allows separation and improved epitope 
availability for immunodetection of the individual components of the multiprotein 
complexes separated by the ﬁrst dimension BN-PAGE including complex I subassemblies.
ﬁgure 3 | Analysis of all modular complex I assembly routes reveals accumulation of 
subassemblies that correspond to intermediates of the proximal and the distal 
P-module.
A) BN-PAGE analysis of control (Ctrl) and patient (Pat) ﬁbroblasts reveal severely reduced levels of 
fully assembled complex I (CI) at approximately 1000 kDa.
B) 2D-BN-PAGE/SDS-PAGE of control and patient ﬁbroblasts followed by simultaneous 
immunodetection using antibodies against Q-module component NDUFS3 and proximal 
P-module component ACAD9. This approach was used to allow a semi-quantitative comparison 
between the NDUFS3 and the ACAD9 signal. The (ﬁrst dimension) BN-PAGE lanes from Fig. 3A are
included for illustration of the method. In NDUFAF3 deﬁcient ﬁbroblasts, a subassembly (sa1) 
containing ACAD9 but none containing NDUFS3 accumulate. In the patient cells, the intensity 
of the subassembly, represented by the ACAD9 signal, is signiﬁcantly stronger than that of holo-
complex I, represented by NDUFS3. 
C) 2D-BN-PAGE/SDS-PAGE analyses of control and patient ﬁbroblasts using antibodies to analyze 
all remaining further routes of the modular assembly pathway of complex I. NDUFA5 represents
another component of all Q-module assemblies, NDUFB11 is a component of the distal P-module 
and NDUFV2 represents the Q-module. Note the accumulating NDUFB11 containing subassemblies
(sa2 and sa3) as well as the increased intensity of the “smear” signal in between the holo-complex 
I signal and these subassemblies in patient cells. The signals at the height of sa2 and sa3 as well as
the “smear” are considered accumulating subassemblies in the patients ﬁbroblasts because their
signal intensity is increased relative to the signal at the height of holo-complex I.
The asterisk (*) marks signals that correspond to physiological complex I subassemblies. They are 
considered physiological because, in control ﬁbroblasts, their signal intensity does not exceed 
the signal intensity of the respective subunit at the height of holo-complex I and, in patient 
ﬁbroblasts, this relation is not shifted towards the subassembly.
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Although NDUFAF3 is part of the Q-module subassemblies of complex I, we have
previously demonstrated that there was no accumulation of subassemblies containing
Q-module subunits in NDUFAF3 deﬁcient patient ﬁbroblasts (Saada et al. 2009). Therefore,
we performed 2D-BN-PAGE/SDS-PAGE experiments, in which we not only examined 
NDUFS3 as well as NDUFA5, as additional Q-module components, but also several other 
proteins representative of the other functional modules of complex I and their assembly 
routes (Fig. 3B, C). For details on the nomenclature of assembly intermediates applied here 
and a detailed overview of complex I biogenesis please see our recently published complex 
I assembly model (Guerrero-Castillo et al. 2016).
The additional subunits and assembly factors we analyzed included the following: (i)
ACAD9 as distinct component of the proximal P-module, (ii) NDUFB11 as representative of
the distal P-module and (iii) NDUFV2 as distinct component of the N-module (Guerrero-
Castillo et al. 2016). Conﬁrming previous observations, there was no accumulation of the
Q-module components NDUFS3 and NDUFA5. Furthermore, no N-module subassemblies 
accumulated. However, there was a clear accumulation of complex I assembly 
intermediates containing ACAD9 as well as subassemblies containing NDUFB11. 
Discussion
Prior to our report, only one manuscript has been published, in which patients with 
pathogenic NDUFAF3 variants are described (Saada et al. 2009). It describes three families: 
in the ﬁrst family three siblings harbored a homozygous variant: c.229G>C; p.(Gly77Arg). 
Their main clinical feature was increased muscle tone but no brain MRI abnormalities
and normal echocardiography, EEG and abdominal ultrasound. In the second family, 
one child harbored the c.365.G>C p.(Arg122Pro) variant. Clinical signs were macrocephaly 
and muscular hypotonia. The third patient was compound heterozygous for the variant 
in the second family and the c.2T>C; (p.Met1Thr) variant. This patient developed diffuse 
leukoencephalopathy and myoclonic seizures. All patients died between the ages of two
and six months.
The patient described in the present manuscript was homozygous for the previously
undescribed c.494C>T; p.(Ala165Val) missense variant. The patient had isolated complex 
I deﬁciency and presented with Leigh syndrome and bilaterally symmetric lesions in the 
basal ganglia and the brain stem as well as a lactate peaks on MRS. She died at the age 
of 21 months. Unlike the rather unspeciﬁc presentations of the previously published 
patients, the patient reported here developed Leigh syndrome, a deﬁned manifestation 
of mitochondrial disease (Baertling et al. 2014). Given the very early deaths of the other 
reported patients, her disease course, although still severe, seemed to be slightly milder.
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We analyzed the different assembly routes leading to formation of holo-complex I by 
performing 2D-BN-PAGE/SDS-PAGE experiments using antibodies representative of each 
functional module’s pathway. This approach allowed us to show that NDUFAF3 deﬁciency
leads to accumulation of complex I subassemblies containing ACAD9, a distinct component
of a part of the proximal P-module (PP-b), and subassemblies containing NDUFB11, a
distinct component of the distal P-module (PD-a). No subassemblies containing distinct
components of the Q-module were detected in the current study (NDUFA5, NDUFS3) 
or our previous work (NDUFS2 (Saada et al. 2009)). However, our recently published 
detailed human complex I assembly model clearly shows that, until the late assembly 
steps, NDUFAF3 is only associated with subassemblies of the Q-module rather than with
subassemblies of the proximal P-module or the distal P-module containing either ACAD9
or NDUFB11 (Guerrero-Castillo et al. 2016). Since subassemblies containing the latter two 
accumulate in NDUFAF3 deﬁcient patient ﬁbroblasts, it is likely that NDUFAF3 is essential 
for late complex I biogenesis where the Q-module and the P-module are joined. NDUFAF3
is presumably required for the speciﬁc step, in which the PP-b/PD-a subassembly and the
Q/PP-a subassembly are connected to form the Q/P-assembly intermediate (Guerrero-
Castillo et al. 2016).
In summary, we further characterized the role of NDUFAF3 in complex I biogenesis by 
pinpointing the assembly step it is involved in. Furthermore, this report expands the
phenotype of NDUFAF3 deﬁciency by adding Leigh syndrome, a deﬁned mitochondrial 
disorder, to its spectrum. Given the fact that the number of reported patients is still rather 
small, further detailed reports are required to further delineate the phenotype.  
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Abstract
Mitochondrial respiratory chain complex I consists of 44 different subunits and can be 
subgrouped into three functional modules: the Q-, the P-, and the N-module. NDUFAF4 
(C6ORF66) is an assembly factor of complex I that associates with assembly intermediates 
of the Q-module. Via exome sequencing, we identiﬁed a homozygous fmissense variant
in a complex I deﬁcient patient with Leigh syndrome. Supercomplex analysis in patient 
ﬁbroblasts revealed speciﬁcally altered stoichiometry. Detailed assembly analysis of 
complex I indicative of all of its assembly routes showed an accumulation of parts of 
the P- and the N-module but not the Q-module. Lentiviral complementation of patient 
ﬁbroblasts with wild-type NDUFAF4 rescued complex I deﬁciency and the assembly defect
conﬁrming the causal role of the variant. Our report on the second family affected by an 
NDUFAF4 variant further characterizes the phenotypic spectrum and sheds light into the 
role of NDUFAF4 in mitochondrial complex I biogenesis.
Keywords  NDUFAF4; OXPHOS; complex I; assembly factor; Leigh syndrome
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Introduction
Mitochondrial respiratory chain complex I (CI, NADH:ubiquinone oxidoreductase) is the
largest component of the oxidative phosphorylation (OXPHOS) system. It is L-shaped and 
can be subgrouped into three functional modules: the Q-module (ubiquinone reduction) 
and the N-module (NADH dehydrogenase), which form the matrix arm, and the P-module
(proton pumping), which makes up the membrane-integrated arm.
CI biogenesis is an intricate process: 37 nuclear-encoded and 7 mitochondrial-encoded 
subunits form numerous assembly intermediates that are assembled in several parallel 
and sequential steps to build the fully assembled complex. Subsequently, CI is integrated 
into supercomplexes, in which it associates with either a complex III (CIII)-dimer (I/III2-
supercomplexes) or with a CIII-dimer and one or multiple copies of complex IV (CIV, I/III2/
IVn-supercomplexes)(Guerrero-Castillo et al. 2017). 
CI assembly depends on the action of several assembly factors that associate with
assembly intermediates but are not part of the holo-enzyme itself. 
NDUFAF4 (C6ORF66) has been categorized as an assembly factor of the Q-module because 
it associates with Q-module subassemblies during CI biogenesis(Guerrero-Castillo et
al. 2017). However, its exact function has not yet been elucidated. So far, one NDUFAF4
variant that affected protein function has been described in a single family(Saada et al. 
2008). Here, we present a patient with a novel NDUFAF4 variant, expand the phenotype 
associated with NDUFAF4 deﬁciency and analyze its role in CI biogenesis.
Materials and Methods
Whole exome sequencing
Exome sequencing and variant ﬁltering was performed essentially as described before 
(Wortmann et al. 2015; Neveling et al. 2013). In short, exome enrichment was performed 
using the SureSelect Human All Exon 50 Mb Kit (Agilent, Santa Clara, CA), covering ~21,000 
genes. The exome was sequenced on a HiSeq2000TM sequencer (Illumina, San Diego, CA,
USA). Colour space reads were iteratively mapped to the hg19 reference genome, and the
called variants and indels were annotated using an in-house annotation pipeline. Common
variants were ﬁltered out based on a frequency of <0.5% in dbSNP v.137 (www.ncbi.nlm.
nih.gov/SNP/) and Exome Aggregation Consortium (ExAC) data (exac.broadinstitute.org/) 
(Lek et al. 2016), and a frequency of <0.5% in our in-house database. Quality criteria were
applied to ﬁlter out variants with less than 5 variant reads and less than 20% variation.
Furthermore, synonymous variants, deep intronic, intergenic and UTR variants were 
excluded.
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Cell culture and enzymatic analysis
Patient-derived skin ﬁbroblasts were cultured using standard procedures in M199 medium
(Pan Biotech, Aidenbach, Germany) supplemented with 10% v/v fetal calf serum (Gibco/
Life Technologies, Grand Island, NY, USA) and 1 % v/v penicillin/streptomycin (Gibco/
Life Technologies) in a humidiﬁed atmosphere with 5% CO2 at 37°C. The activity of the
respiratory chain enzymes, complex V, and citrate synthase in mitochondria-enriched 
fractions of the patient ﬁbroblasts were measured as previously described (Janssen et al. 
2007; Rodenburg 2011). The results were normalized to the activity of citrate synthase.
Lentiviral complementation of patient ﬁbroblasts
C-terminally V5-tagged wild-type NDUFAF4 or C-terminally V5-tagged GFP were cloned
into a pDONR201 vector and recombined with pLenti6.2⁄V5-DEST Gateway Vector using 
the Gateway LR Clonase II enzyme mix (Invitrogen, Carlsbad, CA, USA) as previously 
described (Nouws et al. 2010). HEK293FT cells were transfected in order for them to produce 
lentivirus. The virus particles were harvested after 72 h and were added to the patient 
ﬁbroblasts for 24 h, after which the virus-containing medium was replaced with virus-
free medium. After 48 h, blasticidin (2 μg/ml) was added to the medium to select for the
transfected cells. Control and patient ﬁbroblasts were cultured in selection medium for 14
days, after which the blasticidin resistant cells were used for further analysis. 
Isolation of mitochondrial protein and protein quantiﬁcation
Mitochondrial protein for blue native polyacrylamide gel electrophoresis (BN-PAGE) and 
two dimensional BN-PAGE/sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(2D-BN-PAGE/SDS-PAGE) was solubilised by resuspending mitochondrial fractions 
(isolated by digitonin treatment and centrifugation) in a 2% n-dodecyl-`-d-maltoside 
solution as described previously (Calvaruso, Smeitink, and Nijtmans 2008). To analyse
supercomplex stoichiometry, this solubilisation was performed using digitonin in a
concentration of 4 grams per gram of mitochondrial protein in a buffer consisting of 5mM 
aminohexanoic acid, 50mM imidazole, 2mM MgCl2 and 50 mM NaCl at pH 7,0. Total cell 
lysates were obtained by resuspending the cell pellet in 2% n-dodecyl-`-d-maltoside as 
previously described (Baertling et al. 2015). Protein concentrations were determined using 
the Pierce BCA protein assay kit (Thermo Fisher Scientiﬁc, Rockford, IL, USA). 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
two dimensional Blue Native Polyacrylamide Gel Electrophoresis/SDS-
PAGE (2D-BN-PAGE/SDS-PAGE) and immunoblotting
SDS-PAGE using a 12% SDS gel, 2D-BN-PAGE and immunoblotting were performed as 
previously described (Calvaruso, Smeitink, and Nijtmans 2008). For 2D-BN-PAGE/SDS-PAGE 
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the native protein complexes were separated in a 4-12% BN-PAGE gel. The components 
of these protein complexes were then separated and visualized by a second dimension 
denaturing SDS-PAGE/immunoblotting step using a 12% SDS-PAGE gel. The following 
primary antibodies were used: NDUFS3 (Abcam, Cambridge, UK; Ab14711), SDHA (Abcam; 
Ab14715), UQCRFS1 (Proteintech, Manchester, UK; 18443-1-AP), COX2 (MitoSciences/Abcam; 
MS405), COX5A (MitoSciences/Abcam; MS409), COX4 (Abcam; Ab110261), complex V/d
subunit (CVdSU; MitoSciences/Abcam, MS509), V5 (Invitrogen; R961-25), holo-CIII (gift of 
the “Molecular Bioenergetics” group of the Radboud Centre for Mitochondrial Medicine,
Nijmegen, The Netherlands), GFP (a gift from Frank van Kuppeveld, Nijmegen, the 
Netherlands), ACAD9 (a gift from Jerry Vockley, University of Pittsburgh, USA), ECSIT (gift 
from Michael T. Ryan, Monash University, Melbourne, Australia), NDUFAF4 (gift from Ann 
Saada, Hadassah Medical Centre, Jerusalem, Israel), ND1 (gift of Anne Lombes, Université 
Paris-Descartes, Paris, France), TFAM (gift from Rudolf J. Wiesner, University of Cologne,
Germany). As secondary antibodies peroxidase-conjugated goat anti-mouse or goat anti-
rabbit IgGs (Life Technologies) were used. Proteins were transferred to a nitrocellulose
membrane and visualized using the enhanced chemiluminescence kit (Thermo Fisher
Scientiﬁc) and the Chemidoc XRS+ system (Bio-Rad, Hercules, CA, USA).
Fractionation of mitochondria
Mitochondrial enriched fractions were generated by dounce homogenization and 
subsequent centrifugation at 600g for 15 min to pellet unbroken cells and nuclei. 
The supernatant was again centrifuged for 25 min at 18000g. The resulting pellet was 
resuspended in PBS. One quarter was repelleted and used as whole mitochondrial fraction,
the further three quarters were separately repelleted and resuspended in carbonate 
extraction buffer (0.1 M Na2CO3, pH=11,5) and incubated for 30 min. This step was followed
by ultracentrifugation for 1 h at 100 000g. The resulting supernatant was used as soluble 
protein fraction and the pellet was washed twice and used as membrane protein fraction.
For solubilisation, the pellets from the whole mitochondrial fraction and the membrane 
fractions were resuspended in a 2% n-dodecyl`-d-maltoside solution and incubated for
10 minutes, followed by centrifugation at 18000g for 30 min. The resulting supernatants
were used for SDS-PAGE as described above.
Results
Case report
The patient is the ﬁrst child of consanguineous (ﬁrst cousins) parents of Pakistani
ethnicity. He was born at 38 weeks gestation after induction of labour due to concerns 
regarding intrauterine growth retardation. He weighed 2406 grams.
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At 7 months of age he was presented to the local paediatric services due to a decline in
his milestones. He smiled infrequently, was unable to roll over, sit unsupported and did 
not babble. He was a non-dysmorphic, underweight child with irritability. He had central 
hypotonia and normal to slightly increased limb tone with easily elicited tendon knee 
reﬂexes and no clonus.
Brain MRI revealed diffuse bilateral signal alterations in the basal ganglia and thalami 
indicative of Leigh syndrome. An EEG showed generalised slowing with multifocal spikes 
consistent with an epileptogenic focus. There was no cardiovascular, renal or hepatic
disease.
Urine organic acid analysis revealed increased lactate, ketones and Krebs cycle
metabolites. Plasma lactate was 10.6 mmol/l and CSF lactate was 6.1 mmol/l (reference 
range: 0.8-1.8 mmol/l). Patient-derived skin ﬁbroblasts were examined for the activity of 
the respiratory chain enzymes, which showed isolated CI deﬁciency (32 mU/U of citrate 
synthase, reference range: 163-599) with activities of complexes II, III, IV and V within 
reference range.
Two years after the initial examination, the patient continues to have profound
developmental delay, requires feeding through a PEG-tube and has episodic seizures. 
Whole exome sequencing identiﬁes variants in NDUFAF4.
Via whole exome sequencing a homozygous missense variant in the NDUFAF4 gene
(NM_014165.3) was identiﬁed: c.7G>C; p.(Ala3Pro). This variant is not present in the ExAC-
database (http://exac.broadinstitute.org), the 1000-genomes-database (http://www.
internationalgenome.org) or our in-house-database. The variant has been uploaded 
to “Leiden Open Variation Database” (http://www.lovd.nl/NDUFAF4): variant ID
#0000170856, individual ID #00104960.
Variant prediction softwares predicted different functional effects of this mutation: 
Mutation taster (http://www.mutationtaster.org/) (Schwarz et al. 2014): “polymorphism” 
(probability: 0,84); PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/)(Adzhubei et al. 
2010): “probably damaging” (score: 0.991); SIFT (http://sift.jcvi.org/) (Kumar, Henikoff, and 
Ng 2009): “damaging” (SIFT score 0,04). Sequence alignment showed that the exchanged 
alanine in position 3 of the amino acid sequence is conserved in mammals (Supplementary
Fig. 1)
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The NDUFAF4 variant leads to isolated CI deﬁciency that can be rescued
via lentiviral complementation with wild-type NDUFAF4.
ﬁgure 1 | The NDUFAF4 variant causes isolated complex I deﬁciency that can be rescued by 
lentiviral complementation with wild-type NDUFAF4.
A) Complex I enzymatic activity in control (Ctrl) and patient (Pat) cells either transfected with 
C-terminally V5-tagged wild-type NDUFAF4 (+AF4) or with mock transfected with C-terminally
V5-tagged GFP (+GFP). Values are given relative to the activity of citrate synthase (CS) and as 
average value of two independent experiments. The error bars indicate standard deviation.
Lentiviral complementation with wild-type NDUFAF4, but not mock complementation with
GFP, increases complex I activity in patient ﬁbroblasts into reference range (163-599 mU/U CS).
B) Non-denaturing BN-PAGE electrophoresis/immunoblotting analysis of mitochondrial protein 
(lysed with n-dodecyl-`-d-maltoside) from control and patient ﬁbroblasts either transfected 
with NDUFAF4 or mock transfected with GFP. Holo-complex I (CI, NDUFS3) levels in patient
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ﬁbroblasts are severely reduced in comparison to control ﬁbroblasts. Complementation with 
wild-type NDUFAF4 increases holo-complex I levels. The other OXPHOS complexes are not 
negatively affected: complex V (d subunit, CVdSU), complex III (CIII, UQCRFS1), complex IV (CIV, 
COX4) and complex II (CII, SDHA). C) Immunoblotting analysis of total cell lysates after SDS-PAGE 
with antibodies against subunits representative of the OXPHOS complexes. Levels of complex I 
subunits representative for each functional module (NDUFV2 – N-module, NDUFB11 – P-module,
NDUFS3 – Q-module) are decreased in patient cells and rescued by complementation with wild-
type NDUFAF4. Analysis of NDUFAF4, GFP and V5 conﬁrm successful lentiviral complementation. 
The position of the 25 kDa molecular weight marker is indicated on the right in blots showing the
signals of the NDUFAF4 antibody, the V5 antibody and GFP antibody, respectively. Tubulin serves a
loading control.
Lentiviral complementation with C-terminally V5-tagged wild-type NDUFAF4 was
performed to prove that the NDUFAF4 variant affects protein function (Fig. 1). CI
enzymatic activity was rescued by complementation with NDUFAF4 but not by mock 
transfection with V5-tagged GFP (Fig. 1A). Complementation also rescued reduced levels
of holo-CI, analyzed by blue native polyacrylamide gel electrophoresis (BN-PAGE)/
immunoblotting using n-dodecyl-`-D-maltoside lysed mitochondrial protein (Fig. 1B). CI 
subunit levels, analyzed by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE), also increased in complemented patient ﬁbroblasts (Fig. 1C). NDUFAF4 was
not detectable in patient cells.
Lack of CI in NDUFAF4 deﬁcient patient ﬁbroblasts causes altered 
supercomplex stoichiometry.
Since CI forms supercomplexes with CIII and CIV and the levels of the latter two were
not changed despite CI deﬁciency, we analyzed supercomplex stoichiometry. In order
to maintain supercomplex interactions, mitochondrial protein was solubilised with the 
mild detergent digitonin rather than n-dodecyl-`-D-maltoside and subjected to BN-PAGE/
immunoblotting. In NDUFAF4 deﬁcient patient ﬁbroblasts, the lack of CI led to a decrease
of the I/III2- and I/III/IVn-supercomplexes (Fig. 2A, B, C) with increased levels of CIII-dimers 
and the III2/IV-supercomplexes (Fig. 2B, C). Of note, monomeric CIV levels remained 
unchanged (Fig. 2C).
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ﬁgure 2 | Complex I deﬁciency in patient ﬁbroblasts carrying the NDUFAF4 variant causes 
speciﬁcally altered supercomplex stoichiometry.
Non-denaturing BN-PAGE electrophoresis/immunoblotting analysis of mitochondrial protein 
(lysed with the mild detergent digitonin) from control (Ctrl) and patient (Pat) ﬁbroblasts either 
transfected with wild-type NDUFAF4 (+AF4) or mock transfected with GFP (+GFP). Antibody 
staining was performed to detect A) complex I (NDUFS3), B) complex III (holo-CIII) and C) complex 
IV (COX4), respectively. “Holo-CIII” refers to an antibody raised against bovine holo-complex
III that detects several different complex III subunits. Detection of complex II (SDHA) served as
loading control.
Complex I deﬁciency leads to clearly reduced abundance of the I/III2- and the I/III2/IVn-
supercomplexes (SC) and monomeric complex I (CIM) that is rescued by lentiviral complementation 
with NDUFAF4. NDUFS3 containing subassemblies (sa) are faintly detectable in control ﬁbroblasts.
In patient ﬁbroblasts, complex III dimers (CIII2) and supercomplexes consisting of a complex III 
dimer and complex IV (CIII2/CIV) are increased. Previously described uncharacterized complex 
IV subunit containing entities(Hornig-Do et al. 2012) (#) behave alike. The levels of monomeric
complex IV (CIVM) remain unchanged.
NDUFAF4 deﬁciency leads to accumulation of CI assembly
intermediates containing constituents of the proximal P-module, the 
distal P-module and the N-module.
We analyzed the effects of NDUFAF4 deﬁciency on CI assembly by 2D-BN-PAGE/SDS-PAGE 
experiments in patient ﬁbroblasts (Fig. 3). In the ﬁrst dimension BN-PAGE, native protein 
complexes (i.e. OXPHOS complexes) are separated (see Fig. 1B). The second dimension
SDS-PAGE step allows separation and improved epitope availability for immunodetection 
of the individual components of these native protein complexes including CI assembly
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intermediates. In these experiments, we used antibodies directed against representative 
constituents of assembly intermediates of all functional modules and, therefore, of all 
assembly routes of CI (Supplementary Fig. 2). The Q-module subassemblies containing 
NDUFAF4 or NDUFS3 were not detectable anymore in patient ﬁbroblasts and did not 
accumulate.
However, there was a clear accumulation of proximal P-module subassemblies containing 
assembly factors ACAD9 and ECSIT, of distal P-module subassemblies containing CI 
subunit NDUFB11 and of an N-module subassembly containing CI subunit NDUFV2 (Fig. 3). 
These assembly defects were rescued in patient ﬁbroblasts complemented with wild-type 
NDUFAF4. 
NDUFAF4 is closely associated with NDUFAF3(Guerrero-Castillo et al. 2017; Saada et al. 
2009), another CI assembly factor whose deﬁciency leads to a similar assembly defect
(Baertling et al. 2016). Since NDUFAF3 has been hypothesized to be involved in membrane 
insertion of P-module subunits (Saada et al. 2009), we analyzed the distribution of several
CI subunits in mitochondrial soluble protein fractions and membrane protein fractions of 
patient ﬁbroblasts (Supplementary Fig. 3). In control and patient ﬁbroblasts, P-module
subunits were detectable in the membrane fraction but not in the soluble fraction.
ﬁgure 3 | Patient ﬁbroblasts carrying the NDUFAF4 variant exhibit accumulation of complex 
I assembly intermediates containing parts of the proximal P-module, the distal 
P-module and the N-module but not the Q-module.
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2D-BN-PAGE/SDS-PAGE and subsequent immunoblotting analysis of mitochondrial protein (lysed
with n-dodecyl-`-d-maltoside) from control (Ctrl) and patient (Pat) ﬁbroblasts either transfected 
with wild-type NDUFAF4 (+AF4) or mock transfected with GFP (+GFP).
A) The upper panel demonstrates simultaneous staining with antibodies against NDUFS3, 
which is a component of all Q-module subassemblies and fully assembled complex I (CI), and
proximal P-module assembly factors ACAD9 and ECSIT. The lower panel demonstrates staining
with an antibody against NDUFAF4. In control ﬁbroblasts several NDUFS3 containing Q-module 
subassemblies (saQ) are detectable. NDUFAF4 is most strongly detectable in a low molecular 
weight Q-module subassembly (saQ2) but also faintly as a “smear” reaching into the high 
molecular weight area (Ctrl+GFP, NDUFAF4). In mock transfected patient ﬁbroblasts, Q-module
subassemblies are not detectable and do not accumulate: subassembly saQ1 is clearly detectable 
in control ﬁbroblasts and faintly visible in NDUFAF4 transfected patient ﬁbroblasts but not in 
mock transfected patient ﬁbroblasts. There is an accumulation of a subassembly containing
proximal P-module subassembly components ACAD9 and ECSIT (saPP). Note that the signal 
intensity of NDUFS3 at the height of fully assembled complex I (CI) is severely reduced in mock-
tranfected patient ﬁbroblasts (Pat+GFP) while the signal intensities of both ACAD9 and ECSIT
increase. The arrow indicates the faint signal of the ECSIT antibody in the panel of the mock-
transfected control ﬁbroblasts. This ratio is reversed in patient ﬁbroblasts complemented with
NDUFAF4 (Pat+AF4).
B) Staining with an antibody against distal P-module subunit NDUFB11 reveals accumulation of 
two subassemblies (saPD2 and saPD3). Note that, in mock transfected patient ﬁbroblasts (Pat+GFP),
their abundance is higher than that of high molecular weight subassembly saPD1. This ratio is 
reversed is patient ﬁbroblasts transfected with wild-type NDUFAF4 (Pat+AF4).
C) Staining with an antibody against N-module subunit NDUFV2 reveals accumulation of a 
subassembly (saN2). Note that, in mock transfected patient ﬁbroblasts (Pat+GFP), its abundance is 
higher than that of subassembly saN1. This ratio is reversed is patient ﬁbroblasts transfected with 
wild-type NDUFAF4 (Pat+AF4).
Discussion
Prior to our report, only one NDUFAF4 variant (c.194T>C; p.(Leu65Pro)) had been reported
in one family with several patients who developed encephalopathy and lactic acidosis
shortly after birth(Saada et al. 2008). The patients either died in the ﬁrst week of life due 
to intractable acidosis or developed severe myopathy, impaired neurological development
and recurrent metabolic acidosis. One patient’s brain MRI at the age of 16 months
revealed severe generalized brain atrophy and demyelination. The patients who survived 
the neonatal period passed away between the age of 9 and 18 months due to intractable 
acidosis.
The patient described in the present manuscript carried a novel missense NDUFAF4
variant and presented with Leigh syndrome and developmental delay. This underlines the
neurological phenotype caused by NDUFAF4 deﬁciency while adding Leigh syndrome, a 
deﬁned mitochondrial disease(Baertling et al. 2014), to its spectrum.
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Even though complex I deﬁciency can be accompanied by deﬁciencies of other OXPHOS
complexes (Saada et al. 2012), CIII and CIV are generally stable in the case of complex I
deﬁciency(Schagger et al. 2004). However, their distribution in this setting has not been
studied in patient ﬁbroblasts. We demonstrated that non-complex I associated CIII and 
CIV species do not all increase in an equal manner but are speciﬁcally altered when the 
formation of the I/III- and I/III/IVn-supercomplexes is hampered. 
The consequences of NDUFAF4 variants for CI assembly in patient ﬁbroblasts have 
previously not been studied (Marcus et al. 2013; Saada et al. 2008; Saada et al. 2009). Our 
recently published detailed human CI assembly model has shown that the CI assembly 
process mirrors its modular architecture (Guerrero-Castillo et al. 2017): subunits of the 
different functional modules are assembled separately and most intermodular association
does not take place until the ﬁnal steps of CI biogenesis. NDUFAF4 is associated with 
assembly intermediates of the Q-module (Guerrero-Castillo et al. 2017). This association is 
established during early CI assembly and persists until the last steps of biogenesis where 
NDUFAF4 dissociates just before completion of CI assembly.
Fractionation experiments revealed no P-module subunits in the soluble fraction and,
thus, no evidence of disturbed membrane insertion in patient ﬁbroblasts. However, 
previous studies have shown that P-module subunit ND1 is degraded more rapidly in the 
case of NDUFAF4 deﬁciency (Zurita Rendon and Shoubridge 2012). Thus, this mechanism 
cannot be completely excluded, since disturbed membrane integration followed by 
immediate subunit degradation is a possibility.
We demonstrated accumulation of parts of all modules except for the Q-module, that
NDUFAF4 associates with. The N- and P-module accumulation could be a secondary effect 
caused by hampered Q-module assembly. However, it could also suggest that NDUFAF4 
is required to connect the separately assembled components of the P-module and the 
N-module to the Q-module. NDUFAF4 is most likely required for two assembly steps: (i) 
the connections of the PP-b/PD-a- and Q/PP-a-subassemblies to form the Q/P-subassembly 
(Guerrero-Castillo et al. 2017) and (ii) the addition of the N-module to complete CI 
(Supplementary Fig. 2).
In conclusion, our study expands the phenotypic spectrum associated with NDUFAF4
deﬁciency and sheds light into the role of NDUFAF4 in CI assembly. Future studies will 
focus on the molecular mechanism of action of assembly factors.
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Supplementary ﬁgures
supplementary ﬁgure 1 | Amino acid sequence alignment of NDUFAF4 in different species. 
The amino acid arginine (A) in human NDUFAF4 in position 3 is exchanged for proline (P) in the 
patient. This amino acid is conserved in mammals but not other species.
supplementary ﬁgure 2 | Simpliﬁed mitochondrial complex I assembly scheme based on our
previously published model.
Bold letters indicate the names of assembly intermediates. The antibodies used in our
experiments are given in italics. The NDUFAF4 defect likely affects formation of the Q/P 
subassembly and the ﬁnal addition of the N-module.
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supplementary ﬁgure 3 | P-module subunits are not detectable in the soluble mitochondrial
protein fraction.
SDS-PAGE/immunoblotting analysis of whole mitochondrial protein lysates (W), protein lysates 
from mitochondrial membrane fractions (M) and mitochondrial soluble protein fractions (S) of 
control (Ctrl) and patient (Pat) ﬁbroblasts transfected with either wild-type NDUFAF4 (+AF4) or 
mock transfected with GFP (+GFP). Equal amounts of protein were loaded for each lane. 
Proximal P-module subunit ND1 and distal P-module subunit NDUFB11 are both exclusively
detectable in the membrane fraction but not in the soluble fraction. N-module subunit NDUFV2
and Q-module subunit NDUFS3 are detectable in both the membrane and the soluble fraction as 
they are not part of membrane integrated portion of complex I. 
Mitochondrial matrix protein TFAM serves as control for soluble proteins, complex IV subunit 
COX2 as control for a strictly membrane integrated proteins and COX5A as control for proteins 
that are not membrane integrated themselves but associated with a membrane integrated
multiprotein complex. Bands marked with (*) in COX2 blot indicate remainder of the TFAM signal 
on the membrane.
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Abstract
Mitochondrial respiratory chain complex I consists of 44 different subunits and contains 
three functional modules: the Q-, the N- and the P-module. NDUFA9 is a Q-module subunit 
required for complex I assembly or stability. However, its role in complex I biogenesis has 
not been studied in patient ﬁbroblasts. So far, a single patient carrying an NDUFA9 variant 
with a severe neonatally fatal phenotype has been reported. Via exome sequencing, 
we identiﬁed a novel homozygous NDUFA9 missense variant in another patient with 
a milder phenotype including childhood-onset progressive generalized dystonia and
axonal peripheral neuropathy. We performed complex I assembly analysis using primary 
skin ﬁbroblasts of both patients. Reduced complex I abundance and an accumulation 
of Q-module subassemblies were present in both patients but more pronounced in 
the severe clinical phenotype patient. The latter displayed additional accumulation
of P-module subassemblies, which was not present in the milder-phenotype patient.
Lentiviral complementation of both patient ﬁbroblast cell lines with wild-type NDUFA9
rescued complex I deﬁciency and the assembly defects. Our report further characterizes 
the phenotypic spectrum of NDUFA9 deﬁciency and demonstrates that the severity of 
the clinical phenotype correlates with the severity of the effects of the different NDUFA9
variants on complex I assembly. 
Keywords  NDUFA9; OXPHOS; complex I; assembly; point mutation
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Introduction
Mitochondrial respiratory chain complex I (NADH:ubiquinone oxidoreductase; EC 1.6.99.3)
is the largest component of the oxidative phosphorylation (OXPHOS) system. It contains 
three functional modules: the Q-module (ubiquinone reduction), the N-module (NADH 
dehydrogenase) and the P-module (proton translocation). It has an L-shaped structure
with one arm integrated into the inner mitochondrial membrane and a second arm
protruding into the mitochondrial matrix. The membrane arm represents the P-module
and the matrix arm consists of the Q- and the N-module.
Complex I assembly is an intricate process: 37 nuclear-encoded and 7 mitochondrial-
encoded subunits are brought together to construct the fully assembled complex in
numerous parallel and sequential steps (Guerrero-Castillo et al. 2017). The process depends
on the action of several assembly factors that temporarily associate with complex I
subunits or assembly intermediates but are not part of the holo-enzyme itself.
After its assembly is completed, complex I associates with other OXPHOS complexes to 
form supercomplexes. These consist of either complex I and a complex III-dimer (I/III2-
supercomplexes) or complex I, a complex III-dimer and one or multiple copies of complex
IV (I/III2/IVn-supercomplexes) (Guerrero-Castillo et al. 2017).
Several complex I subunits, including NDUFA9, are not only structural constituents of the 
functional modules but are also essential for complex I assembly or stability (Andrews et 
al. 2013; Stroud et al. 2016; Stroud et al. 2013).
NDUFA9 is a component of the Q-module (Fiedorczuk et al. 2016; Zhu, Vinothkumar, and 
Hirst 2016). So far, one pathogenic NDUFA9 variant has been described in a single patient
with complex I deﬁciency (van den Bosch et al. 2012), yet the effects of NDUFA9 variants on 
complex I assembly have not been studied in patient ﬁbroblasts. Here, we present a novel
patient with a different NDUFA9 variant and expand the clinical phenotype associated 
with NDUFA9 deﬁciency. Furthermore, we demonstrate a detailed analysis of its effects 
on complex I biogenesis in primary skin ﬁbroblasts of both the present and the previously 
reported patient. 
Materials and methods
Whole exome sequencing
Informed consent for diagnostic and research studies was obtained for all subjects in 
accordance with the Declaration of Helsinki and following the regulations of the local 
medical ethics committee.Exome sequencing and variant ﬁltering was performed 
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essentially as described before (Wortmann et al. 2015; Neveling et al. 2013). In short, exome
enrichment was performed using the SureSelect Human All Exon 50 Mb Kit (Agilent, 
Santa Clara, CA), covering ~21,000 genes. The exome was sequenced on a HiSeq2000TM 
sequencer (Illumina, San Diego, CA, USA). Colour space reads were iteratively mapped to
the hg19 reference genome, and the called variants and indels were annotated using an
in-house annotation pipeline. Common variants were ﬁltered out based on a frequency of 
<0.5% in dbSNP v.137 (www.ncbi.nlm.nih.gov/SNP/) and Exome Aggregation Consortium 
(ExAC) data (exac.broadinstitute.org/) (Lek et al. 2016), and a frequency of <0.5% in our in-
house database. Quality criteria were applied to ﬁlter out variants with less than 5 variant 
reads and less than 20% variation. Furthermore, synonymous variants, deep intronic, 
intergenic and untranslated region (UTR) variants were excluded.
Cell culture and enzymatic analysis
Patient-derived skin ﬁbroblasts were cultured in a humidiﬁed atmosphere with 5% CO2 at
37°C using M199 medium (Pan Biotech, Aidenbach, Germany), which was supplemented 
with 10% v/v fetal calf serum (Gibco/Life Technologies, Grand Island, NY, USA) and 1 % 
v/v penicillin/streptomycin (Gibco/Life Technologies). The activity of the respiratory chain 
enzymes, complex V, and citrate synthase (CS) in mitochondria-enriched fractions of
patient ﬁbroblast samples were measured as previously described (Janssen et al. 2007; 
Rodenburg 2011). The results were normalized to the activity of CS.
Lentiviral complementation of patient ﬁbroblasts
Lentiviral complementation was performed as previously described (Baertling, Al-
Murshedi, et al. 2017; Baertling, Sanchez-Caballero, et al. 2017; Nouws et al. 2010). 
HEK293FT cells were transfected in order for them to produce lentivirus containing either 
C-terminally V5-tagged wild-type NDUFA9 or C-terminally V5-tagged green ﬂuorescent 
protein (GFP). The virus particles were harvested 72 h after transfection and added to the 
patient or healthy control ﬁbroblasts for 24 h. Subsequently, the virus-containing medium 
was replaced with virus-free medium; 48 h after infection of the ﬁbroblasts, blasticidin (2 
μg/ml) was added to the medium to select for the transfected cells. Control and patient
ﬁbroblasts were cultured in selection medium for 21 days, after which the blasticidin-
resistant cells were used for further analysis.
Isolation of mitochondrial protein and protein quantiﬁcation
Mitochondrial protein for blue native polyacrylamide gel electrophoresis (BN-PAGE) and 
2 dimensional BN-PAGE/sodium dodecyl sulphate polyacrylamide gel electrophoresis
(2D-BN-PAGE/SDS-PAGE) was solubilised by resuspending mitochondrial fractions, which 
were isolated by digitonin treatment and centrifugation, in a 2% n-dodecyl-`-d-maltoside
solution as described previously (Calvaruso, Smeitink, and Nijtmans 2008; Baertling, Al-
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Murshedi, et al. 2017; Baertling, Sanchez-Caballero, et al. 2017). For supercomplex analysis,
digitonin in a concentration of 4 grams per gram of mitochondrial protein in a buffer 
consisting of 5 mM aminohexanoic acid, 50 mM imidazole, 2 mM MgCl2 and 50 mM NaCl 
at pH 7,0 was used for solubilisation. Total cell lysates were obtained by resuspending the 
cell pellet in 2% n-dodecyl-`-d-maltoside as previously described (Baertling et al. 2015). 
Protein concentrations were determined using the Pierce BCA protein assay kit (Thermo 
Fisher Scientiﬁc, Rockford, IL, USA).
SDS-PAGE, 2D-BN-PAGE/SDS-PAGE and immunoblotting 
SDS-PAGE using a 10% SDS gel, BN-PAGE using a 4-12% gradient gel, 2D-BN-PAGE/SDS-
PAGE using a 12% SDS-Gel and immunoblotting were performed as previously described
(Calvaruso, Smeitink, and Nijtmans 2008; Baertling, Al-Murshedi, et al. 2017; Baertling,
Sanchez-Caballero, et al. 2017). For 2D-BN-PAGE/SDS-PAGE the native protein complexes 
were ﬁrst separated a BN-PAGE gel. The components of these protein complexes were then 
separated and visualized by a second dimension denaturing SDS-PAGE/immunoblotting 
step. The following primary antibodies were used: NDUFS3 (Abcam, Cambridge, UK; 
Ab14711), NDUFV2 (Sigma-Aldrich, St.Louis, MO, USA; HPA003404), NDUFB11 (Abcam; 
ab183716), NDUFA9 (Abcam; Ab14713), SDHA (Abcam; Ab14715), UQCRFS1 (Proteintech, 
Manchester, UK; 18443-1-AP), COX1 (Abcam; Ab14705), COX4 (Abcam; Ab110261), complex 
V/d subunit (CVdSU; MitoSciences/Abcam, MS509), V5 (Invitrogen; R961-25), Tubulin `
(Abcam; Ab6046), holo-CIII (gift of the “Molecular Bioenergetics” group of the Radboud 
Center for Mitochondrial Medicine, Nijmegen, The Netherlands), GFP (gift of Frank van 
Kuppeveld, Nijmegen, the Netherlands), ND1 (gift of Anne Lombes, Université Paris-
Descartes, Paris, France). Peroxidase-conjugated goat anti-mouse or goat anti-rabbit 
IgGs (Life Technologies) were used as secondary antibodies. Proteins were transferred to 
a nitrocellulose membrane and visualized using the enhanced chemiluminescence kit 
(Thermo Fisher Scientiﬁc) and the Chemidoc XRS+ system (Bio-Rad, Hercules, CA, USA).
Results
Case reports
Patient 1
The patient is the ﬁrst child of non-consanguineous parents of Chinese ethnicity. The 
family history was unremarkable. He was born at full term via spontaneous delivery after 
an uneventful pregnancy. His development during the neonatal period and ﬁrst years
of childhood was unremarkable. At the age of 7 years without any obvious trigger, he 
developed deterioration of the right hand function with dystonia in the right upper limb.
At the age of 8 years, dystonia began to affect his right lower limb and at the age of 9 years,
the left upper limb was involved together with dysphagia and speech disturbance. By the 
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age of 10 years, his left lower limb was also affected, he became wheelchair-bound and 
suffered from severe dysarthria. There was no diurnal ﬂuctuation of dystonia. Furthermore, 
there were no signs of intellectual deterioration. At the age of 28 years, axonal motor and 
sensory peripheral polyneuropathy was diagnosed presenting with distal muscle wasting
and depressed deep tendon reﬂexes of the lower limbs. There was no dysmorphism or 
signs of organomegaly. Currently, the patient’s clinical condition had been stable in his
mid-forties. Laboratory tests revealed a mild post-prandial lactate increase to 3.3 mmol/L 
(reference range: <2,1 mmol/L) from a fasting level of 1.2 mmol/L. The lactate proﬁle after
an oral glucose loading test did not show any signiﬁcant increase. Other investigations 
including blood cell counts, blood gas analysis as well as kidney and liver function tests
were normal. Tests with regard to inherited metabolic diseases such as urinary organic 
acids, plasma amino acids, cerebrospinal ﬂuid (CSF) amino acids, CSF neurotransmitters 
and blood ammonia levels did not reveal speciﬁc changes.  Panel genetic diagnostics for 
several hereditary causes of dystonia did not reveal a disease-causing mutation. Magnetic 
resonance imagining (MRI) investigations of the brain revealed progressive bilateral 
putaminal signal alterations compatible with Leigh syndrome (MIM#256000) and atrophy 
of left caudate nucleus. There was no lactate peak detectable by magnetic resonance
spectroscopy. He received symptomatic treatment for dystonia with little success.
Patient 2
The patient presented with neonatally fatal Leigh syndrome and isolated complex I deﬁciency. 
A detailed description of this patient has been previously published (van den Bosch et al. 
2012). The following represents a brief summary of this description: After birth, he presented
with combined respiratory/metabolic acidosis due to severe lactic academia. Additional 
clinical features included hearing loss, apnoeas and retinitis pigmentosa. Brain MRI 
revealed a diffuse loss of supratentorial white matter and reduced brain stem volume with 
T2 hyperintensities of thalamus and putamen. Multiple electroencephalograms displayed 
multifocal sharp waves and a discontinuous pattern, yet no epileptic seizures. He eventually 
developed muscular hypertonia of both legs accompanied by dystonic movements of all
limbs. At the age of 3 weeks he became dependant on ventilator support and died at the
age of 4 weeks due to respiratory insufﬁciency. The patient carried carried a homozygous 
missense variant in NDUFA9: c.962G>C.; p.(Arg321Pro) (van den Bosch et al. 2012).  
Whole exome sequencing identiﬁes a novel pathogenic variant in 
NDUFA9.
Via whole exome sequencing a homozygous missense variant in the NDUFA9 gene 
(NM_005002.4) was identiﬁed in patient 1: c.1078C>T; p.(Arg360Cys). The variant is not 
present in the ExAC-database (http://exac.broadinstitute.org), the 1000-genomes-
database (http://www.internationalgenome.org) or our in-house-database.
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Several mutation prediction softwares unanimously predicted this variant to be 
pathogenic with the respective highest possible score category: MutationTaster (Schwarz 
et al. 2014) (http://www.mutationtaster.org, build: NCBI 37/Ensembl 69): “disease causing”;
AlignGVDV (Mathe et al. 2006; Tavtigian et al. 2006) ( http://agvgd.hci.utah.edu, version
18/09/2014): interference with function “most likely”, class C65; SIFT (Kumar, Henikoff, and 
Ng 2009) (http://sift.jcvi.org): “damaging”, score 0,03); PolyPhen-2 (Adzhubei et al. 2010)
(http://genetics.bwh.harvard.edu/pph2): “probably damaging”, score: 1,000.
There were no other variants present in the exome data that were to be considered 
pathogenic. Pathogenic variants in other genes known or predicted to cause mitochondrial 
complex I (or complex IV deﬁciency) were excluded: there were no variants in subunits or 
assembly factors that could be disease-causing.
Patient ﬁbroblasts carrying the novel c.1078C>T variant in NDUFA9 
exhibit complex I deﬁciency and reduced complex IV abundance
BN-PAGE/immunoblotting analysis using n-dodecyl-`-D-maltoside lysed mitochondrial 
protein revealed reduced levels of native holo-complex I (Fig. 1A). Analysis of the other
OXPHOS complexes additionally revealed reduced complex IV abundance. These 
experiments were repeated with different control cell lines (not shown) also showing 
both reduced complex I and complex IV abundance in the patient cells. The remaining 
OXPHOS complexes were not negatively affected. Levels of different complex I subunits 
representative of each functional module, analyzed by SDS-PAGE, were clearly reduced 
(Fig. 1B). Subunits representative of the other OXPHOS complexes were not lowered with 
the exception of complex IV subunit COX1.
Enzymatic analysis revealed isolated complex I deﬁciency (100 mU/mU CS, reference
range: 163-599; 17% of activity of highest control, 61% of lowest control), with the activity 
of the other OXPHOS complexes within reference range, including complex IV (418 mU/mU 
CS; reference range 288-954). 
In order to analyze changes in supercomplex stoichiometry, BN-PAGE/immunoblotting 
analysis was performed using digitonin lysed mitochondrial protein. Digitonin is a 
mild detergent that does not interfere with supercomplex interactions. We observed a 
reduction of the I/III2- and the  I/III2/IVn-supercomplexes with an increase of complex III-
dimers (Fig. 1C).
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ﬁgure 1 | The novel c.1078C>T variant in NDUFA9 causes reduced abundance of complex I and
complex IV and alters supercomplex stoichiometry.
A) Non-denaturing BN-PAGE/immunoblotting analysis of mitochondrial protein (lysed with 
n-dodecyl-`-d-maltoside) of healthy control ﬁbroblasts (Ctrl) and ﬁbroblasts derived from the 
patient with the c.1078C>T variant (P1). Holo-complex I (CI, NDUFS3) and complex IV (CIV, COX1) 
levels are reduced in patient ﬁbroblasts.
The other OXPHOS complexes are not negatively affected: complex V (d subunit, CVdSU), complex
III (CIII, UQCRFS1) and complex II (CII, SDHA). B) SDS-PAGE/immunoblotting analysis of total 
cell lysates derived from control and patient ﬁbroblasts. Abundances of complex I subunits
representative for each functional module (NDUFV2 – N-module, NDUFB11 – P-module, NDUFS3
and NDUFA9 – Q-module) and of complex IV subunit COX1 are reduced in patient ﬁbroblasts. Note 
that NDUFA9 is still faintly detectable. Levels of representative subunits of the other OXPHOS 
complexes are not reduced: complex V (d subunit, CVdSU), complex III (UQCRFS1) and complex II 
(SDHA). Tubulin ` serves as loading control.
C) Non-denaturing BN-PAGE electrophoresis/immunoblotting analysis of mitochondrial protein
derived from healthy control patient ﬁbroblasts lysed with the mild detergent digitonin. For 
immunodetection, antibodies against complex I (NDUFS3), complex III (holo-CIII) and complex IV
(COX4) were used, respectively. Detection of complex V (d subunit, CVdSU) served as loading 
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control.Reduced abundance of complex I and complex IV causes to reduced abundance of the I/
III- and the I/III/IVn- supercomplexes (SC). NDUFS3 containing subassemblies (sa) are increased in 
patient ﬁbroblasts. In patient ﬁbroblasts, complex III dimers (CIII2) are increased while monomeric
complex IV (CIVM), the CIII2/CIV supercomplexes (*) as well as previously described uncharacterized 
complex IV subunit containing entities (#) (Hornig-Do et al. 2012) are decreased. 
Two distinct NDUFA9 missense variants variably affect complex I
assembly routes as well as complex I abundance.
In order to analyze and compare the effects of different NDUFA9 variants, all complex
I assembly routes were analysed in detail using primary skin ﬁbroblasts of the patient
with the novel c.1078C>T variant and of the previously reported patient with the 
c.962G>C variant (van den Bosch et al. 2012). Complex I assembly was analyzed via BN-
PAGE/immunoblotting and 2D-BN-PAGE/SDS-PAGE. With the ﬁrst dimension BN-PAGE, 
native protein complexes including the OXPHOS complexes and their subassemblies are 
separated. The second dimension SDS-PAGE step allows separation as well as improved
epitope availability for immunodetection of the individual components of native protein 
complexes including low abundant complex I assembly intermediates. Antibodies 
directed against representative subunits of all functional modules were used.
BN-PAGE/immunoblotting revealed a more severe reduction of native complex I levels in
ﬁbroblasts carrying the c.962G>C variant than in those carrying the c.1078C>T variant (Fig.
2A). Complex IV abundance was close to control levels in the patient carrying the c.962G>C 
variant (Supplementary Fig.1).
Assembly analysis of both patient ﬁbroblast cell lines using an antibody directed 
against Q-module subunit NDUFS3, revealed an accumulation of several low and high 
molecular weight Q-module assembly intermediates. This effect was more pronounced
in the patient carrying the c.962G>C variant. Analysis of N-module assembly using an
antibody against N-module subunit NDUFV2 revealed reduced abundance rather than 
accumulation of assembly intermediates in both patient cell lines (Fig. 2B). P-module
assembly was analysed using antibodies against proximal P-module subunit ND1 (Fig. 2D) 
and distal P-module subunit NDUFB11 (Fig. 2C). Interestingly, the c.962G>C variant, but not 
the c.1078C>T variant, led to a clear accumulation of a high molecular weight P-module 
assembly intermediate. 
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ﬁgure 2 | The c.1078C>T variant and the c.962G>C variant in NDUFA9 variably hamper complex I 
assembly.
Non-denaturing BN-PAGE/immunoblotting and 2D-BN-PAGE/SDS-PAGE analyses of mitochondrial 
protein (lysed with n-dodecyl-`-d-maltoside) of healthy control ﬁbroblasts (Ctrl) and NDUFA9 
deﬁcient patient ﬁbroblasts carrying either the c.1078C>T variant (P1) or the c.962G>C variant (P2).
Blots were stained with antibodies directed against representative subunits of different functional 
modules of complex I: A) NDUFS3 and NDUFA9 to detect Q-module subassemblies (saQ). B) 
NDUFV2 to detect N-module subassemblies (saN). C) NDUFB11 as component of distal P-module 
(saPD). D) ND1 as component of the proximal P-module (saPP).
BN-PAGE/immunoblotting analysis demonstrates more severely decreased levels of holo-complex
I (CI) in P2 than in P1. Furthermore, the accumulation of the Q-module subassemblies that is 
present in both patient cell lines, is more pronounced in P2. In control and both patient ﬁbroblast
cell lines, NDUFA9 is detectable in one high molecular weight Q-module subassembly and at the 
height of holo-complex I.
Note that the signals corresponding to P-module subassemblies containing NDUFB11 and ND1 are 
more abundant than the respective signals at the height of holo-complex I in P2 (C, D). In P1, this
ratio reversal is not present and levels of holo-complex I and P-module subassemblies are reduced 
alike. There is also no ratio shift or reversal with regard to the N-module subassemblies (B).
(First dimension) BN-PAGE/immunoblotting experiments using antibodies directed against
NDUFV2 or NDUFA9 did not deliver sufﬁcient signal intensities without the second dimension
SDS-PAGE step. Therefore, they are not shown.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 169
NDUFA9 point mutations cause a variable mitochondrial complex I assembly defect 169
Lentiviral complementation with wild-type NDUFA9 rescues the
assembly defects in both patient ﬁbroblast cell lines
In order to prove that the observed complex I assembly defects in both patients were
caused by the respective NDUFA9 variants, lentiviral complementation was performed. 
Both patient ﬁbroblast cell lines as well as ﬁbroblasts of healthy control subjects were 
either transfected with C-terminally V5-tagged wild-type NDUFA9 or with C-terminally 
V5-tagged GFP as negative control. Reduced complex I abundance, and the respective 
assembly defects were rescued by transfection with wild-type NDUFA9 but not by 
transfection with GFP (Fig. 3A). 
SDS-PAGE/immunoblotting using antibodies against NDUFA9, V5 and GFP (Fig. 3B) was
performed and demonstrated successful lentiviral complementation.
ﬁgure 3 | Lentiviral complementation with wild-type NDUFA9 rescues complex I deﬁciency 
and the assembly defects in patient ﬁbroblasts carrying the c.1078C>T variant or the 
c.962G>C variant.
A) Non-denaturing BN-PAGE/immunoblotting analysis of mitochondrial protein (lysed with
n-dodecyl-`-d-maltoside) derived from healthy control ﬁbroblasts (Ctrl I, Ctrl II) or patient
ﬁbroblasts carrying the c.1078C>T variant (P1) or the c.962G>C variant (P2). Fibroblasts were either 
transfected with V5-tagged wild-type NDUFA9 (+A9) or V5-tagged GFP (+GFP) as negative control.
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Staining with an antibody against NDUFS3 demonstrates increased levels of holo-complex I
(CI) and decreased levels of accumulating subassemblies (saQ) in P1 and P2 after transfection
with NDUFA9 but not after transfection with GFP. Staining with antibodies against NDUFB11 and 
ND1 demonstrate rescue of the additional P-module assembly intermediate accumulation in
P2. The P-module subassemblies (saPD and saPP) are more abundant than holo-complex I in GFP
transfected cells. This ratio is reversed after complementation with NDUFA9.
B) SDS-PAGE/immunoblotting analysis of healthy control ﬁbroblasts and patient ﬁbroblasts 
either transfected with V5-tagged wild-type NDUFA9 or V5-tagged GFP demonstrates successful
lentiviral transfection. In the images showing the NDUFA9 and V5 blots, the position of the 
molecular weight markers are indicated on the right. Tubulin `  serves as loading control.
Discussion
Prior to our report, only one pathogenic NDUFA9 variant (c.962G>C.; p.(Arg321Pro)) has
been described in a single patient who developed fatal mitochondrial disease and died 
four weeks after birth (van den Bosch et al. 2012). He presented with combined respiratory/
metabolic acidosis and lactic acidemia. His brain MRI at the age of 6 days revealed T2-
weighted hyperintensities in the putamen, thalamus and brain stem characteristic for
Leigh syndrome (van den Bosch et al. 2012). 
The novel patient described in the present manuscript carried a different missense 
variant in the NDUFA9 gene and presented with a milder, albeit still severe, phenotype 
with childhood-onset progressive generalized dystonia and adult-onset axonal motor 
and sensory peripheral polyneuropathy without acidosis or intellectual impairment. The 
subsequent clinical course was slowly progressive and until the patient’s mid-forties. 
Brain MRIs revealed progressive bilateral putaminal signal alterations, indicative of Leigh
syndrome, and atrophy of left caudate nucleus. This case underlines the neurological 
phenotype including Leigh syndrome caused by NDUFA9 deﬁciency, while demonstrating a
variable degree of symptom severity. In summary, the symptoms associated with NDUFA9
deﬁciency seem to range from neonatal-onset lactic acidosis, retinitis pigmentosa and
fatal respiratory failure to childhood-onset progressive dystonia.
Both the present patient and the previously reported patient exhibited reduced complex I 
activity, which was more severe in the patient carrying the c.962G>C variant: 2% of control
panel activity (van den Bosch et al. 2012) as opposed to at least 17% of control activity.
In comparison to healthy control ﬁbroblasts, the present patient carrying the c.1078C>T 
variant additionally exhibited reduced complex IV abundance. In the patient carrying the
c.962G>C variant, neither complex IV activity (van den Bosch et al. 2012) nor abundance 
were negatively affected. Given that complex IV enzymatic activity was within reference 
range in the patient carrying the c.1078C>T variant, this observation likely has no relevance 
for the disease phenotype. Of note, the reference range for the enzymatic activity was
generated from measurements of over 40 healthy control subjects.
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The consequences of pathogenic NDUFA9 variants for the complex I assembly pathway 
have previously not been studied in patient ﬁbroblasts. Our recently published detailed
human complex I assembly model has demonstrated that complex I biogenesis mirrors 
its modular architecture (Guerrero-Castillo et al. 2017): the different functional modules
and their subunits are assembled separately and are not connected until the ﬁnal 
stages of complex I assembly. NDUFA9 is a subunit of the Q-module and located in the
proximal matrix arm of complex I (Fiedorczuk et al. 2016; Guerrero-Castillo et al. 2017; Zhu, 
Vinothkumar, and Hirst 2016). During the assembly process, it is added to the Q-module
just before complex I assembly is completed. A previous study conducted with HEK293 
cells, which were artiﬁcially genetically modiﬁed to knock out NDUFA9, demonstrated an 
absence of fully assembled complex I as well as accumulation of a subassembly solely 
containing P-module components (Stroud et al. 2016). Furthermore, it suggested that lack 
of NDUFA9 causes destabilization of the junction between the membrane arm and the 
matrix arm, followed by exclusive degradation of the matrix arm (Stroud et al. 2016).
We performed a detailed complex I assembly analysis using primary skin ﬁbroblasts of
both of the above described NDUFA9 deﬁcient patients. Our experiments showed that
complex I deﬁciency was more severe in the patient with the neonatally fatal phenotype
carrying the c.962G>C variant. Furthermore, we demonstrated accumulation of the same
Q-module subassemblies in both patients’ ﬁbroblasts. However, an accumulation of 
a P-module assembly intermediate was only present in the severe-phenotype patient 
carrying the c.962G>C variant but not in the milder-phenotype patient carrying the
c.1078C>T variant.
These observations give valuable new insight into the effects NDUFA9 deﬁciency and 
suggest differences in contrast to the previously observed effects in HEK293-NDUFA9 
knock-out cells: (i) NDUFA9 point mutations allow complex I biogenesis to proceed 
to the stage of fully assembled complex I and fully assembled complex I-containing
supercomplexes, (ii) NDUFA9 deﬁciency can lead to complex I deﬁciency with accumulation 
of Q-module subassemblies but without P-module subassembly accumulation. These
differences are probably related to the fact that, unlike in NDUFA9 knock-out cells, 
NDUFA9 is still present in low levels in patient ﬁbroblasts. However, our data also suggest
that P-module involvement is secondary to hampered Q-module assembly in patient 
ﬁbroblasts. This is implied by the fact that mildly reduced complex I levels are associated 
with exclusive Q-module accumulation and severely reduced levels are associated with
both Q- and P-module accumulation. Since the increased subassemblies include high 
molecular weight assembly intermediates, our data indicate that NDUFA9 plays a role in 
the late complex I assembly steps, which is in line with previous reports (Guerrero-Castillo 
et al. 2017; Stroud et al. 2013).
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Furthermore, our results demonstrate that similar missense variants in one and the same 
complex I subunit can differentially affect complex I assembly and that there is a spectrum 
of NDUFA9 deﬁciency rather than an identical cellular phenotype. These differences are 
likely related to different variant-associated structural changes in NDUFA9 that hamper its 
interaction with other subunits or assembly intermediates during complex I biogenesis.
Detailed studies of complex I structure revealed NDUFA9 to be crucial in forming the 
NADPH binding site (Fiedorczuk et al. 2016; Zhu, Vinothkumar, and Hirst 2016). However, 
NADPH binding is mediated via the arginine in position 50 of the NDUFA9 amino acid 
sequence (Fiedorczuk et al. 2016). The patients’ variants affect amino acids in positions 
360 and 321, respectively, and should therefore not interfere with NADPH binding. 
Furthermore, they are not involved in inter- or intrasubunit cross links (Fiedorczuk et al. 
2016).
Interestingly, with regard to the two presented patients, more severely impaired complex
I assembly was associated with a more severe clinical phenotype. Future studies including 
additional patients will have to show whether this association underlies a robust
correlation.  
In conclusion, our study expands the phenotypic spectrum associated with NDUFA9 
deﬁciency and demonstrates that NDUFA9 deﬁciency can have variable effects on complex
I assembly that possibly correlate with the severity of the clinical phenotype.
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Supplementary ﬁgure
supplementary ﬁgure 1 | Non-denaturing blue native polyacrylamide gel electrophoresis (BN-
PAGE)/immunoblotting analysis of mitochondrial protein (lysed with n-dodecyl-`-D-maltoside)
derived from healthy control ﬁbroblasts (Ctrl) or patient ﬁbroblasts carrying c.962G>C variant 
(P2). The following oxidative phosphorylation (OXPHOS) complexes are not negatively affected in 
patient ﬁbroblasts: complex V (d subunit, CVdSU), complex III (CIII, UQCRFS1) and complex IV (CIV,
COX4)
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Abstract
We demonstrate that a heterozygous nuclear variant in the gene encoding mitochondrial 
complex I subunit NDUFV1 aggravates the cellular phenotype in the presence of a 
mitochondrial DNA variant in complex I subunit ND1. Our ﬁndings suggest that
heterozygous variants could be more signiﬁcant in inherited mitochondrial diseases than 
hitherto assumed.
Keywords  OXPHOS, mitochondrial DNA, inherited mitochondrial disease
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Introduction
Mitochondrial complex I (CI) deﬁciency is the most frequent cause of inherited
mitochondrial disease in children causing various phenotypes characterized by 
neuromuscular symptoms, ranging from mild myopathy to neonatal death. Genotype-
phenotype correlations in mitochondrial disease are poorly understood.
Mitochondria have their own small genome and protein translation machinery. CI is
composed of 7 subunits encoded by the mitochondrial genome and 37 different subunits
encoded by the nuclear genome. Variants causing CI deﬁciency are found in mitochondrial 
DNA (mtDNA)-encoded genes,(Schon, DiMauro, and Hirano 2012) in nuclear DNA-encoded 
genes(Fassone and Rahman 2012) and in genes encoding CI assembly factors.(Nouws et al. 
2012) The latter associate with CI subassemblies and subunits during CI biogenesis but are 
not part of the ﬁnal holo-complex. 
While mitochondrial disease due to variants in nuclear-encoded genes follows a Mendelian 
pattern, inheritance of mitochondrial-encoded defects is more complex and poses a 
challenge for genetic counseling. mtDNA is inherited maternally, is polyploid with 2-10 
copies per mitochondrion and thousands of copies per cell, and constitutes the basis for the
phenomenon of heteroplasmy (different mtDNA copies per cell) and homoplasmy (identical 
mtDNA copies in every cell)(Taylor and Turnbull 2005). Because homoplasmic variants affect 
all mtDNA molecules, they are passed on from the mother to all her offspring. However, 
some mitochondrial diseases are associated with a sex bias and variable penetrance, which 
suggests that other factors play a role in disease expression (Taylor and Turnbull 2005). An 
inﬂuence of nuclear genome composition and environmental factors has been assumed, 
yet evidence of such contributors is scarce (Hudson et al. 2005). 
Methods
Cell culturing, generation of transmitochondrial cybrids and enzymatic 
analysis
Patient-derived skin ﬁbroblasts were cultured in a humidiﬁed atmosphere with 5% CO2
at 37°C using M199 medium (Pan Biotech, Aidenbach, Germany) supplemented with 10% 
v/v fetal calf serum (Gibco/Life Technologies, Grand Island, NY, USA) and 1% v/v penicillin/
streptomycin (Gibco/Life Technologies). The activity of the OXPHOS enzymes and citrate 
synthase were measured as previously described.(Rodenburg 2012) All measurements were 
performed at least twice and values are given as averages. Transmitochondrial cybrids
were generated as previously described(King and Attadi 1996; Ugalde et al. 2007) via fusion
of 143B206 TK− rho zero cells with either enucleated control ﬁbroblasts or enucleated 
ﬁbroblasts derived from the ﬁrst-born son.
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Genetic analyses
Whole exome sequencing and mitochondrial DNA sequencing were performed as 
previously described (Baertling et al. 2017; Ugalde et al. 2007)
Lentiviral complementation of patient ﬁbroblasts
Lentiviral complementation with C-terminally V5-tagged wild-type NDUFV1 or C-terminally 
V5-tagged GFP was performed as previously described.(Baertling et al. 2017)
Isolation of mitochondrial protein and protein quantiﬁcation
Mitochondrial protein for blue native polyacrylamide gel electrophoresis (BN-PAGE) and 
two dimensional BN-PAGE/sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(2D-BN-PAGE/SDS-PAGE) was isolated by solubilisation of mitochondrial fractions, which 
were generated by 2% digitonin treatment and centrifugation, using 2% n-dodecyl `-d-
maltoside as described previously.(Calvaruso, Smeitink, and Nijtmans 2008) Total cell
lysates were obtained by resuspending the cell pellet in 2% n-dodecyl `-d-maltoside.
Protein concentrations were measured using the Pierce BCA protein assay kit (Thermo 
Fisher Scientiﬁc, Rockford, IL, USA).
BN-PAGE, SDS-PAGE, 2D-BN-PAGE/SDS-PAGE and immunoblotting
BN-PAGE (4-12% gradient gel), SDS-PAGE (10% gel), 2D-BN-PAGE and immunoblotting were 
performed as previously described.(Calvaruso, Smeitink, and Nijtmans 2008) For 2D-BN-
PAGE/SDS-PAGE the native mitochondrial protein complexes (100ug of protein) separated 
by BN-PAGE were further separated and visualized by a second dimension denaturing 
SDS-PAGE (12% gel)/immunoblotting step. This allows analysis of the composition of
the native complexes separated by BN-PAGE including CI and its assembly intermediates. 
The following primary antibodies were used: NDUFS3 (Abcam, Cambridge, UK; Ab14711; 
1:10000), SDHA (Abcam/MitoSciences; MS204; 1:1000), NDUFAF2 (gift of Professor M.
Tsuneoka, Takasaki University, Japan; 1:1000), V5 (Invitrogen; R961-25; 1:1000). As secondary 
antibodies, peroxidase-conjugated goat anti-mouse or goat anti-rabbit IgGs (Life
Technologies) were used. Proteins were transferred to a nitrocellulose membrane and 
visualized using the enhanced chemiluminescence kit (Thermo Scientiﬁc, Waltham, MA, 
USA) and the Chemidoc XRS+ system (Biorad, Berkeley, CA, USA).
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Results
Case reports
The individuals described here are all members of a non-consanguineous Dutch family 
comprised of two parents and their three children (“mother”, “father”, “daughter”, “ﬁrst-
born son” and “second-born son”, for pedigree see Fig. 1A). 
ﬁgure 1 | Family members carrying the additional heterozygous NDUFV1 variant exhibit reduced
complex I abundance, but not those carrying the ND1 variant alone.
A) Pedigree overview of the reported family including clinical symptoms. Subjects include the 
father (Fa), the mother (Mo), their daughter (Da), their ﬁrst-born son (So1) and their second-born
son (So2). Light grey ﬁlling indicates presence of the homoplasmic ND1 variant (m.3460G>A) and 
additional darker grey ﬁlling indicates presence of the heterozygous NDUFV1 variant (c.1268C>T, 
p.(T423M)). Symptoms and variant segregation are indicated below each family member. B) BN-
PAGE/immunblotting analysis of complex I (CI, NDUFS3) levels in skin ﬁbroblasts of the mother,
the daughter and the ﬁrst-born son. Levels of complex II (CII, SDHA) serve as loading control. C) 
BN-PAGE/immunblotting analysis of complex I (CI, NDUFS3) levels in transmitochondrial cybrids
carrying healthy mitochondria (CyCtrl) or mitochondria with the patients’ ND1 variant (CyND1mut).
Levels of complex II (CII, SDHA) serve as loading control. 
The mother’s medical history was signiﬁcant for transient Erb’s paresis after birth and 
was uneventful until the age of 18 years, when she suddenly developed paresis of both 
legs. The paresis improved spontaneously after several days, yet increasing difﬁculties in 
walking and maintaining balance remained. She developed progressive gait instability 
and increased muscle tone in both legs over the following years. A diagnostic work-up
revealed apparent cervical spinal stenosis, which was then suspected as cause of the 
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problems. However, laminectomy did not lead to improvement. At the age of 40 years, 
physical examination revealed markedly increased spasticity in both legs and a spastic-
ataxic gait. Her vision was not impaired. An MRI revealed atrophy in the cervical spine. 
She gave birth to her three children at the age of 25 (daughter), 26 (ﬁrst-born son) and 27 
(second-born son).
The daughter was a twin pregnancy that was complicated by spontaneous abortion
of her twin during the 11th week of gestation. She was born at term and her neonatal 
period, infancy and early childhood were uneventful, except for decreased exercise 
tolerance and muscle weakness. At the age of 11 years, she developed signs of depression, 
physical fatigue, insomnia and aphonia along with a sudden change in personality.
Due to suspected conversion disorder or separation anxiety, she underwent psychiatric
treatment, which led to no improvement. In the further disease course, she developed 
progressive myopathy with severe weakness that was more pronounced in the proximal 
than the distal muscle groups and did not affect her ﬁne motor skills. Tendon reﬂexes 
were normal and there were no signs of a sensory disturbance. EEG, ECG and MRI of the
brain and spinal cord revealed no abnormalities. Laboratory examinations revealed
elevated lactate levels in blood (between 1.7–4.4 mmol/L, reference range: 0.5-2.2) and CSF 
(2,35 mmol/L, reference range: 1.1-2.1). Alanine in serum was 498 μmol/L (reference range: 
150-450). Ophthalmologic investigations were unremarkable. Eventually, she became
unable to stand up and walk without assistance and became wheelchair-dependent. 
Furthermore, she required help for daily life tasks and was unable to further attend a
regular school. At the age of 19 years, a muscle biopsy was performed and revealed isolated 
CI deﬁciency (7% of lowest control). 
The ﬁrst-born son was born after an uneventful pregnancy and his medical history was 
unremarkable until the age of 21 years when he developed rapidly progressive vision loss 
and eventually turned blind within three weeks after being hospitalized because of a 
motorcycle accident. MRI of the brain revealed no abnormalities. Based on the ﬁndings of 
serial ophthalmologic examinations and family history, Leber’s hereditary optic atrophy
(LHON) was diagnosed. He died at the age of 23 years in an accident unrelated to the disease.
The second-born son was born after an uneventful pregnancy and his medical history
was unremarkable. In the course of a suspected viral infection at the age of 17 years, he 
transiently showed severe fatigue, a decrease in physical performance and a tremor of his 
hands. These symptoms completely resolved.
Genetic analyses reveal concurrence of homoplasmic ND1 variant and
heterozygous NDUFV1 variant
Sequencing of the mtDNA revealed that the mother and all three siblings, but not the 
father, carried the homoplasmic m.3460G>A variant in the ND1 gene (NCBI reference 
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sequence: NC_012920.1). The mtDNA haplotype was J1c. Via candidate gene sequencing, 
a heterozygous variant in the NDUFV1 gene (NCBI reference sequence: NG_013353.1) was 
additionally detected in the mother and daughter and conﬁrmed via Sanger sequencing: 
c.1268C>T, p.(T423M). The latter variant was not present in either son or the father (Fig. 1A).
Whole exome sequencing was performed for the daughter and revealed no other known 
genetic defect to explain her symptoms or any other defect associated with or predicted to 
be associated with mitochondrial disease (Table 1). Nine additional heterozygous variants 
were detected in genes associated with autosomal recessive disease not related to 
OXPHOS deﬁciency or the patient’s symptoms. One heterozygous variant was detected in
the PIEZO2 gene associated with autosomal dominant arthrogryposis, but this variant was 
predicted to be benign. All other heterozygous variants are located in genes not known to 
be associated with disease. 
table 1 | Variants detected by whole exome sequencing in the daughter.
Columns with blue background include basic variant information and columns with yellow 
background include variant pathogenicity prediction scores using different independent 
algorithms. Columns with green background indicate known disease associations of variants and
variant classiﬁcation.
Gene
name
genomic variant
(GRCh37)
transcript
variant
protein 
variant 
PolyPhen-2 SIFT Align 
GVGD
disease
association
variant 
classi-
ﬁcation 
EPHA8 chr1:22927529
G>A
NM_020526:
c.2677G>A
hetero-
zygous
p.(Asp893Asn) 0,387 0,18 C0 Class 2
PRPF38B chr1:109242013
delAGTCGC
NM_018061:
c.1017_1022del 
hetero-
zygous 
p.(Ser342_Arg-
343del) 
in frame
deletion
Class 3
EML6 chr2:55056587
C>G
NM_001039753:
c.820C>G
hetero-
zygous
p.(Leu274Val) 0,997 0,23 C0 Class 3
B3GNT2 chr2:62449758
C>T
NM_001319075:
c.403C>T 
hetero-
zygous 
p.(Pro135Ser) 0,074 0,06 C25 Class 3
EPB41L5 chr2:120849142
A>C
NM_020909:
c.1055A>C
hetero-
zygous 
p.(Glu352Ala) 1 0 C65 Class 4
ZRANB3 chr2:136033214
C>T
NM_032143:
c.1078G>A
hetero-
zygous 
p.(Glu360Lys) 0,056 0,09 C15 Class 3
FRZB chr2:183730812
C>G
NM_001463:
c.469G>C
hetero-
zygous 
p.(Asp157His) 0,211 0,04 C0 Class 3
PLXNB1 chr3:48459873
C>T
NM_002673:
c.3034G>A
hetero-
zygous 
p.(Ala1012Thr) 0,013 0,06 C0 Class 3
ARIH2 chr3:49004558
G>A
NM_001349213:
c.388G>A
hetero-
zygous 
p.(Val130Ile) 0,009 0,21 C0 Class 2
LAMB2 chr3:49160449
T>C
NM_002292:
c.4261A>G 
hetero-
zygous 
p.(Ser1421Gly) 0,985 0 C55 Pierson
syndrome  (AR)
Class 4
NEK4 chr3:52802459
G>C
NM_003157:
c.255C>G
hetero-
zygous 
p.(Phe85Leu) 0,991 0,03 C0 Class 3
ERC2 chr3:56114904
G>A
NM_015576:
c.1582C>T 
hetero-
zygous 
p.(Arg528Cys) 0,993 0,01 C0 Class 3
NFKBIZ ch3:101576028_
101576029
delinsCC 
NM_031419:
c.1935+1_1935+
2delinsCC 
hetero-
zygous 
p.? (splice) predicted to 
remove 5’
splice-site 
Class 4
LSG1 chr3:194362840
T>G
NM_018385:
c.1934A>G
hetero-
zygous
p.(Lys645Arg) 0,669 0,21 C0 Class 2
GNPDA2 chr4:44705096
delCTT 
NM_138335:
c.831_*2del
hetero-
zygous 
p.(*277
Trpext*8) 
extends 
ORF with 8 
amino acids 
Class 3
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MTRR chr5:7878215
T>G
NM_024010:
c.641T>G
hetero-
zygous
p.(Ile214Ser) 0,001 0,15 C0 Homocystin-
uria-megaloblastic
anemia, cbl E type 
(AR)
Class 2
ANKRD33B chr5:10618506
G>A
NM_001164440:
c.428G>A
hetero-
zygous 
p.(Cys143Tyr) 0,999 0 C0 Class 3
CEP120 chr5:122754131
delG
NM_153223:
c.128del
hetero-
zygous
p.(Pro-
43Leufs*14)
frameshift  Short-rib thoracic
dysplasia 13 with or 
without polydactyly  
(AR)
Class 4
RGS14 chr5:176795796
G>A
NM_006480:
c.928G>A
hetero-
zygous 
p.(Asp310Asn) 0,996 0 C15 Class 3
SYNJ2 chr6:158508015
C>A
NM_003898:
c.3337C>A
hetero-
zygous
p.(Pro1113Thr) 0,996 0,28 C0 Class 3
TMEM248 chr7:66416004
C>T
NM_017994:
c.662C>T
hetero-
zygous
p.(Thr221Ile) 0,899 0 C65 Class 4
ACTL7B chr9:111617651
T>C
NM_006686:
c.560A>G
hetero-
zygous
p.(Tyr187Cys) 1 0 C0 Class 3
SHTN1 chr10:118711425
C>T
NM_001127211:
c.529G>A
hetero-
zygous
p.(Glu177Lys) 0,154 0,02 C15 Class 3
CARS chr11:3041482
C>T
NM_001014437:
c.1234G>A
hetero-
zygous
p.(Gly412Arg) 0,997 0 C65 Class 4
CCDC73 chr11:32663616
C>G
NM_001008391:
c.952G>C 
hetero-
zygous
p.(Asp318His) 0,921 0,01 C0 Class 3
OR8U1 chr11:56143544
T>C
NM_001005204:
c.445T>C 
hetero-
zygous
p.(Tyr149His) 0,163 0 C65 Class 3
BBS1 chr11:66297406
C>T
NM_024649:
c.1456C>T
hetero-
zygous
p.(Leu486Phe) 0,716 0,05 C0 Bardet-Biedl syn-
drome 1   (AR, DR) 
Class 3
NDUFV1 chr11:67379696
C>T
NM_007103:
c.1268C>T
hetero-
zygous
p.(Thr423Met) 0,788 0 C0 Mitochondrial 
complex I deﬁciency  
(AR)
Class 5
CPT1A chr11:68530187
G>A
NM_001876:
c.1783C>T 
hetero-
zygous
p.(Arg595Trp) 0,989 0 C65 CPT deﬁciency, he-
patic, type IA  (AR)
Class 5
FDX1 chr11:110333149
T>C
NM_004109:
c.512T>C
hetero-
zygous
p.(Val171Ala) 0,576 0,05 C0 Class 3
HSP90B1 chr12:104336446
C>G
NM_003299:
c.1516C>G
hetero-
zygous
p.(Leu506Val) 0,993 0 C0 Class 3
TCHP chr12:110340925
C>T
NM_032300:
c.94C>T 
hetero-
zygous
p.(Gln32*) nonsense
mutation
Class 4
SIRT4 chr12:120741780
G>C
NM_012240:
c.416G>C
hetero-
zygous
p.(Trp139Ser) 0,173 0,13 C0 Class 2
CHFR chr12:133424727
C>G
NM_001161344:
c.1627G>C 
hetero-
zygous
p.(Asp543His) 0,8 0 C65 Class 4
ARHGEF7 chr13:111896613
C>T
NM_001113511:
c.985C>T
hetero-
zygous
p.(Leu329Phe) 1 0,29 C0 Class 3
ALDH1A3 chr15:101448629
G>A
NM_000693:
c.1408G>A
hetero-
zygous
p.(Ala470Thr) 0,184 0,18 C0 Microphthalmia (AR) Class 2
CLN3 chr16:28498813
delC
NM_001042432:
c.424del 
hetero-
zygous
p.(Val-
142Leufs*39) 
nonsense
mutation
 Ceroid lipofuscino-
sis, neuronal, 3 (AR)
Class 5
DNAI2 chr17:72305471
delACC
NM_023036:
c.1291_1293del
hetero-
zygous
p.(Thr431del) in frame
deletion
Ciliary dyskinesia
(AR)
Class 4
PIEZO2 chr18:10857089
C>T
NM_022068:
c.613G>A
hetero-
zygous
p.(Ala205Thr) 0,958 0,19 C0 arthrogryposis (AD) Class 2 
FBXL12 chr19:9922165
C>T
NM_017703:
c.388G>A
hetero-
zygous
p.(Glu130Lys) 0,777 0,03 C15 Class 3
KRI1 chr19:10665992
A>G
NM_023008:
c.1669T>C 
hetero-
zygous
p.(Trp557Arg) 0,999 0 C0 Class 3
ANO8 chr19:17442202
C>T
NM_020959:
c.605G>A
hetero-
zygous
p.(Arg202His) 0,902 0,05 C0 Class 2
ZNF805 chr19:57765985
G>A
NM_001023563:
c.1798G>A 
hetero-
zygous 
p.(Glu600Lys) 0,005 0,83 C0 Class 2
TNRC6B chr22:40660766
G>A
NM_001162501:
c.532G>A
hetero-
zygous
p.(Gly178Ser) 0,296 0 C55 Class 3
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The ND1 variant causes CI deﬁciency without compromising CI 
abundance
Diagnostic enzymatic activity measurements revealed similarly reduced CI activities 
in the mother, the daughter and the ﬁrst-born son (Table 2). The activities of the other 
oxidative phosphorylation (OXPHOS) complexes were within reference range in all three
subjects (BN-PAGE/immunodetection revealed CI abundance near control levels in the 
ﬁrst-born son. The mother and the daughter displayed reduced CI levels (Fig. 1B). 
To further analyse the effects of the family’s ND1 variant, transmitochondrial cybrids 
carrying the homoplasmic ND1 variant were generated. This allows analysis of mtDNA 
alterations in cells with identical nuclear genetic composition. Enzymatic analyses
revealed reduced CI activity in cybrids carrying mitochondria with the patients’ ND1
variant (26 mU/U CS) in comparison to cybrids carrying control mitochondria (206 mU/U
CS) without signiﬁcantly reduced CI abundance in BN-PAGE/immunoblotting analysis 
(Fig. 1C).  
table 2 | Oxidative phosphorylation complex activities in ﬁbroblasts of three family members.
Values are given relative the activity of citrate synthase (CS) and as average of two independent
experiments. Mo: mother; Da: daughter; So1: ﬁrst-born son.
Lentiviral complementation with wild-type NDUFV1 increases CI levels 
in patients carrying the heterozygous NDUFV1 variant but not in other 
subjects
As opposed to the ﬁrst-born son and the ND1-deﬁcient cybrids, the mother and the 
daughter exhibited reduced CI abundance suggesting a possible effect of the heterozygous 
NDUFV1 variant on the cellular phenotype. To further investigate this, we performed 
lentiviral complementation and, thereby, reintroduced wild-type NDUFV1 into patient 
cells (Fig. 2A; online).
Mo Da So1
activity activity activity
(mU/U CS) (mU/U CS) (mU/U CS) ref. range
Complex I 68 86 96 163 - 599
Complex II 564 756 601 335 - 888
Complex III 863 1001 1001 570 - 1383
Complex IV 465 594 706 288 - 954
Complex V 729 997 680 193 - 819
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BN-PAGE/immunodetection after complementation with wild-type NDUFV1 revealed
increased CI abundance in the mother’s and the daughter’s ﬁbroblasts but not the 
ﬁrst-born son’s ﬁbroblasts. CI activity slightly increased in complemented cells but not 
signiﬁcantly (Fig. 2C; online).
As negative control, transfection with wild-type NDUFV1 was additionally performed 
with two healthy control ﬁbroblast cell lines and with patient ﬁbroblasts carrying a 
homozygous variant in the gene encoding CI subunit NDUFS4. Deﬁciency of the latter 
leads to a CI assembly defect similar to the one caused by homozygous NDUFV1 variants.
(Vogel et al. 2007; Assouline et al. 2012) In all of these three cell lines, complementation
did not increase CI abundance or activity. As positive control, we used patient ﬁbroblasts 
carrying compound heterozygous variants in NDUFV1 including the family’s heterozygous 
variant: c.1268C>T, p.(T423M); c.175C>T (p.R59X). These cells displayed increased CI levels 
and activity after complementation with wild-type NDUFV1. Successful complementation
was conﬁrmed by enzyme assay (Fig. 2C; online) and SDS-PAGE/immunodetection (not
shown).
ﬁgure 2 | The heterozygous NDUFV1 variant causes a complex I assembly defect that is rescued
by lentiviral complementation with wild-type NDUFV1.
A) BN-PAGE/immunoblotting analysis of complex I (CI, NDUFS3) levels in primary skin ﬁbroblasts 
either transfected with C-terminally V5-tagged wild-type NDUFV1 (+NDUFV1) or mock transfected 
with C-terminally V5-tagged GFP (+GFP). Levels of complex II (CII, SDHA) serve as loading control.
The subjects include the mother (Mo), the daughter (Da), the ﬁrst-born son (So1), a patient with
homozygous NDUFS4 variant (S4) and a patient with a compound heterozygous NDUFV1 variant
(V1ch) B) 2D-BN-PAGE/SDS-PAGE analysis of primary skin ﬁbroblasts either transfected with
C-terminally V5-tagged wild-type NDUFV1 or mock transfected with C-terminally V5-tagged GFP.
Membranes were simultaneously stained with antibodies against complex I subunit NDUFS3, 
which indicates complex I (CI), and against complex I assembly factor NDUFAF2. The speciﬁc 
NDUFAF2-containing complex I subassembly with an approximate molecular weight of 830 kDa
is labeled “sa830”(Vogel et al. 2007). Note that complementation with NDUFV1 decreases its 
abundance, while the signal intensity at the height of fully assembled CI increases.  C) Complex 
I activity in ﬁbroblasts of all subjects after lentiviral complementation. Values are given relative 
the activity of citrate synthase (CS) and as average of two independent experiments. Error bars 
indicate standard deviation.
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The heterozygous NDUFV1 variant causes a speciﬁc CI assembly defect
that is rescued by lentiviral complementation with wild-type NDUFV1
Homozygous variants in genes encoding CI subunits of its N-module (i.e. NDUFV1 and 
NDUFS4) lead to accumulation of a speciﬁc CI subassembly that contains CI assembly
factor NDUFAF2.(Vogel et al. 2007; Assouline et al. 2012) This subassembly is also part of 
the regular CI assembly pathway,(Guerrero-Castillo et al. 2017) but due to its transient 
nature it is not detectable in healthy control ﬁbroblasts via 2D-BN-PAGE/SDS-PAGE.(Vogel 
et al. 2007; Assouline et al. 2012) To investigate if the heterozygous NDUFV1 variant in the 
mother’s and the daughter’s ﬁbroblasts also give rise to the accumulation of this assembly
intermediate, we performed 2D-BN-PAGE/SDS-PAGE followed by immunoblotting
using an NDUFAF2 antibody to detect this assembly intermediate. It was detectable in 
the ﬁbroblasts of the mother, the daughter and of the patient carrying the compound
heterozygous NDUFV1 variant (positive control) and in a patient with a homozygous
NDUFS4 variant, but not in healthy control ﬁbroblasts or the ﬁrst-born son’s ﬁbroblasts 
(Fig. 2B; online). Transfection with wild-type NDUFV1 reduced the abundance of this 
assembly intermediate in the ﬁbroblasts of the mother, the daughter and the compound 
heterozygous NDUFV1-deﬁcient patient, but not in ﬁbroblasts of a patient with a 
homozygous NDUFS4 variant (negative control). This demonstrates that the occurrence of
the NDUFAF2-containing subassembly is speciﬁcally caused by the heterozygous NDUFV1
variant.
Discussion
We demonstrate a family, in which one member suffering from LHON carries a 
homoplasmic mtDNA ND1 variant, which commonly causes this disorder, whereas two
other family members, who also carry this variant, developed unique mitochondrial
disease courses. The latter two additionally carry a heterozygous variant in the NDUFV1
gene. In ﬁbroblasts studies, we demonstrate a CI assembly defect, which can be attributed 
to the NDUFV1 variant, in carriers of both variants but not in the carrier of the ND1
variant alone. This assembly defect and complex I abundance were rescued via lentiviral
complementation with wild-type NDUFV1. Therefore, we propose that, at least on a 
cellular level, the heterozygous NDUFV1 variant contributes to the phenotype and could be
a signiﬁcant disease modiﬁer.
The ND1 and NDUFV1 subunits have no direct interaction and belong to different CI 
modules and CI assembly branches (Guerrero-Castillo et al. 2017). We demonstrate that 
the ND1 variant does not compromise CI abundance but leads to severe CI deﬁciency, 
which is in line with previous studies (Pello et al. 2008). The heterozygous NDUFV1 variant 
causes decreased CI abundance and an assembly defect characteristic of compound
heterozygous/homozygous variants this gene (Vogel et al. 2007). The fact that CI activity is
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not rescued by complementation with wild-type NDUFV1 suggests that, while the NDUFV1
variant inﬂuences CI abundance, the severe catalytic defect caused by the ND1 variant is
the dominant factor hampering CI activity in the patients. Hence, the blots match the 
clinical proﬁles better than the enzyme activities.
Heterozygous NDUFV1 variants are commonly considered not to cause disease on their
own, yet possible effects of heterozygous variants on metabolic pathways have previously 
been proposed. The theory of “synergistic heterozygosity” comprises that multiple 
concurring heterozygous variants, that each cause partial enzyme deﬁciencies within 
the same metabolic pathway, might together be pathogenic (Vockley et al. 2000). The
presence of the heterozygous NDUFV1 variant likely leads to mild CI deﬁciency or a mild CI
assembly defect that is not sufﬁcient to cross a certain threshold in order to be disease-
causing on its own. However, our data demonstrate that – at least on a cellular level – a 
heterozygous variant in a related nuclear gene can inﬂuence and aggravate the cellular 
phenotype in the presence of a mtDNA variant.
Clinical causality of the heterozygous NDUFV1 variant in the presented patients cannot 
be proven by our data. The family’s ND1 variant commonly causes LHON(Yu-Wai-Man et
al. 2009) as was the case in the ﬁrst-born son. LHON is characterized by painless visual 
failure in teenagers or young adults. Over ninety percent of LHON cases are caused by
homoplasmic point mutations in mitochondrial genes encoding CI subunits(Dimitriadis
et al. 2014) with four out of ﬁve patients being male. Interestingly, the two individuals 
carrying the heterozygous NDUFV1 variant in addition to the ND1 variant were female and
developed uncommon disease courses. The mother’s symptoms of CNS neurodegenerative 
disease have been described as a feature of LHON-causing variants in mtDNA-encoded CI
subunits, yet they rarely occurred without vision loss.(Pfeffer et al. 2013) The daughter’s 
disease course, albeit compatible with mitochondrial disease, has not been described in 
patients carrying ND1 variants alone. Therefore, we speculate that heterozygous variants 
such as the one described here might facilitate disease manifestation in carriers of 
potentially disease-causing mtDNA variants or even contribute to shaping the clinical
phenotype. 
Because whole exome sequencing plays an increasingly important part in the diagnostic 
process of mitochondrial diseases, heterozygous variants are regularly detected and may 
be ignored.
Our study strongly suggests that these variants may be of greater importance than
hitherto assumed on a cellular level. However, further research on more families and 
individuals is needed to show whether there is a solid case for heterozygous variants 
affecting the clinical presentation of children with mitochondrial diseases. If so, the 
information on heterozygous variants that is already available for many children with 
mitochondrial diseases will prove valuable for genetic diagnostics and counseling. 
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Additionally, previously unnoticed recessive variants may play a role in the unexplained 
large clinical phenotype variation in mitochondrial diseases.  
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Introduction
Mitochondria are pivotal organelles of the cell due to their central role in cell metabolic
pathways, such as the tricarboxylic acid (TCA) cycle, `-oxidation of fatty acids (FAO), the 
urea cycle and the oxidative phosphorylation (OXPHOS) system. This thesis is focused
in the later, the OXPHOS system, comprised by the electron transport chain (ETC) and 
the mitochondrial ATP synthase (also called complex V). In brief, electrons from the TCA 
and the FAO are transferred to the ETC, the energy from the redox reactions is used to
translocate protons from the matrix to the intermembrane space of the mitochondria, 
creating a proton electrochemical gradient needed to synthetize ATP. The ATP generated 
in the mitochondria represents the majority of the ATP generated in the cell. Thus, 
mitochondria are essential organelles in the evolution of aerobic organisms, without 
them, cells would be dependent on anaerobic glycolisis for all the ATP, but the anaerobic 
system is limited in its capacity. Whereas the aerobic system has a very rapid response to 
meet energy demands and is more efﬁcient, giving more ATP per metabolite. 
Complex I construction
Particularly, this thesis is focused on the ﬁrst enzyme of the OXPHOS. Complex I 
(CI) catalyzes the transport of electrons from NADH to ubiquinone (coenzyme Q), a
mitochondrial electron carrier of the ETC, and helps in generating the electrochemical 
proton gradient, used for the synthesis of ATP. CI was discovered to associate with
complex III (CIII) and complex IV (CIV) into higher mass complexes called supercomplexes 
(Schagger and Pfeiffer 2000). There were many hypothesis related to the function of 
these rearrangements, albeit the most likely hypothesis seems to be helping in keeping 
the reducing power. CI has ubiquinol as a substrate, once the ubiquinol is reduced needs
to go to CIII (active) to be oxidized. Before, it was thought that there must be a deﬁned
conduct from CI to CIII, but there is no evidence to support that hypothesis. Nonetheless, 
the close proximity and orientation of both complexes (Sousa et al. 2016) will ensure that 
the ubiquinol pool will be oxidized by CIII as soon as there is a binding site available. 
Additionally, the rearrengments of CI and CIII2 are conserved among different organisms 
(Davies, Blum, and Kuhlbrandt 2018), making this hypothesis even more plausible. But it is
likely that there is more than one reason for the existence of supercomplexes.
CI is composed by 44 different subunits, 37 nuclear encoded and 7 encoded by the 
mitochondrial DNA. The 7 mitochondrial encoded hydrophobic subunits, together with
7 nuclear encoded hydrophilic subunits, are the central subunits, they are capable of
performing the core bioenergetic funtions in the prokaryotic enzyme. CI from humans, 
which is the one this thesis is focused on, has extra subunits, called accessory subunits 
or supernumerary subunits. They are arranged around the core subunits, in the peripheral 
arm and also in the membrane integral arm. 25 of them have been proven as essential 
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for the assembly of CI and 1 of them, NDUFAB1, essential for cell viability (Stroud et al. 
2016). Although, most probably, the cell lethality caused by the deletion of NDUFAB1 is 
due to its participation in the mitochondrial FAS system and its importance in monitoring 
cell metabolism, not due to its role in CI (Feng, Witkowski, and Smith 2009; Schonauer 
et al. 2008). The physiological role of the accessory subunits has not been established 
yet, although some roles have been proposed. As NDUFS6, that harbors a functional Zn
site essential for stable insertion of FeS clusters (Kmita et al. 2015), or NDUFA10, which is 
needed for the binding and/or reduction of ubiquinone (Morais et al. 2014).
A very well orchestrated process is needed to put together all the different subunits 
from two different genomes. Starting from the import machinery that translocates all
those proteins from the ribosomes, where they are made, to the speciﬁc place into the 
mitochondria where they belong. Also, extra proteins, called assembly factors, are involved
in the insertion of cofactors, post translational modiﬁcations and insertion of subunits
into the inner membrane, up to having a fully and active assembled enzyme, that will
associate with CIII and CIV to form supercomplexes. The assembly factors, commented 
aboved, could be described as construction workers whom participate in the assembly
of the enzyme. Albeit in the recent years studies with patients, and developing new 
techniques, allowed us to identify a great number of them, it is expected that CI must have
a number of assembly factors analogous to CIV, so there are still more to be discovered.
Recently, several studies depicted CI assembly in-depth via different approaches: 1D BN- 
PAGE or 2D BN/SDS-PAGE followed by immunoblocking or more recent mass spectometry 
approaches and pulse-chase experiments followed by SDS-PAGE are the most common 
approaches (Guerrero-Castillo et al. 2017; Stroud et al. 2016; Antonicka et al. 2003; Vogel et 
al. 2005; McKenzie et al. 2011). All of them, lead to the same conclusion, CI is assembled via 
different pre-assembled intermediates. The intermediates associate ones with others to 
form the fully assembled CI. The path described in the most recent papers of CI assembly
(Stroud et al. 2016; Guerrero-Castillo et al. 2017) was very similar as the one our review 
proposed (Sanchez-Caballero, Guerrero-Castillo, and Nijtmans 2016). The various pre-
assembled intermediates seem to follow an established path, that is the main path, but 
there are several alternatives. Deﬁning CI assembly as a convoluted process, instead of the
previously believed, more static, sequential model.
Impaired complex I assembly 
As explained above, CI assembly requires pre-assembled intermendiates and, in vitro, 
in human cells, it seems that the interactions between those intermediates are well 
established. The impairment of CI assembly, not only reduces the amount of fully 
assembled CI that could be active, it could also modify the order in which different
intermediates are associated, and leads to the accumulation of CI assembly intermediates, 
which might be deleterious (Miwa et al. 2014).
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Previously, CI deﬁciencies were studied to prove a speciﬁc gene as disease causing, and in 
this way, many assembly factors were discovered. But many of those studies did not go in 
deep to study the speciﬁc impairment in the enzyme. In this thesis, we took advantage
of the expertise in the RCMM group in a recent approach, complexome proﬁling, to study
in deep and to pinpoint the exact impairment of the enzyme for the ﬁrst time in patients 
(Sanchez-Caballero et al. 2016), which was proven to be very informative and useful for the
study of patients. We could also ﬁnd a putative CI disease gene, TMEM126A, as we detected in
TMEM126B patient, its paralogue, TMEM126A, which was present in the intermediates where
TMEM126B was expected (Heide et al. 2012). In contrast, in controls cells TMEM126A was not 
in any intermediate. The fact that TMEM126A could replace TMEM126B when mutated, gave 
us a plausible explanation for the mild phenotype of the three unrelated patients studied. 
All the patients studied in this thesis, present an aberrant CI assembly with speciﬁc 
intermediates accumulations, consistent with the recent knowledge of its assembly 
pathway (Guerrero-Castillo et al. 2017). Defects on CI assembly might reduce the efﬁciency
of substrate utilization and increase reactive oxygen species (ROS) production. Moreover, 
accumulation of CI intermediates has been proven in mouse to associate with a decrease 
in longevity (Miwa et al. 2014).
Diagnosis and phenotype
For the diagnosis of mitochondrial disorders (Rodenburg 2011), in this case, CI deﬁciency, 
whole exome sequencing (WES) is normally the most successful strategy. It is performed
when laboratory diagnostics, clinical phenotype and family history of the patient point
towards a mitochondrial deﬁciency. Mitochondrial CI deﬁciency (Rodenburg 2016), as
OXPHOS deﬁciencies in general, has an imprecise genotype/phenotype correlation that
makes the diagnosis and the treatment of these patients challenging, not only due to 
the heterogeneity of the symptoms, but also to the variety of the clinical course of the
disease. The majority of the patients presenting CI deﬁciency, as majority of mitochondrial 
pediatric patients in general, present Leigh syndrome (Ortega-Recalde et al. 2013; Rahman
et al. 1996), a fatal, rapidly progressive, neurodegenerative disorder (Lee et al. 2016; Gerards, 
Sallevelt, and Smeets 2016). But they could have other presentations as LHON (Leber’s
hereditary optic neuropathy), MELAS (mitochondrial encephalomyopathy, lactic acidosis, 
and stroke-like episodes), NARP (neuropathy, ataxia and retinitis pigmentosa) or a broader 
spectrum. It could vary among organs, and it could be manifested as fatal neonatal or as 
an adult-onset syndrome. Mitochondrial CI deﬁciency can have any mode of inheritance 
but could also be sporadic. It has been postulated that the different phenotypical 
presentation of CI deﬁciency could be due to the difference in heteroplasmy, when 
affecting the mitochondrial DNA. But there are many cases of CI deﬁciency associated
to mutations in the nuclear DNA. Also, patients harboring mutations affecting the same
amino acid or identical mutations in different patients have a different outcome. Majority 
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of the mutations causing isolated CI deﬁciency are non-recurrent with few exceptions,
being NDUFB3 (p.Trp22Arg) (Alston, Howard, et al. 2016), NDUFS6 (p.Cys115Tyr) (Kirby et al.
2004) and TMEM126B (p.Gly212Val) (Sanchez-Caballero et al. 2016; Alston, Compton, et al.
2016) founder mutations. This makes very difﬁcult to make any reliable conclusion about
phenotype:genotype correlations. In this thesis, we provide a relation between the severity 
of the biochemical defect and the clinical phenotype in patients harboring mutations 
in NDUFA9 and in ND1/NDUFV1. Furthermore, we introduce the concept of synergistic 
heterozigosity (Vockley et al. 2000; Tong et al. 2004) to explain such phenotypic diversity 
in one family. Synergistic heterozygosity is described as multiple heterozygous variants 
that coincide in the same metabolic pathway, causing partial enzyme deﬁciencies, that 
together might become pathogenic.
The general decline of functional capabilities of an organism (aging) is accompanied 
by the appearance of several diseases. Cellular senescence (Lopez-Otin et al. 2013), cell
cycle arrest in response to several damaging stimuli, when in excess in a tissue, can be
favorable for the progression of age-related diseases and cancer (Sharpless and Sherr 
2015). CI deﬁciency is also involved in the ageing process, as there is less CI activity in long-
lived animals (Bowling et al. 1993; Miwa et al. 2014). Some of the functional impairments
of aging seem to be corretated with an increase of oxidative stress. The increase of the
oxidative stress is related to defects in the enzymes of the OXPHOS system, in particular 
CI. CI deﬁciency might be a pathogenic mechanism for age-related neurodegenerative
diseases, like Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and 
amyotrophic lateral sclerosis (Giachin et al. 2016) helping in the progression of the disease.
Combined deﬁciencies
Apart from isolated deﬁciencies in any of the OXPHOS complexes, there are also combined 
OXPHOS deﬁciencies, when more than one complex is affected. Nowadays, as the study 
of assembly factors increased it was shown how there are assembly factors which were 
proposed originally to be speciﬁc for a certain complex, that are involved in the assembly 
of more than one complex. As is the case, for example, of COA1(Mick et al. 2012), TMEM70
(as discussed in chapter 4) or C1QBP (Yagi et al. 2017; Feichtinger et al. 2017).
Future perspectives
Despite that there are still some unsolved questions regarding this enzyme, we have
progressed a lot in the understanding of CI function, structure and assembly. The
current status was achieved thanks to all the new technologies and approaches and the
knowledge shared by many scientists. But, we still need to keep up in new technologies 
and approaches to try to solve the unanswered questions.
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Direct interaction between proteins and lipids has been undermined in the study 
of OXPHOS function in the past and now will need some attention. As the use of
detergents, which are commonly used to isolate mitochondrial complexes, but modify 
the native environment, they could cause destabilization of the complex and erase the 
possibility of discovering the putative role that speciﬁc lipids have into the mechanism 
and assembly. Thus, new approaches need to be developed to deepen in the function 
of OXPHOS complexes in its own environment, to avoid neglecting crucial information, 
which could potencially lead to jump into wrong conclusions.There are still many putative
mitochondrial patients without a diagnosis. Probably, many of them are caused by yet 
not discovered assembly factors that have loose interactions that make more difﬁcult 
its identiﬁcation, or they could be tissue speciﬁc. Post translational modiﬁcations
might help in the regulation of the assembly/degradation ratio of the complex, as the 
case of TMEM126B (Fuhrmann et al. 2018), as its ubiquinitation in hypoxia results in its
degradation, leading to CI deﬁciency. 
A monogenic and/or polygenic disease? The diverse phenotypical consequences of same 
mutations in different patients could be explained by environmental factors or it could
be the result of more than one mutation in different genes. In the study and diagnosis
of mitochondrial diseases, many times we search for mutations in known genes that are
known to be the cause of mitochondrial disorders. If we ﬁnd one, and then we see some 
rescue in the phenotype when the patient cell line gets complemented with the wild type 
gene, then, we conclude that the particular mutated gene was the direct cause of the 
deﬁciency. But, it could also be that other genes are involved in the phenotype that the
patient presents, aggravating the phenotype. 
Mitochondrial impairment is a high burden for cell sustainability. Therefore, cells need to 
respond with the activation of different pathways to overcome it. Those responses could be 
either enduring, as epigenetic responses that will activate protective signaling pathways 
(Wang and Hekimi 2015), or transitory, as the mitochondrial unfolded response (Lin and 
Haynes 2016). The differences of an organism into its capacity to activate protective or
adaptive responses might also explain such phenotypical diversity in patients. So, there
is most likely, not only one answer to why there is diversity of clinical and biochemical 
manifestations in patients with CI deﬁciencies (OXPHOS deﬁciencies in general).
In this thesis, I did not deepen into supercomplexes, but it is clear that supercomplexes 
(SC) play a crucial role in the OXPHOS functioning, and there are many questions that need 
to be solved in the near future. The main is to decipher which is its functional role(s). One 
of the hypothesis was that the formation of SC helps into channeling (Bianchi et al. 2004)
and/or sequestering substrates (Enriquez 2016; Lenaz et al. 2016; Lapuente-Brun et al. 2013;
Genova and Lenaz 2014). But it is more feasible that the formation of SC might help into 
getting the proper orientation of the complexes, reducing the loss of reducing power and 
thus making more efﬁcient fuel of electrons, as explained in the beginning of this chapter, 
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without any sequestring or physical tunnel (Fedor and Hirst 2018). But it is also likely that 
they have more roles, as giving extra stability to the individual complexes (Acin-Perez et al. 
2004; Minai et al. 2008; Diaz et al. 2006), or making more efﬁcient the electron transport, 
specially in high energy demanding conditions (Greggio et al. 2017). Additionally, knowing 
all the factors that participate in the SC formation/stability, apart from SCAF1(Lapuente-
Brun et al. 2013) and mitoregulin (Stein et al. 2018), will help in the understanding of how
they operate. Once the role of SC is understood, some other questions would be easier to 
be solved, as why the ratio of supercomplexes differs between species and tissues, or if it 
could vary in response of different metabolic demands.
Concluding remarks
This thesis presents the current state of the art on CI assembly not only in health but also 
in disease. With our extensive study of its assembly in different scenarios we were able:
– To conﬁrm genetic alterations as cause of disease.
– To pinpoint the speciﬁc consequence that each of them has in the assembly of CI and 
to provide a relation with the biochemical and clinical phenotype.
– To discover new phenotypes correlated to gene alterations in assembly factors.
– To establish the role of the assembly factor, TMEM126B, in disease and ﬁnd a putative
participant of CI assembly under TMEM126B absence, TMEM126A.
– To describe a new role of TMEM70 in CI assembly for the ﬁrst time. Being now a protein 
that participates in CI and CV assembly.
– To provide a new concept, synergestic heterozigosity, to understand CI deﬁciency and
its phenotypical diversity, although we assume that more families must be studied to 
make any ﬁrm conclusion.
To sum up, CI is assembled by putting together modules that are pre-assembled, but
depending on the scenario (disease) the order and composition of those pre-assembled
modules might vary. The concept of what an assembly factor is might need to be rediﬁned, 
as there are assembly factors that participate in the construction of more than one 
complex in the inner membrane, so they are not speciﬁc of one particular enzyme. Also,
there could be proteins that only become assembly factors in case of disease. 
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Summary
The focus of this thesis is the biogenesis of mitochondrial complex I in man. In the 
course of evolution this protein arose by combining at least three enzymes to form a 
membrane bound proton transfering hydrogenase. The enzyme has acquired and lost
subunits to become a complex, which contains 44 different subunits originating from the 
mitochondrial and nuclear genome. The enzyme plays an important role in the energy
generating pathways of the cell. Its construction and regulation is a sophisticated process
and needs to be tightly controlled. The main aim of this thesis is to comprehend how this 
complex is assembled and how this process is regulated to understand diseases caused by
malfunctioning of this enzyme.  
Chapter 2 summarizes the known gene defects and the accompanying spectrum of 
clinical symptoms associated with oxidative phosphorylation (OXPHOS) deﬁciency. 
These defects can be caused by mutations in numerous mitochondrial or nuclear genes 
encoding proteins involved in several aspects of the OXPHOS system maintenance. This 
involves subunits or assembly factors of the OXPHOS complexes, proteins required for 
mitochondrial DNA maintenance and translation (i.e. mitochondrial ribosomal subunits 
and mtDNA polymerases), proteins involved in cofactor biosynthesis (i.e. coenzyme Q) 
and proteins necessary for mitochondrial homeostasis. 
Chapter 3 focuses on the main topic of this thesis, mitochondrial complex I assembly.
It provides the state-of-the-art background, which serves as a starting point for the 
experimental work presented in this thesis. Complex I assembly depends on the 
coordination of several, crucial processes that need to be tightly interconnected and 
orchestrated by a number of assembly factors. The understanding of complex I assembly 
evolved from simple sequential concept to the more sophisticated modular assembly 
model, describing a convoluted process. According to this model, the different modules 
assemble independently and associate afterwards with each other to form the ﬁnal 
enzyme. In this chapter, we unravel the intricacy of complex I assembly and provide the
latest insights in this fundamental and fascinating process. 
One intriguing aspect of complex I assembly is the ﬁnding of speciﬁc assembly factors, 
which are required to make this complex. Our previous studies indicated that a protein 
called TMEM70 could be such an assembly protein involved in complex I assembly. 
However, this protein has been described as a speciﬁc assembly factor for complex V. This 
discrepancy prompted us to further investigate the role of TMEM70. Our study described 
in Chapter 4 demonstrates that TMEM70 has a function beyond complex V as disrupting
this protein affects besides the assembly of complex V also the assembly of complex I. In 
depth analysis indicated that TMEM70 acts at the stage of membrane protein insertion 
both in complex V and complex I. Evolutionary analysis indicates that TMEM70 is part of a
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larger protein family and has two human homologs TMEM186 and TMEM223. We show that
these proteins are also in the mitochondrial inner membrane and might have a function 
similar to TMEM70. 
In Chapters 5-9 we applied our obtained knowledge on complex I assembly to understand 
and explain the molecular defects observed in complex I deﬁcient patients. 
In Chapter 5 we identiﬁed complex I assembly factor TMEM126B as a cause for disease. 
We report three complex-I-deﬁcient adult subjects with relatively mild clinical 
symptoms, including isolated, progressive exercise-induced myalgia and exercise
intolerance but with normal later development. Genetic analysis revealed alterations 
in the gene encoding complex I assembly factor TMEM126B in these patients. Thanks to 
our knowledge in complex I assembly we could establish that the assembly defect of 
complex I was consistent with a defect in TMEM126B. As lentiviral complementation of 
the wild type TMEM126B cDNA restored the enzymatic and biochemical defect, we could
conclude that the TMEM126B gene alterations were the cause for the complex I deﬁciency
in these patients. Interestingly, we observed a possible compensatory effect of the
protein TMEM126A, which is a paralogue of TMEM126B. This might provide an explanation
for the relative mild phenotype of these patients when compared with other complex I 
deﬁciencies. 
In Chapters 6 and 7 we describe novel mutations in complex I assembly chaperones and 
we describe how CI assembly is speciﬁcally affected by these mutations. NDUFAF3 is an
assembly factor of mitochondrial respiratory chain complex I. To date, only one report 
exists describing mutations in the NDUFAF3 gene as a cause of severe multisystem 
mitochondrial disease. In chapter 6, we report a novel homozygous variant in the gene
encoding NDUFAF3 in patient presenting with Leigh syndrome, a clinical feature which 
has not been associated with NDUFAF3 deﬁciency until now. Our study of this patient
ﬁbroblasts supports that complex I deﬁciency is caused by the mutation in the NDUFAF3
gene. Analysis of complex I assembly allows us to link the NDUFAF3 defect to a speciﬁc
impairment in complex I assembly, which is consistent with our described complex I
assembly model.
In Chapter 7, we identiﬁed a homozygous missense variant in the gene encoding NDUFAF4
(C6ORF66) in a complex I deﬁcient patient with Leigh syndrome. Western blot analysis
of two dimensional gels using different complex I subunit antibodies indicative of the
different assembly module routes showed an accumulation of parts of the P-module but 
not the Q-module. Supercomplex analysis in patient ﬁbroblasts revealed a speciﬁcally 
altered stoichiometry of the complexes. Our report on this second family affected by an
NDUFAF4 variant further characterizes the phenotypic spectrum and sheds light into the 
role of NDUFAF4 in mitochondrial complex I biogenesis.
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In Chapter 8 we address if the clinical phenotype is reﬂected by the molecular severity of
the defect in patients with mutations in a speciﬁc subunit (NDUFA9). NDUFA9 is a complex 
I subunit situated in the interface between the quinone binding module and the proton 
pumping module of complex I. It’s integrated in complex I assembly in late stages, however, 
its role in complex I biogenesis has not been studied in patient ﬁbroblasts. So far, a single 
patient carrying an NDUFA9 variant with a severe neonatal fatal phenotype has been 
reported. We identiﬁed a patient with a novel homozygous NDUFA9 missense variant. The
clinical phenotype of this patient was milder compared to the phenotype of the previously
reported patient. It included childhood-onset progressive generalized dystonia and axonal 
peripheral neuropathy. Complex I assembly analysis using primary skin ﬁbroblasts of 
both patients revealed reduced complex I abundance and an accumulation of Q-module
subassemblies in both patients, but more pronounced in the patient with a more severe
clinical phenotype. In the last , we observed accumulation of P-module subassemblies,
which was absent in the milder-phenotype patient. Lentiviral transduction of ﬁbroblast
cell lines of both patients with wild-type NDUFA9 partially restored complex I deﬁciency 
and the assembly defects. This indicates that genetic alteration in the NDUFA9 gene 
causes complex I deﬁciency in both patients. Interestingly the relationship between the 
severity of the clinical phenotype and the biochemical complex I defects in these patients 
suggests a genotype phenotype correlation, although this cannot be concluded on the 
basis of two patients.
In Chapter 9 we report a unique case of a patient with complex I deﬁciency in which a 
heterozygous nuclear encoded complex I subunit mutation may have a synergistic effect 
on a homoplasmic mitochondrial encoded complex I subunit mutation. A genetic scenario 
which has not been described before. The patient displayed exercise intolerance and growth
retardation with a severe complex I deﬁciency. This complex I deﬁciency can be explained 
by the presence of a homoplasmic mutation in the gene encoding the mitochondrial 
complex I subunit ND1 (3460 G>A). This mutation has been described before and is 
associated with Leber hereditary optic neuropathy. In addition, we found heterozygous
mutation in the nuclear gene encoding complex I subunit NDUFV1 (T432M). This mutation 
was reported also before and when homozygously present, it was associated with severe 
complex I deﬁciency. Our detailed biochemical study provided good indications that 
both mutations play a role in the phenotype of the patient. The clinical phenotype of this 
patient is different and more severe compared to patients with only the ND1 mutation.
Western blot analysis of BN-PAGE of this patient reveals accumulation of complex I 
subcomplexes similar to the patient with a homozygous NDUFV1 mutation (also T432M) 
which could be rescued by transfection of the wild type NDUFV1 gene . This illustrated that 
the NDUFV1 mutation is on the cellular level a modiﬁer. Although our data do not provide 
full evidence of the synergistic effect of these mutations, this study might have some 
major implications. It indicates that disorders may be caused by simultaneous mutations 
in two genomes. Heterozygous autosomal recessive mutation may be genetic modiﬁers
and contribute to pathogenic defects observed in patients. It opens the possibility that 
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the diversity in the phenotype presented in patients with OXPHOS deﬁciencies nests in 
the polygenic nature of them.
In Chapter 10, I discuss the major ﬁndings of this thesis and their implications and 
signiﬁcance in the context of mitochondrial disorders. Our increased knowledge of 
the assembly of complex I and discovery of novel assembly factors provides basis to 
understand how this complex is regulated and how defects lead to disorders. Nevertheless 
still many questions need to be resolved and this chapter addresses several options for
future research.
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Samenvatting
Dit proefschrift beschrijft mijn onderzoek naar de biogenese van het mitochondriële
complex I bij de mens. Dit enzym is ontstaan door de combinatie van drie enzymen die
uiteindelijk een proton transfererende hydrogenase vormden. Gedurende de evolutie 
zijn er subeenheden af gegaan en toegevoegd aan dit enzym en is er uiteindelijk een 
complex van 44 verschillende subeenheden ontstaan. Deze subeenheden worden zowel
door het mitochondriële als het nucleaire genoom gecodeerd. Het enzym complex speelt 
een belangrijke rol in de energie productie van de cel. Het maken van dit complex is een 
geavanceerd proces dat goed gereguleerd wordt. Het doel van deze studie is te begrijpen 
hoe dit complex in elkaar gezet wordt en hoe dit proces gereguleerd wordt. Hierdoor 
krijgen we inzicht in het ontstaan van ziekten die veroorzaakt worden door defecten in 
dit enzym. Dit zal ons in staat stellen om uiteindelijk tot een snellere diagnose en betere 
behandeling voor patiënten te komen.
Hoofdstuk 2 geeft een overzicht van gen defecten en de bijbehorende ziekte 
verschijnselen die beschreven zijn voor het oxidatieve fosforylerings (OXFOS) systeem. 
Deze defecten kunnen veroorzaakt worden door mutaties in mitochondriële of kern genen
die coderen voor eiwitten die nodig zijn voor het handhaven van een goed functionerend
OXFOS systeem. Dit kunnen subeenheden of assemblage factoren van deze complexen 
zijn, eiwitten die betroken zijn bij het mitochondriële DNA onderhoud en translatie 
(zoals bijvoorbeeld mitochondriële ribosomale subeenheden en mtDNA polymerasen), 
eiwitten nodig voor cofactor biosynthese (bv. coenzyme Q) of eiwitten betrokken bij 
mitochondriële homeostase. 
Hoofdstuk 3 richt zich op het hoofdonderwerp van dit proefschrift namelijk de
assemblage van mitochondrieel complex I. Het beschrijft de huidige stand van zaken 
en dient als startpunt voor het experimentele werk dat in dit proefschrift gepresenteerd 
wordt. De assemblage van complex I hangt af van de coördinatie van verschillende 
processen die nauw samenwerken en geregeld worden door verschillende factoren. Ons 
idee over complex I assemblage heeft zich ontwikkeld van een eenvoudig sequentieel
concept naar een meer geavanceerd modulair assemblage model. Volgens dit model 
worden de verschillende modules onafhankelijk gevormd en associëren deze later om
het uiteindelijke complex te vormen. In dit hoofdstuk ontrafelen we de complexiteit van 
complex I assemblage en geven de meest recente inzichten in dit boeiende proces.
Een interessant aspect van complex I assemblage is de ontdekking van speciﬁeke 
assemblage factoren. Wij vonden aanwijzingen dat het complex V assemblage eiwit 
TMEM70 ook betrokken zou kunnen zijn bij de assemblage van complex I. In hoofdstuk 
4 van dit proefschrift onderzoeken we deze hypothese. We vonden in cellen waar we het 
eiwit TMEM70 uitschakelden dat niet alleen de assemblage van complex V aangedaan was 
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maar ook complex I. Verdere analyse suggereert dat het eiwit TMEM70 een rol speelt bij de 
membraan insertie van de mitochondriële subeenheden van zowel complex V als complex 
I. Evolutionair onderzoek liet zien dat TMEM70 deel uitmaakt van een familie van eiwitten 
en twee homologe eiwitten werden gevonden namelijk TMEM186 en TMEM223. We laten
zien dat deze twee eiwitten ook in de mitochondriële binnenmembraan zitten op een 
vergelijkbare manier als TMEM70. Het feit dat deze eiwitten geconserveerd zijn in soorten 
die oxidatieve fosforylerings complexen hebben, suggereert dat ze een rol spelen in de
biogenese van het OXFOS systeem.
In hoofdstuk 5-9 gebruiken we de opgedane inzichten over complex I assemblage om de 
moleculaire defecten die we vinden in complex I deﬁciënte patiënten te begrijpen en te
verklaren.
In hoofdstuk 5 beschrijven een nieuw ziekte gen voor complex I deﬁciëntie, te weten het
gen coderend voor complex I assemblage factor TMEM126B. We besschrijven drie volwassen
patiënten met een complex I deﬁciëntie met relatief milde klinische symptomen zoals
spierpijn, inspanning intolerantie maar met verder een normale ontwikkeling. Genetische
analyse in deze patiënten onthulde afwijkingen in het gen dat codeert voor complex I 
assemblage factor TMEM126B. We vonden dat het complex I assemblage defect in deze 
patiënten overeenkomt met wat we verwachten bij een defect in TMEM126B. Omdat het 
biochemische defect in deze patiënt cellen weer herstelde door deze te transfecteren 
met een virus dat de correcte gen bevatte konden we concluderen dat de gevonden
genetische afwijking in het TMEM126B gen de oorzaak was van de complex I deﬁciëntie in 
deze patiënten. Opmerkelijk was dat we in de patiënten een mogelijk compensatie effect
vonden door het eiwit TMEM126A, dat een paraloog is van TMEM126B. Dit zou mogelijk een 
verklaring kunnen zijn voor het relatief mildefenotype in deze patiënten. 
In de hoofdstukken 6 en 7 beschrijven we patiënten met nieuwe mutaties in complex I 
assemblage chaperones NDUFAF3 en NDUFAF4. Van assemblage factor NDUFAF3 is er 
tot nu toe slechts een publicatie die beschrijft dat afwijkingen in dit gen de oorzaak zijn 
van ernstige mitochondriële ziekten. In hoofdstuk 6 laten we zien dat een homozygote
genetische afwijking in dit gen kan leiden tot Leigh syndroom, een klinisch beeld dat 
niet eerder met NDUFAF3 defecten is geassocieerd. In onze studie laten we zien dat het
gendefect ook de oorzaak is van de complex I deﬁciëntie en biochemische analyse van
complex I assemblage in deze patiënt geeft aan op welke plaats in de assemblage route
dit eiwit een rol speelt,wat overeenkomt met ons model over complex I assemblage zoals 
beschreven in hoofdstuk 3. 
In hoofdstuk 7 beschrijven we een Leigh syndroom patiënt met een homozygote
afwijking in de assemblage factor NDUFAF4. Met behulp van Western blotting analyse 
gebruikmakend van antilichamen tegen subunits van verschillende complex I modules
konden we aantonen dat sommige gedeelten van complex I, de P-module, ophoopten in
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deze patiënten in tegenstelling tot andere gedeelten zoals de Q-module. Onze rapportage 
van deze familie, die aangedaan is door afwijkingen in NDUFAF4, geeft niet alleen meer 
inzicht in het klinische spectrum maar ook in de rol die dit eiwit speelt in de assemblage 
van complex I.
In hoofdstuk 8 onderzoeken we of het klinische fenotype weergegeven wordt door de 
ernst van het moleculaire defect in patiënten met mutaties in subunit NDUFA9. Deze
subunit verbindt de quinone binding-module met de proton pomp-module en wordt
pas laat in de assemblage aan complex I toegevoegd. Over de rol van deze subunit in 
complex I is nog niet zoveel bekend en dit is ook niet eerder bestudeerd in patiënten
ﬁbroblasten. Tot nu toe is er slechts één rapportage van een NDUFA9 patiënt met een zeer
ernstig neonataal fataal fenotype. Wij identiﬁceerden hier een patiënt met een nieuwe 
homozygote missense mutatie in de subunit NFUFA9. Het klinische beeld van deze 
patiënt is een stuk milder vergeleken met de eerder beschreven patiënt. Het bestond uit 
progressieve gegeneraliseerde dystonie die begon tijdens de kindertijd en axonale perifere 
neuropathie. Bestudering van complex I assemblage in ﬁbroblasten van beide patiënten
liet een afgenomen hoeveelheid van complex I zien en een ophoping van Q-module 
subassemblages in beide patiënten, maar het defect was meer uitgesproken in de meer 
aangedane patiënt. Complementatie door lentivirale transductie van het wild type gen 
gaf een gedeeltelijk herstel van de complex I deﬁciëntie en het assemblage defect, wat 
impliceert dat de NDUFA9 mutaties de oorzaak zijn van het complex I defect. Het is 
opmerkelijk dat er een duidelijke relatie is tussen het biochemische complex I defect en 
het klinische beeld van deze patiënten. Dit suggereert een genotype-fenotype correlatie,
hoewel dit niet geconcludeerd kan worden op basis van slechts twee patiënten.
In hoofdstuk 9 beschrijven we een patiënt met een complex I deﬁciëntie waarbij een 
heterozygote mutatie in de nucleaire subunit NDUFV1 een versterkend effect heeft op het 
cellulaire fenotype in aanwezigheid van een homoplastische mutatie in mitochondriële 
subeenheid ND1. Dit is een genetisch scenario wat nog niet eerder beschreven is.
De homozygote mutatie in ND1 komt vaker voor en wordt geassocieerd wordt met 
Leberserfelijke opticus neuropathie. De NDUFV1 mutatie is ook al eerder beschreven
als oorzaak van een ernstige complex I deﬁciëntie, maar alleen als deze homozygoot 
aanwezig is. Heterozygote varianten van complex I subeenheden zijn tot nu toe niet eerder 
geassocieerd met ziekten. Dankzij uitgebreid biochemisch onderzoek laten wij zien dat
de beide mutaties in deze patiënt van invloed zijn op de complex I deﬁciëntie en mogelijk 
de ziekte verschijnselen. Met behulp van cybriden laten we zien dat de ND1 mutatie een
sterke verlaging in de activiteit te zien gaf, maar een normale hoeveelheid geassembleerd 
complex. Twee dimensionale electroforese liet zien dat de heterozygote NDUFV1 mutatie 
een speciﬁek assemblage defect gaf die hersteld werd door lentivirale complementatie 
met het wild-type gen. Deze bevindingen impliceren dat heterozygote mutaties wellicht 
een grotere rol kunnen spelen in het ontstaan van erfelijke mitochondriële aandoeningen 
en dat het mitochondriële genotype hier ook van invloed op kan zijn. 
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In hoofdstuk 10 bediscussieer ik de belangrijkste bevindingen van dit proefschrift en het 
belang hiervan in de context van mitochondriële ziekten. Dankzij onze toegenomen kennis 
over de assemblage van complex I en het ontdekken van nieuwe assemblage factoren zijn
we in staat beter te begrijpen hoe dit complex gereguleerd wordt en hoe defecten kunnen 
leiden tot ziekten. Er blijven desalniettemin nog veel vragen onbeantwoord. Dit laatste
hoofdstuk behandeld sommige van deze vragen en schetst een aantal mogelijkheden voor 
toekomstig onderzoek.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 217
217
Acknowledgments
During these years, many people had contributed to the development of this thesis that I
would like to thank, but the ﬁrst words will go for the person that inspired me the most. To 
my supervisor and to the person this thesis is dedicated to, to Leo Nijtmans.
Leo and I meet in November 2013, and since November 2013 he was the most encouraging 
and always enthusiastic supervisor. 
Leo, I always knew and appreciated how much you tried to be there to support me and to 
guide me as good as you could. You always kept a bit of energy for me, no matter how hard 
the days were. Even in our last meeting you spent all the minutes trying to encourage me 
to continue, to ﬁnish, always with a smile in your face. Thank you for giving me the energy 
you didn’t have. It was hard Leo, but if I had to choose again, I would deﬁnitely do it, I hope
you left knowing that. It was refreshing to listen to your ideas, the passion you had for 
your work, your interest in letting people grow professionally, to see how much you enjoy
our success. I envied your patience and your courage, how humble and human you were. 
Leo, I learnt a lot with you and I am deeply thankful. I will always be.
Apart from his scientiﬁc contribution in the mitochondrial ﬁeld, Leo gave all of us a lesson 
of strength and kindness, in such a selﬁsh world. 
A very special gratitude goes out to his family, for helping Leo and all the members of the 
group to keep it going, for their support and kindness.
I would also like to thank Prof. Dr. Jan Smeitink and Prof. Dr. Ulrich Brandt. I learnt a lot 
from both of you, and I will try my best to apply all the knowledge acquired to become a 
better professional in the ﬁeld. I really appreciated the meetings we had to be updated 
with my work and with the general situation, and for the support later on.
I am also grateful to all our collaborators in and out the department for their contribution 
in the manuscripts and into my professional growth, and to the ITN-MEET consortium and 
the UMDF for their support during these years. 
Since I came here, there has been someone next to me everyday. No matter what, she was 
always smiling and ready to help and keep up the good work. Mariel, there will not be 
enough pages in any book to thank you sufﬁciently. It was a real pleasure to have you as
my colleague. I hope I have contributed something good to you as well. Deﬁnitely this 
thesis is as it is thanks to you, for all the professional and personal support. Thanks for 
being the best colleague a person could ever have.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 218
218 Acknowledgments
A special mention goes to Sergio as well. Gracias por tu contribución, por tu entusiasmo, 
por escucharme y ayudarme en todo lo que podías. He disfrutado mucho trabajando 
contigo, incluso conociendo tus micro movimientos volvería a hacerlo de nuevo. Gracias 
por la parte profesional, sin lugar a duda, pero también por la personal. Conocerte me ha
enriquecido en ambas. Espero seguir estando en contacto y al menos seguir compartiendo 
los bares, los bailes y las charlas.
And Fabian, also known for the person that made the gigantic disaster with the 
Coomassie Blue, that will always be remembered. A very special gratitude goes for you, 
it was refreshing to have you as a colleague to share and learn new things. Thank you for
encouraging me and for the meetings we had, for being my translator sometimes too, and
for all the work done.
I would like to express my gratitude to Martijn, my mentor during this PhD. Thank you for
always having time to listen to me. Even though there was not much that could be done, 
being able tot talk to you helped me a lot to keep it going. Also, I would like to thank you 
for your always-appreciated scientiﬁc contribution in our projects and for your patience.
To Ian Holt with whom I worked together for a short period. Thank you for interest in our 
work, for your advices, and for your patience during those months. 
I would also like to express my gratitude to Sara, when you came the lab felt more like
home. Siempre te recordaré como la compañera más  lista y generosa. Me encantó tenerte 
a mi lado en el laboratorio, contigo no sólo aprendí muchísimo, sino que también hiciste 
que mis días fuesen mucho más llevaderos dentro y fuera del laboratorio.
Also I need to thank Soﬁa, the funniest one. Ojalá y te hubieses podido quedar un poquito 
más, para poder aprender y compartir mucho más la una de la otra. Te deseo lo mejor en tu
futuro, tanto profesional como personal.
Y gracias también a la segunda incorporación de habla hispana, Alfredo, por estar ahí, por 
intentar ayudar siempre y por los buenos ratos compartidos. Por el baile, por las tardes, 
por las comilonas, y por las pláticas. 
Another person that I am very grateful to is Miski. Since I meet you everything turned way 
easier and fun. Being next to you made this period full of lovely and funny moments I will
never forget, no doubt. You are the kindest, funniest person ever and I am the luckiest to
have met you and have you as a friend. 
Daisy, I remember you as a student in Leo’s group, a very focused, helpful and shy
colleague. You were always happy to help and very calm. It was a real pleasure to meet you
here and I wish all the best for you.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 219
219
Thanks also to Anke, my almost PhD colleague. It lasted few time but a great friendship 
was built. We were quite different people, one with no ﬁlter, the other one a drama queen,
but things changed fast. Now we can read each other’s mind and be always ready for the 
other. If one day I was sad or stressed, you felt it and came to help me, giving me ﬂowers, 
picking me up for beers…I appreciated a lot having you around, only with that, things 
were already better. I hope you didn’t need these words to be certain about how much I 
appreciate you.
And with Anke comes Angel, the lab felt always like home with you there, you made it fun 
with all of your double sense sentences. And after the lab you were always up for beers, or 
cocktails, or dinners and some dancing, so it couldn’t be better. Thank you for all our times 
together inside and outside the lab. Thanks also to Walinka for being always so nice with
me.
Well, if I say beers I say Hans. Thanks Hans for your support. I know I became a wimp in the 
matter of drinking beers, but you need to understand that I am much smaller than you, so 
I cannot follow your path. I always felt understood by you, unfortunately our lives made us 
go through the same thing, I knew it since long time ago, and I knew I could count on you.
Thanks also to Sirin, Fenna, Selma and the latest incorporation, Alisa, for the gossips, for 
the psychological treatment, that especially Fenna gave me, and for the happy moments
that we shared in the ofﬁce and in the lab. And to Roel and Daan, the 2 men in the ofﬁce for 
the nice moments shared in the ofﬁce.
From Richard group I also need to thank everyone, to be always helpful and kind to me.
Specially Richard, Lisebeth, Berendien and Gera for all their help with the enzymatic 
activities and all other kind of help in the lab. Also to Antonia, although we almost didn’t 
work there you were always there in case I needed something. To Theo for always being 
ready to solve any small issue I had, and being always that funny and kind. And also to
Sharita, although it was for a short time I had lovely moments with you as well, we laugh 
and you were there to give me advice and support. And Jackeline for always sharing her 
nice smile with me and be around to help with any crazy thing I had. 
Now is the turn of Özlem. Thank you dear, you always helped me with any small thing 
I needed and you did it always with your biggest smile. Thank you also for coming and
asking about how things were going, for caring about me and for being my dancing
partner together with Liesbeth. And Frans as well, thank you for your patience and your
help, always. 
Elena, thanks for your support, for our small chats and for cheering me up. To Annelies 
I also need to express my most sincere gratitude. It was fun to meet you as well, and
rewarding. It’s crazy because I am saying it all the time with everyone, I guess I am the 
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 220
220
luckiest, but it’s very true. You were there every time I came up with something that I 
needed to ﬁnd, or something I wanted to do, and for that and for all the fun I am truly 
thankful. You also searched me just to joke and laugh, and also for feeding me and taking
a bit care of me, and that is priceless. I still remember when I just mention that I had some
pain, and after some minutes you came to me with some pills and sweets. I have so many 
good memories to thank for… And Thea, every time you knew you could help you were the
ﬁrst, I have many examples but the funniest and the sweetest was when you came with
me to the nitrogen to help me ﬁnd some criovials, do you remember ourselves dancing at
the -2 to prevent the light to turn off? Thanks to Joop for being so cheerful and eager to 
help as well, and to Sanne, one of my ﬁrst colleagues when I arrived to the Netherlands. 
I would like to express my gratitude to the secretaries, especially Heidy, Annette and Cony. 
Thank you for your being so fast and collaborative with me every time. You made my day 
many times as well.
I also thank all the students that work with me: Janine, Suzanne and Samara, thank you for 
all the work done in the lab. And to Chiara for all the joy you brought to me.
A special mention goes here to Sasha, Eliska, Umut, Selena and Lavinija, with whom I had 
the opportunity to share many wonderful moments in many different countries during all 
the conferences and workshops.
There were also people that supported me even outside the lab. Thanks to everyone in the 
restaurant for being so cheerful and kind with me. Especially to Nell, thank you for being
always there with the biggest smile, asking how things were, being worried if I didn’t 
appear for some days. Also, I need to thank Eric, with whom we laugh so much. How nice
were you always with us is priceless. And also I have to thank to Manuela for her kindness.
I also need to say thanks to Sharon, she always had a smile for me, and my desk is not an
easy thing to clean, but she is lovely. So, thank you for being so nice with me and sorry for
the mess.
I would like to thank Michel and Kyah for being so helpful and fast.
Fuera del laboratorio siempre tuve a mis chicas. Renata, gracias por nuestras tardes, por el
amor que pones cuando escuchas mis historias, y por la paz que me transmites siempre. 
Gina, gracias por todo el tiempo que has compartido conmigo, que me ha llenado de 
alegría y fuerza. Os deseo todo lo mejor.
Marta, petita, amb tú m’he desfogat moltíssim. Part de que no estigui fatal del cap també 
t’ho dec a tu. A tenir les nostres converses, les nostres escapades, a saber que si la cosa
pinta malament sempre tindrem un abraçada gegant esperant-nos sigui quan sigui. Al 
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 221
221
Suades i a l’Edu també els hi he posat el cap ple d’histories. Gràcies per escoltar-me i per
totes les birres i sopars i/o dinars que em compartit, pels viatges i per tots els consells,
l’estima, i tots els riures (ben necessaris) que em brindeu sempre. I a l’Anna per les estones 
compartides que em feien recargar forces.
Gracias a Ainara y a Enrique por introducirme en el mundo de la investigación. Os sigo
admirando muchísimo y recordando con mucho cariño. A Ainara su perseverancia y 
entusiasmo, a Enrique hacer de preguntas muy complejas diseños experimentales simples 
y robustos. 
Si alguien ha tenido que aguantar los estragos de este doctorado, ese has sido tú, Dei. 
Tenerte a mi lado durante estos años me ha sacado fuerzas de donde no había. Gracias por 
toda la paciencia que me brindas, por el apoyo constante, por creer siempre en mi y en mis 
capacidades, por todos los buenos momentos compartidos a pesar de cuales fueran las 
circunstancias, por todas las risas que me sacas hasta en el peor de los escenarios, y por 
todo lo que esté por venir.
Gracias a mis padres, Rosi y Luis, por hacer lo imposible siempre. Por creer en mi. Por 
haberme enseñado tanto acerca de la vida y de las personas, por inculcar en mi el ejemplo 
del esfuerzo y la valentía. Por vuestro coraje. Sois, y seréis siempre, mi ejemplo a seguir.
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 222
222
Curriculum Vitae
Laura M. Sánchez Caballero was born in Terrassa, Spain, on January 23rd 1989. She joined
Universtitat Autonoma de Barcelona to purse a Bacheor in Biochemistry and a Master 
in Neurosciences, for which she received a full scholarship from the Spanish Ministry of 
Education, Culture and Sports. After several internships in molecular biology, she obtained 
her bachelor degree in 2011 and her Master’s degree in 2012. Her major thesis entitled 
“Lipid droplets fuel beta-oxidation and promote survival of nutrient deprived cells” was 
completed under the supervision of Dr. Enrique Claro at the laboratory of Cell Signalling 
mechanisms in health and metabolic, mental and cancer diseases at the Neurosciences
Insitut of the Universitat Autonoma de Barcelona..At the end of 2013 she moved to 
Nijmegen, the Netherlands, to start her PhD as a Marie Curie Early Stage Researcher under
the supervision of Dr. Nijtmans. During her PhD she studied mitochondrial complex I
biogenesis aiming to understand its regulation and to ﬁnd chaperones involved in this 
process. The results of her research are described in this thesis and were presented in
several international conferences (Euromit 2014, MIP 2015, EBEC 2016, Euromit 2017). In the 
last year of her PhD she wrote, in cooperation with Dr. Leo Nijtmans a project entitled: 
“Mitochondrial complexome proﬁling provides a novel tool to diagnose, and understand, 
complex I deﬁciency”, that was funded by the UMDF to succesfully ﬁnish her PhD. 
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 223
223
List of publications
Baertling, F.1, Sanchez-Caballero L.1, S. Timal, M. A. van den Brand, L. H. Ngu, F. Distelmaier, R.
J. Rodenburg, and L. G. Nijtmans. “Mutations in Mitochondrial Complex I Assembly Factor
Ndufaf3 Cause Leigh Syndrome.” Mol Genet Metab 120, no. 3 (Mar 2017): 243-46.
Baertling, F.1, Sanchez-Caballero L.1, M. A. M. van den Brand, F. Distelmaier, M. C. H. Janssen,
R. J. T. Rodenburg, J. A. M. Smeitink, and L. G. J. Nijtmans. “A Heterozygous Ndufv1 Variant
Aggravates Mitochondrial Complex I Deﬁciency in a Family with a Homoplasmic Nd1 
Variant.” J Pediatr 196 (May 2018): 309-13 e3.
Baertling, F.1, Sanchez-Caballero L.1, M. A. M. van den Brand, C. W. Fung, S. H. Chan, V. C. Wong,
D. M. E. Hellebrekers, et al. “Ndufa9 Point Mutations Cause a Variable Mitochondrial
Complex I Assembly Defect.” Clin Genet 93, no. 1 (Jan 2018): 111-18.
Baertling, F.1, Sanchez-Caballero L.1, M. A. M. van den Brand, L. T. Wintjes, M. Brink, F. A. van den 
Brandt, C. Wilson, R. J. T. Rodenburg, and L. G. J. Nijtmans. “Ndufaf4 Variants Are Associated
with Leigh Syndrome and Cause a Speciﬁc Mitochondrial Complex I Assembly Defect.” Eur J 
Hum Genet 25, no. 11 (Nov 2017): 1273-77.
Cabodevilla, A. G., Sanchez-Caballero L., E. Nintou, V. G. Boiadjieva, F. Picatoste, A. Gubern, and 
E. Claro. “Cell Survival During Complete Nutrient Deprivation Depends on Lipid Droplet-
Fueled Beta-Oxidation of Fatty Acids.” J Biol Chem 288, no. 39 (Sep 27 2013): 27777-88.
Sanchez-Caballero, L.1, S. Guerrero-Castillo1, and L. Nijtmans. “Unraveling the Complexity of
Mitochondrial Complex I Assembly: A Dynamic Process.” Biochim Biophys Acta 1857, no. 7 (Jul 
2016): 980-90.
Sanchez-Caballero, L.1, B. Ruzzenente1, L. Bianchi, Z. Assouline, G. Barcia, M. D. Metodiev, M. 
Rio, et al. “Mutations in Complex I Assembly Factor Tmem126b Result in Muscle Weakness 
and Isolated Complex I Deﬁciency.” Am J Hum Genet 99, no. 1 (Jul 7 2016): 208-16.
Sanchez-Caballero L.1, Dei M. Elurbe1, Fabian Baertling, Sergio Guerrero-Castillo, Mariel van
den Brand, Joeri van Strien, Teunis J. P. van Dam, Richard Rodenburg, Ulrich Brandt, Martijn
A. Huynen and Leo G.J. Nijtmans . TMEM70 is involved in the assembly of complex I and 
complex V. Manuscript in preparation.
Baertling, F.1, F. Al-Murshedi1, Sanchez-Caballero L., K. Al-Senaidi, N. P. Joshi, H. Venselaar, M. 
A. van den Brand, L. G. Nijtmans, and R. J. Rodenburg. “Mutation in Mitochondrial Complex
Iv Subunit Cox5a Causes Pulmonary Arterial Hypertension, Lactic Acidemia, and Failure to 
Thrive.” Hum Mutat 38, no. 6 (Jun 2017): 692-703.
Sanchez-Caballero L.1, Fabian Baertling1, Leo Nijtmans, Jan AM Smeitink. Oxidative 
Phosphorylation System: Nuclear Genes and Genetic Disease. eLS, book chapter, 2017
1Contributed equally
528793-L-bw-Cabellero
Processed on: 11-2-2019 PDF page: 224
“Alone we can do so little; together we can do so much.”
Helen Keller
Elucidating complex I  
assembly in health  
and disease
Elucidating com
plex I assem
bly in health and disease
laura m
. sánchez-caballero
laura m. sánchez-caballero
